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1 .  EP IDEMIOLOGY  OF  CERVICAL  CANCER 
With 529.512 new patients in 2008, cervical cancer accounts for 8.8% of all cancers in women 
worldwide. Globally, cervical cancer is the third most common cancer in women, with an age-
standardised incidence rate (ASIR) of 15.2 per 100,000 women.1-2 
Approximately 85% of all cases occur in developing countries, where this disease accounts 
for 13.1% of all female cancers. The cumulative risk of being diagnosed with cervical cancer 
before the age of 75 years in these countries is 1.9%. In more developed countries cervical 
cancer is responsible for 3% of all female cancers, and the cumulative risk at the age of 75 years 
is 0.9% (Figure 1.1).1-2 
The mortality rates are substantially lower. The global age-standardised mortality rate 
(ASMR) is 7.8 per 100,000 women, with a total of 274,967 women who died of the consequences 
of cervical cancer in 2008. These rates vary between 9.7 per 100,000 in developing countries, 
being approximately 55% of the women diagnosed, and 3.2 per 100,000 in developed countries, 
representing roughly 36% of the diagnosed group.1-2 Globally, cervical cancer is the fourth most 
common cause of cancer-related death in women, however, for women aged between 15 and 
44 years it ranks second.1  
The most important factor that influences the observed trends in incidence and mortality 
rates is structural cervical cancer screening, which results in earlier detection of cervical cancer 
and consequently to detection of this disease in lower stages with better survival.3
The Netherlands is a country with an effective screening programme 4-5 (see paragraph 
2.2) and had a declining mortality rate over the last 20 years. The incidence initially decreased 
as well, but seems to have reached its lowest point in 2003 (Figure 1.2).6 Since then the 
number stabilised, and in 2009 707 new cases were diagnosed with an ASIR of 6.0 new cases 
per 100,000 women. The ASMR has been estimated at 1.3 deaths per 100,000 women with a 
< 7.0 7.0 - 12.9 12.9 - 20.3 20.3 - 29.8 29.8 - 56.3
Figure	1.1	World Standard cervical cancer incidences by country (rate per 100,000) [Source: GLOBOCAN 2008].2
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total of 209 women who died in 2009.7-8 In this year, cervical cancer accounted for 2.1% of all 
newly diagnosed malignant tumours in Dutch women and for 1.3% of all cancer-related female 
deaths.7 The 5-year overall survival in the Netherlands is 67%.7
2.  PATHOLOGY AND DETECTION OF CERVICAL 
CANCER
2.1  Cervica l  cancer  and the  transformation zone of  the  cervix
The uterine cervix is the lower part of the uterus and is positioned at the edge between the 
uterus and the vagina. It consists of two parts; the inner part (the cervical canal, i.e. endocervix) 
covered by a single layer of mucus-secreting columnar epithelium and the outer part (ectocervix) 
which is lined by stratified non-keratinizing squamous epithelium. The boundary between 
these two types of epithelium is called the squamo-columnar junction (SCJ). The original 
SCJ is the site at which the columnar epithelium of the cervical canal touches the squamous 
epithelium that covers the ectocervix and vagina at time of birth. Due to hormonal changes 
the border between columnar and squamous epithelium shifts towards the cervix, forming the 
new SCJ. The area between the original and the new SCJ is called the transformation zone (TZ). 
This zone is easily visible on the outer part of the cervix in the majority of women between 20 
and 40 years of age. In post-menopausal women it is often withdrawn into the endocervical 
canal and no longer visible during examination. At the TZ the metaplastic transformation of 
columnar into squamous epithelium occurs. This is a physiological process and arises from the 
Figure	1.2	 World Standardised Incidence and mortality rate of cervical cancer in the Netherlands [Source: 
Netherlands Cancer Registry]. 7
WSR, World Standardised Rate.
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sub-columnar reserve cells. These CK17-positive cells mount up and are able to differentiate 
in both columnar and squamous epithelium.9 As long as the squamous metaplastic process in 
the TZ has not completed, the TZ is assumed to be vulnerable for oncogenic influences, such 
as an infection with high-risk types of the human papillomavirus (hrHPV).10-11 It is assumed that 
especially the reserve cells are susceptible for hrHPV infection. Most of these infections are 
cleared spontaneously, but in about 20% of the cases chromosomal instability with activation 
of oncogenes and inactivation of tumour suppressor genes occurs, leading to the development 
of cervical cancer precursor lesions (cervical intraepithelial neoplasia) and if no intervention is 
performed, finally to cervical cancer in the TZ. These lesions can be identified by colposcopic 
examination and diagnosed by histology.
2 . 2  Detec t ion  o f  cerv ica l  cancer
Cervical cancer is classified into different histological types of which squamous cell carcinomas 
(SCCs), accounting for 80% of all cervical cancers, adeno-squamous and adenocarcinomas 
(ACs), comprising approximately 15%, are the most important. The remaining 5% include rare 
tumours, among which neuro-endocrine carcinomas and clear-cell carcinomas.
SCCs, which derive from squamous cells, are preceded by dysplastic precursor lesions 
characterised by a disturbed epithelial architecture and cellular atypia. In the late 1960s the 
concept of cervical intraepithelial neoplasia (CIN) was introduced, assuming that cervical 
cancer develops from non-invasive premalignant stages.12 CIN lesions were categorised into 
three groups of which CIN1 shows dysplasia in less than one third of the epithelium, CIN2  in two 
third of the epithelium (moderate dysplasia) and CIN3 in more than two third of the epithelium 
(severe dysplasia or carcinoma in situ). Invasive SCC is present when the basal membrane has 
been invaded (Figure 1.3). 
Even without treatment most CIN lesions will regress, but the higher the CIN grade, the less 
often regression occurs. Approximately two third of CIN1 lesions will regress, but only one third 
of CIN3 lesions reverts.13-14 To reflect their relative risk to progress to cervical cancer, CIN2 and 
CIN3 are also called high-grade CIN, whereas CIN1 lesions are called low-grade CIN.14-15 
Less is known about the precursor lesions of ACs. These tumours arise from the glandular 
cells in de endocervix and are often preceded by adenocarcinoma in situ (AIS).16 Due to the 
lack of criteria to define reproducible precursor lesions which can be distinguished from AIS 
16, a classification similar to the squamous precursor lesions has been suggested,17 but not 
established. 
The recognition that cervical cancer develops through different premalignant stages 
(precursor lesions) which can be detected years before cervical cancer appears 10, 15, has 
resulted in the organisation of population-based screening programmes. The ultimate goal of 
population-based screening is to decrease the mortality of cervical cancer. This is achieved by 
early detection and treatment of precursor lesions and early stages of cervical cancer by which 
the development of advanced-stage cervical cancer can be prevented.5
Because the introduction of cervical screening programmes preceded the development 
of randomised controlled trials, screening effectiveness has not been investigated with 
what nowadays is considered the gold standard of scientific evidence.18 Instead the effect of 
screening has been evaluated by tracking incidence and mortality rates over a certain time 
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period. Most of these data showed a positive effect of screening.4-5, 19-22 For all that, in both 
the Netherlands and the United Kingdom (UK) a decreasing cervical cancer incidence was 
already visible before the introduction of screening programmes, possibly due to improved 
sexual hygiene.6, 20 Prerequisites for an effective programme are a high level of participation, 
a sensitive and specific test, availability of an adequate intervention, and adequate follow-up 
examinations after initial detection of an abnormality.10 As can be seen from the decreasing 
incidence and mortality rates in relation to the costs, the Netherlands has, compared to other 
countries, an effective screening programme.4-5 
2 . 2 .1  Cy to log ica l  sc reen ing
Already in the 1940s Dr. Papanicalaou described the relationship between exfoliated cells of 
the vagina and the presence of (precursor lesions of) cervical cancer.23	This finding eventually 
evolved into the cytological smear, also known as PAP-smear, and resulted in the worldwide 
implementation of cytology-based screening as a diagnostic tool to identify cervical disease. 
By cytomorphologic examination of the obtained squamous and columnar epithelial cells from 
the TZ, cervical lesions may be detected.24 The original PAP-classification ranges from PAP0 
to PAP5 and reads as follows: PAP0 inadequate specimen, PAP1 normal cytomorphology, PAP2 
borderline dyskaryosis, PAP3 mild-severe dyskaryosis, (in the Netherlands divided in PAP3a1 
mild dyskaryosis, PAP3a2 moderate dyskaryosis and PAP3b severe dyskaryosis), PAP4 suspect of 
carcinoma in situ and PAP5 suspect of at least micro-invasive cancer. Women with an abnormal 
test result (i.e. ≥PAP2) are followed in the screening programme more closely by either repeat 
cytology or referral for colpscopy than women with normal cytology as they have an increased 
Figure	1.3	 Schematic representation of histological classification during the development of cervical cancer 
[Adapted from: Snijders et al 2006].15
CIN, Cervical Intraepithelial Neoplasia; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade 
squamous intraepithelial lesion.
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risk of developing cervical cancer. This PAP-classification has been improved in the past years 
and has resulted in the Bethesda 2001 classification that is currently used in most countries.25 In 
the Netherlands the CISOE-A classification (in Dutch KOPAC-B) is in use, which has resulted in 
a high quality and reproducibility of cytological results (see also paragraph 3.1 and Table 1.1).26 
Although effective, cytological screening has several shortcomings. The first weakness is 
the low sensitivity to detect cervical lesions. Reasons for this limited sensitivity are sampling 
errors in which abnormal cells are not obtained from the cervix, and reading errors in which the 
few abnormal cells are not identified between the magnitudes of normal cells.24, 27-28 Cytology 
has a sensitivity of approximately 65%29 (range 30-87%).27-28 To limit the high number of false 
negative test results, repeated testing over a (relatively) short interval is required.28 This enables 
the detection of abnormalities during the relatively long interval between the first cytological 
abnormalities and the development of cervical cancer (see paragraph 2.3). The second 
weakness is the moderate specificity of approximately 95%29 (range 86-100%).27-28 This results 
in a substantial number of women with minor abnormalities who do not harbour underlying 
high-grade disease. The third weakness is that although cytological screening has resulted in 
a decline in incidence and mortality of the most common type of cervical cancer, SCCs, the 
incidence of ACs has been stable or has even increased3, 10, 16, suggesting that cytology fails to 
detect ACs and its precursors in an efficient manner. Finally, the interpretation of cytology is 
subjective and therefore has a moderate reproducibility.27 
While cytological screening has proven its efficiency, the search for improvement is a 
continuing story. Previous enhancements in cytological screening have been the introduction 
of the endocervical brush, which has improved sampling and has lead to a better identification 
of premalignant lesions30, and liquid-based cytology, which did not result in a higher sensitivity, 
but did lower the number of inadequate smears31-32 and has the possibility to use excess material 
for additional molecular testing.33
2 . 2 . 2  Human  pap i l lomavi rus  test ing
2 . 2 . 2 .1  C lass i f i cat ion  of  HPV
Human papillomaviruses (HPVs) are non-enveloped, double–stranded DNA viruses of 
approximately 8000 base pairs and belong to the family of Papillomaviridae.34 The viral genome 
can be subdivided in an early (E) encoding region, containing 6 genes (E1, E2, E4, E5, E6, 
and E7) and a late (L) encoding region, containing 2 (L1 and L2) genes. Of the early genes, 
two regulatory proteins (E1 and E2) modulate replication and transcription, while oncogenic 
proteins E5, E6, and E7, alter the transformation process which results in the malignant alteration 
of cervical cells.34 The E6 and E7 proteins interfere with the hosts tumour-suppressor genes 
p53 and Rb, deregulate cell-cycle and apoptosis control and thereby induce genetic instability 
(see paragraph 2.3.1). The two late genes encode two structural proteins composing the major 
(L1) and minor (L2) capsid proteins.34 Nowadays over 120 different HPV types are identified. 
Since the L1 gene is the most conserved gene within the genome, it has (together with E6 and 
E7) been used for classification of new HPV types, subtypes and variants.34 A new type has a 
maximum overlap of 90% with a known HPV type, a subtype has a similarity between 90 and 
98%, and if more than 98% is shared, it is considered a variant.34 
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HPVs can be divided in cutaneous and mucosal types based on their privileged site of 
infection. While cutaneous HPV types primarily infect the skin, the approximately 40 different 
mucosal types infect the mucosal epithelium of the ano-genital, respiratory and upper-
digestive tract.34 The latter comprise low-risk HPV types (lrHPV), associated with benign 
conditions as genital warts (condylomata accuminata), and high-risk, or oncogenic, types 
(hrHPV), associated with (pre)malignant lesions.35 According to the World Health Organization 
the following HPV types are oncogenic: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66.36 In 
addition HPV type 26, 53, 68, 73 and 82 are considered probably carcinogenic.35 Not all hrHPV 
types have the same risk of inducing cervical lesions. HPV16 is most frequently found in both 
AC and SCC, and accounts for over half of all cases of cervical cancer. HPV18 is more associated 
with AC, and responsible for approximately 20% of all cervical cancer cases.10, 37 HrHPV does not 
only play a causal role in the development of cervical cancer; but also in the majority of vaginal 
and anal cancers. In addition, a fraction of cancers of the vulva, penis, and SCCs of head and 
neck, including oral cavity, larynx and pharynx are caused by hrHPV.35-37
2 . 2 . 2 . 2  HPV  detect ion  methods
Because HPVs cannot be cultured efficiently and the clinical performance of serological 
assays is poor, alternative methods have been developed to detect and type these viruses.38-39 
Nowadays, diagnosis relies on the molecular detection of viral nucleic acids, particularly DNA 
and is based on either liquid hybridization or polymerase chain reactions (PCR).39
The first method involves hybridization of the target HPV DNA to labelled RNA probes in 
situ.39-40 The commercially available Hybrid Capture 2 system (HC2, Digene Corporation, USA) 
is based on this principle. This test, approved by the Food and Drug Administration (FDA), uses 
a cocktail of probes and can only identify samples as positive or negative for 13 hrHPV types, 
without genotyping. The detected signal is expressed in relative light units and is proportional 
to the amount of HPV DNA present in the specimen (viral load). The cut-off can therefore be 
used to inform about viral load on a semi-quantative basis.
The second method is based on PCR amplification of the target HPV DNA directed by 
primers that bind to the highly conserved regions within the L1 gene of all mucosal HPV types.39 
As several different genotypes may be the cause of cancer, so-called consensus or general 
primer PCR systems have been developed that test up to 37 different types concurrently.41 
Examples of these PCR-based consensus primers are GP5+/6+42-43,  PGMY09/11 44, and SPF10 38, of 
which only the GP5+/6+ test has been clinically validated. The read-out systems for detecting 
the PCR product comprise enzyme immuno-assays, which are most often used for the detection 
of hrHPV types in general43 and reverse line blot assays45 or line probe assays46 which identify 
individual genotypes.39 
The sensitivity of detecting HPV is higher in PCR methods than in liquid hybridization 
tests as the HC2 test, however not in all situations the test with the highest sensitivity should 
be used.41 Considering analytical purposes, needed to identify the epidemiological burden 
of HPV infections in the monitoring of vaccination studies, the sensitivity should be as high 
as possible. Analytical sensitivity refers to the proportion of HPV-positive women who are 
correctly identified by a positive test result. The SPF10 test has a very high analytical sensitivity.47 
In general, very low levels of HPV do not reflect a clinically meaningful infection, i.e. associated 
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with a high-grade CIN lesion or cervical cancer, but rather a transient or latent infection and 
a distinction between relevant and irrelevant infections should be made. Clinical sensitivity 
refers to the proportion of women with (pre)malignant disease who are correctly identified 
by a positive test result. Testing with a too sensitive test will result in a low positive predictive 
value and in the diagnosis of more irrelevant infections, which could result in an excess of 
follow-up tests, referrals and treatment. It is evident that a HPV test in a clinical setting should 
correctly identify all women at risk of developing pre-existent (pre)malignant cervical disease 
and preferably gives a negative test result for women not at risk. In order to be of clinical value, 
a HPV test should balance between a high clinical sensitivity as well as a high clinical specificity. 
In this, the HC2 and GP5+/6+ have the best results.41, 47 
2 . 2 . 2 . 3  HPV  in fect ion
Since the nineteenth century it has already been recognised that cervical cancer is associated 
with sexual activity. In the 1970s, Harald zur Hausen identified HPV as the causal factor in cervical 
cancer, because the epidemiological pattern was similar to that of condylomata accuminata, 
which were known to be HPV related.48 Since the late 1990s, epidemiological and biological data 
have demonstrated without a doubt that HPV is the main causative agent for cervical cancer, 
being necessary for the development, maintenance and progression of (precursor lesions of) 
cervical cancer.10, 37, 49 Therefore, HPV can be detected in almost all cervical SCCs 49 and in 94% 
to 100% of all  ACs 37, 50, and this resulted in the presumption that incorporation of HPV testing 
in screening programmes might better identify women at risk of developing cervical disease.37 
hrHPV is a common sexually transmitted virus and the majority of both men and women are 
infected shortly after starting sexual intercourse.51-52 Its prevalence in young women in Western 
countries aged 20-25 years with normal cytology is approximately 20%, and diminishes with 
increasing age to approximately 5% in women aged 30 years and above.54 This decrease could 
be attributed to the acquisition of type-specific immunity during life.53 In women with CIN the 
prevalence of hrHPV is even higher, and varies between roughly 40% in women with CIN1 to 
80% in women with CIN3 and almost 100% in women diagnosed with invasive carcinoma.49 It is 
assumed that the life-time risk to acquire a genital HPV infection is at least 80%.55 An increasing 
number of sexual partners, increasing promiscuity of male partners51 53, lack of condom use56, 
a younger age at first intercourse, and smoking51 53 are associated with an augmented risk of 
infection. At the transformation zone viral particles gain access to the epithelial basal layer via 
tiny tears to the mucosa and enter the basal cells.11, 35 The attachment of the virus to the host cell 
can be prevented by neutralizing antibodies against HPV, which can be elicited by prophylactic 
HPV vaccination.57
2 . 3 	Cervica l   carc inogenes is
2 . 3 .1  hrHPV re lated  carc inogenes is
Cervical cancer is a multistep process in which hrHPV persistence reflects the first step, but 
many other steps are required to result in invasive cancer (Figure 1.4).10, 15 
Despite the fact that the human immune system is not easily alerted by the virus, 
approximately 80% of hrHPV infections will be cleared by the hosts’ immune system within 1-2 
years after exposure.57-61 HPV evades the immune system through several mechanisms. One of 
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these is that HPV replication and release takes place in cells (keratinocytes) that are already 
programmed to die. By delaying nuclear condensation in the differentiating keratinocytes, 
koilocytes are formed, and viral replication is permitted. As basal cells further differentiate 
to produce the protective barrier normally provided by the epithelial cells, and the cells 
disintegrate, new and infectious viral particles are formed and released in the environment.15, 57 
This productive infection does not necessarily reflect a premalignant stage.11 Another evasion 
mechanism is that Langerhans cells, the antigen presenting cells of squamous epithelium, are 
not activated by uptake of HPV capsids. As a result the Langerhans cells fail to migrate to the 
draining lymph node to process and present the HPV antigens to naive T-cells, and thereby 
delaying the priming of the cellular immune response.57 
As a second step, the persistent infection has to induce the development of a premalignant 
lesion. Although the process between first infection and evidence of a premalignant lesion usually 
requires many years, time can be as short as 2 to 3 years.15, 61-62 Of all HPV-infected women only 
1-2% will have a transforming infection37, which could ultimately result in invasive cancer.13, 15 An 
infection changes from a productive into a transforming infection when the viral DNA integrates 
into the cellular genome of the host, characterised by methylation of E2 binding sites and 
expression of viral oncoproteins E6 and E7 in dividing basal cells. This results in genetic instability 
leading to additional genetic changes with an increased expression of E6 and E7 proteins.15 37 These 
oncogenes suppress the hosts tumour suppressor genes p53 and Rb11, 15, 37 which are responsible 
for cell-cycle control and apoptosis by methylation of their promoter regions.63-64 
Ultimately this constant over-expression of viral proteins E6 and E7 will, together with 
additional genetic alterations lead to immortalisation and invasive growth: invasive cancer.15 
This final step takes on average 10-12 years.15 
Only just a minority of precursor lesions will, if left untreated, eventually develop into 
invasive disease. While HPV infections are frequently found in sexually active women, cervical 
Figure	1.4	 Progression model of cervical cancer  [Adapted from: Snijders et al 2006].15
CIN, Cervical Intraepithelial Neoplasia; HPV, Human papillomavirus.
a  Activation of oncogenes, loss of tumour suppressor gene function.
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cancers are relatively rare, and for that reason should be considered as an uncommon 
complication of a HPV infection.65
2 . 3 . 2  Non  HPV-re lated  carc inogenes is
As stated previously, hrHPV can be detected in almost all cases of cervical cancer37, 49, however 
in a few rarely occurring subgroups of ACs the causal relationship between HPV and invasive 
cancer has not (yet) been established.66-67 In for instance minimal deviation carcinomas and 
clear-cell adenocarcinomas (CCACs) other factors may be involved. Approximately 60% of all 
CCACs are associated with prenatal exposure to diethylstilbestrol (DES).68 In the remaining 40% 
repression of the INK4a-ARF locus, mutations, or deletions in tumour suppressor genes p53 or 
Rb may be involved, but the exact aetiology is still unknown.  
3  PREVENTION OF  CERVICAL  CANCER
3.1  P re - t reatment
3.1 .1  Screen ing  programme in  the  Nether lands 
In the 1970s cytology-based screening in the Netherlands started with a pilot study in three 
regions (Rotterdam, Nijmegen and Utrecht) covering 24% of the Dutch female population. 
However, prior to disclosure of the results of this pilot study, further screening projects 
were developed. In 1989 a nationwide 3-yearly screening programme started for women 
aged 35-54 years. In the 1990s evidence pointed towards a suboptimal performance of the 
screening programme, in terms of both organisation and efficiency.69 Therefore, the screening 
programme was revised in 1996: the screening interval was lengthened to 5 years and the age 
range broadened to 30-60 years.70 This resulted in increased coverage and efficiency and a 
decrease in the number of smears taken outside the screening programme (opportunistic 
screening).4 Also a descriptive extension was added to the PAP classification, CISOE-A (in 
Dutch KOPAC-B).26, 70 This increased the reproducibility of different diagnoses and lead to more 
strict criteria for a PAP2 diagnosis, which resulted in a decrease of PAP2 diagnoses from 10% in 
1990 to 2% in 2000.26 In the CISOE-A classification 5 items are scored: C for Composition, I for 
Inflammation, S for Squamous epithelium, O for Other abnormalities and endometrium, and E 
for Endo-cervical columnar epithelium. The A stands for adequacy of the smear. The S, O, and 
E are the only parameters specifying the smear classification as used in other nomenclatures 
concerning cytological pathology. The CISOE-A classification can be easily translated in 
classifications used in other countries (Table 1.1).26 
Nowadays approximately 800,000 Dutch women are annually invited for the population-
based screening programme.33 The attendance rate is 65% and the coverage, which is the 
proportion of women who had a smear taken in the preceding 5 years, is 77%.4 To increase 
the coverage of the screening programme, self-sampling seems a good procedure.33, 71-72 Over 
half of all invasive cancers arise in women who are not adequately screened, and increase of 
the participation rate is therefore desirable.73 Women with normal cytology (PAP1), comprising 
96.5% of all screened women, are recalled at the subsequent screening round after 5 years.
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3.1 . 2  Women wi th  abnormal  cy to logy
In the Dutch screening programme approximately 3.5% of the women have an abnormal 
cytological test result (≥PAP2, in CISOE-A: ≥S2, ≥O3, and/or ≥E3).33, 74 
In 2.5% (n=12.500) of screened women these results are borderline or mild dysplasia (BMD, 
similar to PAP2 and PAP3a1, CISOE-A: S2-4, O3, E3-5).33, 75 As the vast majority of women with 
BMD results have no underlying high-grade cervical lesion, but will regress over time, they 
are not directly referred to a gynaecologist as this would result in substantial over-diagnosis 
and overtreatment.13, 59, 74, 76 However, the risk of developing invasive cancer in women with 
BMD results is not insignificant: approximately 0.2% of them will develop cervical cancer 
within 24 months.77 Therefore repeat cytology after 6 and 18 months is recommended.26, 74, 78 
Approximately one-third of the women with BMD are referred for colposcopic examination, 
because the abnormality persists or progresses at either of these repeat visits.26 When the test 
result is normal at 6 and 18 months, women are not recalled until the next screening round.26, 79
Besides triaging women with BMD by cytology, triaging by hrHPV is also possible.58, 74, 80-85 
Since 2006, the Netherlands Society of Pathology (NVVP) recommends an additional HPV test 
in the six month follow-up visit of women with BMD.86 Women with a repeat smear of BMD and 
testing positive for hrHPV are referred to a gynaecologist, while those with a negative hrHPV 
test will get a repeat smear 12 months after the first repeat test (Figure 1.5).
Approximately 1% of the women in the screening programme (n=3500) has a test result of 
moderate dyskaryosis or worse (>BMD, similar to ≥PAP3a2, CISOE-A: ≥S5, ≥O4, and/or ≥E6).4 These 
women have an increased risk of (pre)malignant disease and are referred to the gynaecologist 
for a colposcopic examination.78-79 
3.1 . 3  Co lposcopy
Colposcopy was first described in 1925 by Dr. Hinselmann, correlating visual findings at 
colposcopy with histopathology.87 Nowadays, colposcopy is, in combination with cytology 
and histology, well established for the detection of premalignant lesions. A colposcope has 
Table	1.1	Terminologies in use for classifying cervical cytology. [Adapted from: Bulk et al 2006 and Bulkmans et al 2004] 
26, 78
CISOE-A C0
S1,E1-2, 
O1-2
S2-3, O3, E3 S4, E4-5 S5, O4-5 S6,O6,E6 S7,E7
S8-9, O7-8, 
E9
PAP PAP0 PAP1 PAP2 PAP3a1 PAP3a2 PAP3b PAP4 PAP5
Description Inadequate normal Borderline Mild Moderate Severe 
Carcinoma 
in situ
Carcinoma
BETHESDA  
2001
Unsatisfactory 
for evaluation
negative Atrophy
ASC-H
HSIL SCC
ASC-US LSIL
AGC AGC favour neoplastic AIS AC
CISOE-A, C composition, I inflammation, S squamous epithelium, O Other abnormalities and endometrium, and E 
endo-cervical columnar epithelium; ASC-H, atypical squamous cells cannot exclude HSIL; ASCUS, atypical squamous 
cells of undetermined significance; AGC, atypical glandular cells; LSIL, low grade squamous intraepithelial lesion; HSIL, 
high grade squamous intraepithelial lesion; AIS, endocervical adenocarcinoma in situ; SCC, squamous cell carcinoma; 
AC, adenocarcinoma
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6-40 fold stereoscopic magnification and allows visualisation of the microscopic changes of 
the cervix after application of an acetic acid solution (3-5%). This solution causes a reversible 
coagulation of the nuclear proteins in cells, resulting in a white discoloration and swelling 
of columnar and abnormal epithelium. The colposcopist determines whether the entire 
transformation zone can be visualised (satisfactory) or not (unsatisfactory), and also whether 
lesions are present. The most abnormal area is identified to perform a directed biopsy for histo-
pathological diagnosis.   
Figure	1.5	 Flowchart for the follow-up of women with BMD cytology in the Netherlands. [Adapted from: Van 
Kemenade et al 2007].85
HPV, high-risk type of human papillomavirus; PBS, population-based screening.
a  If cytology result PAP1 return to PBS, all other results (≥PAP2) referral for colposcopic examination.
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Colposcopy has several limitations. The first restriction is that the choice of biopsy site 
remains subjective and is hampered by the suboptimal correlation between visual changes 
and disease severity.88-89 A second restriction is that the prediction of disease is related to the 
experience and skill of the colposcopist.90 Inter-observer variation is moderate, but levels of 
agreement increase as cervical lesions become more severe.90 These two restrictions result 
in a modest sensitivity of only 55% to distinguish high-grade from low-grade lesions.88 As a 
consequence of this inaccuracy, all detected acetowhite lesions should be assessed with 
biopsy.91 A final restriction is that a diagnostic procedure, such as endocervical curettage, is 
required when the colposcopy is unsatisfactory.90 This is done to avoid unnecessary treatment 
as well as to rule out endocervical carcinoma. Therefore, trained colposcopists are of the 
utmost importance in an effective screening programme.
3. 2  Treatment
Depending on the histology results of the biopsies taken at colposcopy treatment is performed. 
A conservative approach is recommended for women diagnosed with CIN1, as the majority of 
these lesions will regress. Follow-up of these women consists of a cytological smear every year, 
until there have been at least two consecutive normal smears.
Each year approximately 5000 women in the Netherlands are diagnosed with high-grade 
cervical disease (CIN2, CIN3, or AIS) and treated according to national guidelines.79 The 
presence of a high-grade lesion indicates that the entire transformation zone (TZ) is at risk and 
therefore, the total TZ is treated.10 The type of treatment needed depends on the severity and 
extension of the lesion, also taking into consideration the patients age and potential child wish. 
Nowadays, the most popular procedure is the large loop excision of the transformation zone 
(LLETZ). Advantages of this method are the possibility to perform this procedure under local 
anaesthesia at the outpatient clinic, and to examine the removed tissue histologically. When 
more extended tissue has to be removed (e.g. AIS, or suspected micro-invasive carcinoma) a 
cold-knife or laser conisation is most often performed. Other procedures include cryotherapy, 
which has the disadvantage that the tissue is destroyed and may not be examined, and more 
extensive operations such as trachelectomy and hysterectomy.
3. 3  Post- t reatment
Despite close surveillance, women treated for premalignant cervical disease have a risk of 
approximately 10%82 to be diagnosed residual or recurrent high-grade disease.82, 92-93 Treated 
women are therefore subject to close surveillance. Between countries, the guidelines vary 
greatly in length and intensity of follow-up.79, 94-95
3. 3 .1  Current  post- t reatment  gu ide l ines  in  the  Nether lands
After treatment for a high-grade cervical lesion, women in the Netherlands are followed-up by 
cervical cytology 6, 12 and 24 months after treatment. Once three consecutive negative smears 
are found, women return to the regular screening programme.79 Women diagnosed with AIS 
have a higher risk of multifocal disease and are more difficult to follow-up as their lesion is 
located on the endocervix. Therefore these women remain are under closer surveillance for at 
least 5 years.79
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3. 3 . 2  A l ternat ive  post- t reatment  a lgor i thms
Studies have shown that successful treatment of high-grade CIN is associated with hrHPV 
elimination.96-97 Because hrHPV persistence is necessary in the development of post-treatment 
high-grade disease, incorporating hrHPV testing in post-treatment surveillance could enhance 
the identification of women at risk of being diagnosed with residual and/or recurrent disease.82, 
92, 97-99 Combined testing of hrHPV and cytology has a very high negative predictive value 
(>99%), so women who test negative for both tests during follow-up may be monitored less 
intensively.92, 97-99 
4  A IM AND OuTLINE  OF  THIS  THES IS
The search for the perfect instrument to prevent cervical cancer is a continuing process. 
Although the causal link between hrHPV and most types of cervical cancer has been proven 
indisputably, this association has not (yet) been established in some rare subgroups of cervical 
adenocarcinoma. In Chapter	2 we summarize the published literature and add new information 
on the association between the relatively rare clear-cell adenocarcinoma (CCAC) and hrHPV.
The second part of this thesis focuses on the risk-assessment of women with abnormal 
cytological test results and women treated for high-grade cervical lesions. Many studies 
describe the follow-up of women with abnormal cytological test results up to 5 years after 
diagnosis, studies concerning the long-term follow-up of these women are rarely found. In 
Chapter	3 a cohort of women with abnormal cytological test results is described with a follow-
up of up to 20 years. The risk of developing CIN2+ lesions in these women is assessed by 
comparing different test result combinations of cytology and hrHPV testing.
Women treated for high-grade cervical lesions are closely monitored as their risk of 
developing residual and/or recurrent disease is increased. As the risk of (unnecessary) treatment 
and thereby cervical damage, increases by more frequent monitoring due to false positive test 
results, it is of the utmost importance to determine the most optimal surveillance strategy for 
these women. For this reason we have followed a cohort of women treated for high-grade 
cervical disease for up to 20 years and compared different test result combinations of cytology 
and hrHPV-testing in assessing the risk of developing post-treatment disease (Chapter	4.1). In 
addition we systematically reviewed all literature published between 2003 and 2011 to determine 
whether hrHPV testing should be incorporated in post-treatment testing (Chapter	4.2). 
The general discussion (Chapter	5) summarizes the findings of this thesis and discusses 
possible future prospects and clinical consequences.
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Introduct ion 
Over 90% of all cervical adenocarcinoma are caused by a transforming infection with a high-risk 
type of the human papillomavirus (hrHPV). Previous studies demonstrated that the association 
between hrHPV positivity and cervical clear-cell adenocarcinoma (CCAC) varies between 0% 
and 100%. As approximately 60% of all CCAC are associated with intra-uterine diethylstilbestrol 
(DES) exposure, we determined in a cohort of both DES-exposed and DES-unexposed women 
the prevalence of hrHPV infections, and the potential etiological role of hrHPV by additional 
analysis of p16INK4a and p53 expression. 
Methods
Representative slides of 28 women diagnosed with CCAC were tested for hrHPV by two PCR 
methods (the clinically validated GP5+/6+ PCR and the very sensitive SPF
10
PCR/LiPA
25
). Fifteen 
women were DES-exposed, 10 unexposed and of 3 women DES-exposure was unknown. 
Twenty-one cases with sufficient material were immuno-histochemically stained for p16INK4a 
and p53. 
Resu l ts
Seven tumours, of which four DES-exposed and two DES-unexposed, tested positive for hrHPV 
with GP5+/6+ PCR. Thirteen tumours, of which five DES-exposed and seven DES-unexposed, 
tested positive with SPF
10
PCR/LiPA
25
. In one woman with unknown exposure, a CCAC tested 
positive in both assays. Only three cases, none in DES-exposed women, and all positive with 
both hrHPV assays, revealed diffuse p16INK4a immuno-staining and weak p53 staining as well, 
supporting indisputable hrHPV involvement.
Discuss ion
Although the prevalence of hrHPV was high, only two DES-unrelated CCAC (25%) and one 
tumour in a woman with unknown exposure could be attributed to hrHPV.  
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INTRODuCTION
Clear cell adenocarcinomas of the cervix (CCAC) are relatively rare tumours of the lower genital 
tract and are characterized by abundant clear cytoplasm and hobnail cells.1-2 CCAC have a 
bimodal age distribution, with one peak in the early twenties and another after menopause.3-4 
In 1971, intrauterine exposure to the non-steroid oestrogen diethylstilbestrol (DES), used 
between 1938 and 1978 to prevent miscarriage and other pregnancy-related problems 5, was 
found to be associated with CCAC.6 DES-exposed women have a 40-fold increased risk of 
developing CCAC, resulting in a cumulative incidence of 0.1-0.2%.7-8 As this tumour is still very 
rare in DES-exposed women, DES is suggested to be an incomplete carcinogen.7 Most CCAC 
are found at a relatively low stage and therefore have a good prognosis with a 5-year survival 
rate of 90%.3-4, 9 Although 60% of CCAC are detected in DES-exposed women, 40% develop 
in DES-unexposed women, indicating the involvement of alternative etiological factors.2, 4, 7, 10 
A factor of interest might be a transforming infection with a high-risk human 
papillomavirus (hrHPV) type, the key causative factor in almost all cervical squamous cell- and 
adenocarcinomas.11-13 Transformation is provoked by inactivation of tumour-suppressor proteins 
by viral oncoproteins E6 and E7.14-15 The E6-oncoprotein degrades p53 and can thereby block 
p53-mediated apoptosis. The E7-oncoprotein interferes with cell-cycle control by blocking 
retinoblastoma (Rb) (Figure 2.1), ultimately leading to immortalization and invasive growth.14-
15 As a consequence, hrHPV-induced cancers are generally characterized by absence of p53 
whereas cancers without hrHPV often display an increase in p53 protein reflecting stabilization 
caused by mutations in this gene.13-16 In addition, hrHPV-induced cancers are characterized by 
over-expression of p16INK4a 13-15, 17 most likely reflecting an oncogenes senescence-like response 
triggered by E718, but functionally ineffective because Rb is blocked downstream in the 
pathway (Figure 2.1). HrHPV-positive tumours without these characteristics reflect transient, 
Figure	2.1	Simplified scheme of hrHPV-mediated carcinogenesis effecting Rb and p53 activity.
HrHPV-E7 degrades Rb, which results in inhibiting the cell cycle arrest, and triggers over-expression of p16INK4a 
.14,15, 18 HrHPV E6 degrades p53 leading to a block of p53-mediated apoptosis and cell cycle arrest. 14,15
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sometimes productive, infections which are commonly found in the general population. Only 
few studies have explored the association between hrHPV and CCAC (Table 2.1). In these small 
studies hrHPV positivity varied between 0% and 100%, thereby hampering any conclusion to 
be made about its potential causal role.1, 16, 19-28 Only two studies provided information about 
immuno-histochemical staining. In one study the inverse relation between hrHPV presence 
and p53 presence was displayed in 11 CCAC16, the other showed that extensive p16INK4a staining 
was absent in 3 CCAC.24  
The aim of this study was to determine in both DES-exposed and DES-unexposed women 
whether hrHPV infections present in CCAC could be etiologically involved, or rather represent 
non-transforming infections. Therefore, we studied tissue specimens for the presence of 
hrHPV DNA and for the expression of p16INK4a and p53.
MATERIALS  AND METHODS 
Tumour  spec imens
Twenty-eight paraffin-embedded CCAC samples registered in the Central Netherlands Registry 
(CNR) for CCAC were collected from four university medical centres and reviewed by an expert 
in gynaecologic pathology (JB). Of these samples, diagnosed between 1975 and 2005, fifteen 
were FIGO stage 1, 12 stage 2, and one stage 3. Follow-up varied between 14 and 405 months 
Table	2.1	Summary of hrHPV detection in CCAC.
Study Year Country Primer n
β-globin hrHPV
DESpresent present 16 18
Other	hrHPV	
types
Milde–Langosch25 1993 Germany MY09/MY11 1 1 0 ns
Waggoner16 1994 USA L1-concensus 14 11 3 0 0 HPV31 (3x) 9
Duggan21 1995 Canada DBH,  L1 1 1 1 1 0 ns
Tenti28 1996 Italy PCR 3 3 2 0 2 ns
Pirog1 2000 USA SPF10 4 4 0 ns
Ding20 2004 Taiwan ns 1 1 0 0
Stewart27 2006 USA ISH 1 1 0 0
Hadzisejdic23 2007 Croatia E6/E7 consensus 5 5 5 0 2
HPV33, HPVX, 
HPV16/18/33
ns
Chen19 2007 Taiwan ns 1 1 1 0 1 0
Guo22 2009 China Nested PCR 1 1 1 0 1 ns
Nofech-Mozes26 2010 Canada  L1 3 3 2 ns ns 0
Houghton24 2010 Ireland PCR 4 3 0 ns
Total 39 35 15 1 6
This study 2011 Netherlands SPF10, GP5+/6+ 28 28 13 7 2
HPV31, HPV45, 
HPV 51, HPVX
15
hrHPV, high-risk type of the human papillomavirus; DBH, dot-blot-hybridization; PCR, polymerase chain reaction; ISH, 
in situ hybridization; DES, diethylstilbestrol exposition; ns, not stated.
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and depended on date of diagnosis and date of death, or last known visit to the outpatient 
clinic. The total number of women years in our study was 350. During follow-up, five women 
developed recurrent disease, four of them died of progression within 32 months. None of 
these women had a history of DES exposure. Another two women died of unrelated disease, 
respectively 81 and 220 months after diagnosis. Considering the similarities between the total 
CNR cohort and our sample, we believe the latter was representative (Table 2.2).29 
Series of 4-μm sections were cut using a new blade for each tissue sample to prevent 
contamination. Outer sections were used for histological confirmation and immuno-
histochemical assays, while inner sections were collected for DNA extraction and hrHPV 
analyses. Ethical approval was waived, since study material was anonymized according to Dutch 
regulation.30
DES-exposure
Previously, DES exposure was not specified uniformly and varied between a statement 
concerning exposure by mother, daughter, or physician, and confirmation of exposure by 
hospital birth records.3, 8-10, 29 We collected information regarding intra-uterine DES exposure 
from CNR patient files.29 Three categories were distinguished: (1) exposed (confirmation: (a) in 
medical record; or (b) by mother/daughter and clinical signs), (2) unknown (no data available), 
and (3) unexposed ((a) stated in medical record; or (b) DES denial by mother/daughter).
HrHPV test ing
To ensure adequate DNA preparation, all samples were subjected to β-globin PCR. We used 
the primer combination PCO3 and PCO5 to generate a 209 bp product.31 Detection of hrHPV 
was performed by two PCR-based assays; GP5+/6+-PCR and the ultrasensitive SPF
10
PCR/LiPA
25.
32 
The clinically validated GP5+/6+-PCR with enzyme-immuno assay read out uses a cocktail probe 
for 14 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68), according to established 
protocols.33-34 The PCR products of hrHPV-positive women were subsequently genotyped by 
Table	2.2	Baseline characteristics.
Characteristics
Study	cohort	(n=28) CNR	cohort	(n=144)29
median range median range
Age at diagnosis  (years) 29.0 17-54 25.0 8 -54
Follow-up (months) 151 14-405 161 
n % n %
Recurrence 5/28 17.9 34/123 27.6
Deceased 6/28 21.4 32/127 25.2
DES-exposure 15/25a 60.0 76/122 62.3
Tumour FIGO stage 1 15/28 53.6 55/123 44.7
10-years survival (95%CI) 81.2  (66.2-96.2) 77.6 (69.8-85.0)
CNR, Central Netherlands Registry for clear-cell adenocarcinoma; DES, diethylstilbestrol.
a Exclusion of three women with unknown DES-exposure
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reverse line blot hybridization. The SPF
10
PCR/LiPA
25
 (version 1) was performed according to 
specifications of the manufacturer (Labo Bio-Medical Products, Rijswijk, Netherlands) to detect 
and genotype 25 HPV genotypes.35 For both HPV detection assays, samples that were positive 
in the enzyme-immunoassay format, but negative for any specific probe in the genotyping 
format were considered positive for uncharacterized HPV (sub) types or variants (HPVX). 
Immuno-h is tochemist ry  ( IHC)  
Immuno-histochemical staining was performed according to manufacturers’ instructions: 
p16Ink4a (E6H4, MTM-Laboratories, Heidelberg, Germany) and p53 (BP53-12, BioGenex-
Laboratories, San Ramon, USA). 
Sections were deparaffinised and incubated with the primary mouse monoclonal 
antibodies against p16INK4a or p53 after which they were incubated with a secondary biotinylated 
rabbit-anti-mouse bridging antibody followed by incubation with streptavidin-biotinylated 
peroxidase coupled with horse radish peroxidase conjugate. The peroxidase activity was 
detected with DAB (diaminobenzidine; Fluka, Sigma Aldrich, Buchs SG, Switzerland). They were 
then counterstained, washed, dehydrated and coverslipped. For positive controls sections 
from a breast carcinoma were used for p53 and sections from a CIN3 lesion for p16INK4a. The 
negative controls were provided by performing the standard procedure replacing the primary 
antibody with BSA (1% bovine serum albumen).
The immuno-reactivity of p16INK4a and p53 was scored according to the percentage of 
tumour cells that stained positive as follows: no (≤10% cells), weak (>10% but ≤25% cells), 
moderate (>25% but ≤50% cells) and extensive (>50% cells) staining. Intensity of staining was not 
taken into account. All light-microscopic evaluations were scored blinded by two pathologists 
(CM, FS). In cases of discrepancy, slides were reviewed until consensus was reached. 
Stat i s t ica l  ana lys i s
The main outcome of this retrospective cohort study was the number of hrHPV-positive CCAC 
and the number of tumours staining positive for p16INK4a, and/or p53. The relationships between 
various parameters and the outcomes in women with and without intra-uterine DES-exposure 
were evaluated with 2x2 tables, Fisher-Exact, Cox-regression and Mann-Whitney analysis. All 
calculations were performed using SPSS Version 17.0 (SPSS Inc, Chicago Illinois, USA). For all 
tests, the level of significance was set at 0.05.
RESuLTS
DES-exposure
Fifteen women were DES-exposed in utero, 10 were unexposed and of three women DES-
exposition was unknown (Table 2.3). Exposed women developed CCAC at a younger median 
age than unexposed women (21 versus 35 years, p<0.001). Although no difference in tumour 
stage (p=0.23), growth pattern (p=0.09), nuclear atypia (p=0.83), or lymph-vascular invasion 
(p=0.67) could be demonstrated, DES-unexposed women had a worse overall survival (p=0.04, 
Hazard Ratio 0.10, 95%CI 0.01-0.86). 
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Table	2.3	 Characteristics of study population: age at diagnosis and status of human papillomavirus, p16INK4a and 
p53.
Nr
Agea
(years) Yeara DES
hrHPV Immuno-histochemistryb
Putative	
aetiologyGP5+/6+	(type) SPF
10
	(type) p16INK4a	 p53	
1 20 1975 + + (16) + (16) n.m. n.m. DES
2 21 1981 + - - n.m. n.m. DES
3 21 1982 + - + (18) n.m. n.m. DES
4 19 1983 + + (16) + (16) n.m. n.m. DES
5 19 1983 + - - 25 10 DES
6 17 1984 + + (16) + (16) n.m. n.m. DES
7 20 1989 + + (16) + (16) <5 <1 DES
8 21 1989 + - - 25 0 DES
9 19 1990 + - - 50 0 DES
10 27 1990 + - - 10 <5 DES
11 24 1991 + - - 0 <5 DES
12 37 1993 + - - 50 0 DES
13 27 1993 + - - 45 60 DES
14 38 1995 + - - 60 35 DES
15 29 2001 + - - 20 40 DES
16 33 1985 U + (45) + (45) 100 10 hrHPV
17 44 1997 U - - 90 5 unknown
18 41 1997 U - - 90 5 unknown
19 29 1982 - - + (51) 30 0 unknown
20 41 1997 - - + (X) 10 10 unknown
21 36 2000 - - + (16) n.m. n.m. unknown
22 54 2002 - - + (31) 50 60 unknown
23 28 2003 - - + (16) 30 60 unknown
24 34 2004 - + (16) + (16) 100 5 hrHPV
25 30 2005 - + (18) + (18) 100 5 hrHPV
26 33 2000 - - - 50 50 unknown
27 44 2000 - - - n.m. n.m. unknown
28 48 2001 - - - 5 60 unknown
DES, diethylstilbestrol exposure; hrHPV, high-risk type of the human papillomavirus; SPF
10
, SPF
10
PCR/LiPA
25
;
 
n.m, 
no material available; U, DES-exposition unknown; X, HPV infection, unable to type.
a at diagnosis;
b indicated are the percentages of immuno-positive tumour cells.
HrHPV presence
DNA quality was sufficient for all samples. With GP5+/6+ PCR testing seven specimens tested 
hrHPV-positive. Six more tested positive by SPF
10
PCR/LiPA
25
, resulting in 13 (46.4%) positive 
tumours for either or both assays. Amongst hrHPV-positives, HPV16 was the most prevalent type 
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(7/13, 53.8%), followed by HPV18 (2/13, 15.4%). The remaining four tumours all contained a different 
hrHPV type: HPV31, HPV45, HPV51 and HPVX (Table 2.3).  Multiple infections were not found. 
Immuno-h is tochemist ry
Of 21 tumours sufficient material remained for additional IHC. These included specimens of 
10/15 DES-exposed women, of 8/10 unexposed women, and of 3/3 women with unknown DES-
exposure (Figure 2.2). 
Two CCAC of DES-unexposed women (Table 2.3, nr 24, 25) and one CCAC of a woman 
with unknown exposure (Table 2.3, nr 16) displayed characteristics supporting a causal hrHPV 
involvement, i.e. extensive diffuse p16INK4a immuno-staining in all tumour cells, and only weak, 
focal p53 staining. All these cases were positive by GP5+/6+ PCR and SPF
10
PCR/LiPA
25
. These 
three tumours all had a high nuclear mitotic activity and a mainly solid growth pattern (data not 
shown). All other hrHPV-positive cases (Table 2.3, nr 7, 19, 20, 22, 23) displayed a wide variation 
in p53 expression (0%-60% of tumour cells) and at maximum moderate p16INK4a staining (<50% 
of tumour cells). None of the tumours found in DES-exposed women that were analyzed with 
all parameters, showed both hrHPV presence and extensive, diffuse p16INK4a immuno-staining in 
combination with no, or weak, focal p53 staining. 
In three other tumours, one of a DES-exposed woman (Table 2.3, nr 14) and 2 of women with 
unknown exposure (Table 2.3, nr 17, 18) extensive p16INK4a staining in more than 50% of all tumour 
cells was found. However, none of these CCAC tested positive for hrHPV.
None of the hrHPV assays or immuno-histochemical profiles was significantly associated 
with tumour stage, age at diagnosis, or survival rate. Table 2.3 lists the putative aetiology for 
each tumour.
DISCuSS ION 
In a relatively large group of CCAC we showed that hrHPV has a limited role in the carcinogenesis 
of CCAC. Taking into account that in hrHPV-positive women diffuse p16Ink4a staining and absence 
or weak p53 immuno-staining can be seen as a cellular correlate to E6/E7 mRNA expression 
of hrHPV and thus as functional involvement of hrHPV13-14, 16, only three of 28 tumours could 
be attributed to a transforming hrHPV infection. None of these were found in DES-exposed 
women. Interestingly, all these three tumours tested positive in both hrHPV assays (Table 2.3). 
The fact that 3 out of 4 fully analyzable GP5+/6+-PCR positive tumours versus 3 out of 8 fully 
analyzable SPF
10
PCR/LiPA
25
 positives fulfilled the criterion of a clinically meaningful infection 
is in line with the higher specificity of a clinically validated PCR (i.e. GP5+/6+-PCR) for relevant 
disease caused by hrHPV.32, 36 Hence, hrHPV positivity detected solely by SPF
10
PCR/LiPA
25
 most 
likely reflects non-transforming, transient hrHPV infections, which are also characterized by 
the presence of more diverse hrHPV types.
Overall, 60% (15/25) of all analyzed CCAC developed in DES-exposed women.4, 7, 16 The 
estrogenic effects of DES interfere with foetal development resulting in adenosis. This tissue is 
thought to be more susceptible to malignant transformation.4 In DES-exposed women CCAC 
were diagnosed at a younger age than in unexposed women.3-4 Furthermore, these women had 
a better five-year survival.4, 10
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In our study hrHPV was detected in 46.4% (13/28) of all CCAC, similar to the overall 
percentage of 43% (15/35) found in literature (Table 2.1). When limited to DES-unexposed 
women the prevalence increased to 70% (7/10). Although similar to other reported frequencies 
in CCAC 26, 28, this is lower than the prevalence found in common cervical adenocarcinoma.1, 
12 It is unlikely that this reflects deletion of sequences targeted by our PCR assays because of 
viral integration in the host DNA, since in most tumours no sign of viral activity reflected by 
diffuse p16INK4a immuno-staining was found. P16INK4a immuno-staining is now widely considered 
a cellular correlate of the oncogenic expression of E6/E7 mRNA.14, 17, 24, 37  Extensive p16INK4a 
immuno-staining was only found in three hrHPV-negative tumours. This may also reflect 
Figure	 2.2	 Expression of p16INK4a and p53 
in cervical clear-cell adenocarcinoma. 
a shows the typical features of a clear cell 
adenocarcinoma, composed of polygonal 
cells with distinct cell membranes and 
clear cytoplasm (H-E staining). b clear-cell 
adenocarcinoma after staining with p16INK4a, 
note both nuclear and cytoplasmatic 
staining. c p53 staining showing distinct 
nuclear staining in approximately 60% of 
the nuclei.
a
b
c
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undetectable hrHPV with L1-based PCR assays applied 37, however, it is more likely to reflect an 
hrHPV independent mechanism triggering p16INK4a.24
As can be seen from Table 2.1, most previously described CCAC were positive for HPV1819, 
22-23, 28, followed by HPV31.16 In contrast, HPV16 was most commonly found (7/13) in our cohort. 
HPV18 was only found in two CCAC, which was surprising as in most cervical adenocarcinoma 
HPV18 is more13 or equally 1, 11 often found as HPV16. However, 14/28 women in our cohort were 
younger than 30 years at time of diagnosis. Because HPV DNA testing is not very specific under 
the age of 30 38, the frequency of hrHPV-types might have been distorted due to the detection 
of transient hrHPV infections. Indeed, when we considered only the three CCAC with likely 
hrHPV aetiology, HPV16 and HPV18 both occurred in one tumour.
A limitation of our study is that only 21/28 samples enclosed enough material to perform 
immuno-histochemical assays, hampering to draw conclusions about 7 tumours remaining. 
Five of these tumours were positive for hrHPV of which three in both assays (Table 2.3, nr 1, 4, 
6). As IHC could not be performed in these three DES-exposed CCAC, a causal role of hrHPV in 
DES-exposed tumours might have been missed.
A second limitation is the young median age in our cohort. Although consistent with 
previously published data 3, 8, 29 we can only comment on hrHPV-related carcinogenesis 
concerning the first peak in the bimodal age distribution.3-4 
Conc lus ions
In summary, we limited our conclusions to the 21 of 28 fully analyzed CCAC. In none of the 10 
DES-related tumours a causal role of hrHPV could be identified. Overall, three tumours were 
likely caused by a transforming hrHPV infection. Two were found in DES-unexposed women 
(2/8) and one in a women of whom the DES-exposition was unknown (1/3). In the remaining 
8 tumours (6 in DES-unexposed women and 2 in women with an unknown exposure) the 
aetiology remains unclear, leaving room for other, unexplored factors in its carcinogenesis.
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Introduct ion
Many studies have examined the short-term value of high-risk human papillomavirus (hrHPV) 
testing in predicting cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer 
(CIN3+). This study focuses on long-term CIN3+ risk after initial wait and see policy.
Methods
A total of 342 women with abnormal cytology of borderline/mild dyskaryosis (BMD) or worse 
(>BMD), included between 1990 and 1992, were followed-up by cytology and hrHPV-testing 
until 1996 and monitored by cytology thereafter. Primary endpoint was cumulative CIN3+ risk 
by December 2009.  
Resu l ts
Women with BMD had a 5-year CIN3+ risk of 22.5% (95%CI 17.0-29.1) and of 0.7% (0.1-4.5) in the 
subsequent 5 years. HrHPV-negative women with BMD had a 5-year risk of <0.01% (95%CI 0.0-
5.1) and of <0.01% (0.0-5.7) in the following 5 years, while for hrHPV-positive women these risks 
were 37.5% (29.0-46.9) and 1.6% (0.2-9.5), respectively. Women with >BMD had a 5-year risk of 
45.1% (36.4-54.1) and of 3.5% (0.9-12.2) in the subsequent 5 years. HrHPV-negative women with 
>BMD had a 5-year risk of 7.3% (2.0-23.6) and hrHPV-positive women of 56.6% (46.4-66.3).
Discuss ion
Women with BMD have an elevated CIN3+ risk for 5 years only; afterwards their risk is similar 
to the general population. HrHPV-negative women with BMD may return to regular screening 
directly. All other women with ≥BMD should be referred for additional testing and/or colposcopy. 
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INTRODuCTION 
The incidence of cervical cancer has been lowered by the implementation of population-
based screening programs in which women are screened by cytological testing.1-3 However, the 
sensitivity of cytological testing for cervical intraepithelial neoplasia grade 3 or cervical cancer 
(CIN3+) is moderate and compensated for by repetitive screening.4-5 In The Netherlands, an 
abnormal cytological test result is detected in approximately 2-4% of all screened women.3, 6-7 
In most developed countries, women with minor cellular abnormalities of borderline and mild 
dyskaryosis (BMD) will be followed by cytology, and will be referred for colposcopy if the smear 
remains abnormal.3, 6, 8 Women with moderate and severe abnormalities (>BMD) are referred for 
colposcopy.3, 6 However, a substantial proportion of women with abnormal cytology will regress 
or do not harbour clinically meaningful cervical disease and will therefore be unnecessarily 
retested or referred. 
Infection with a high-risk type of human papillomavirus (hrHPV) is the causative agent in 
cervical cancer.9-10 Molecular testing for hrHPV has a higher sensitivity than cytology to detect 
CIN3+.4-5, 8, 11-14 In women with abnormal cytology, studies focus on the additional value of hrHPV 
in triaging women with equivocal or mildly abnormal cytological test results in order to increase 
efficiency of patient management (i.e. referral for colposcopy) and to identify women with an 
increased risk for high-grade CIN. Because most of these studies had a restricted follow-up of 
at maximum six years, little is known on risk profiles with longer periods of follow-up and the 
effect of hrHPV testing in those situations.5, 11, 14-25 Only few studies have reported about a follow-
up period of over 10 years.26-28
In this study we followed a group of women who were diagnosed with an abnormal cytology 
result of ≥BMD for a maximum of 19 years and evaluated their long-term cumulative risk of 
developing CIN3+. Also the value of hrHPV testing for risk assessment was established as well as 
the duration of follow-up needed for women with dyskaryosis.
MATERIALS  AND METHODS  
S tudy  Populat ion
For this cohort study we followed-up women who had participated in a previous study that 
studied the association between the presence of hrHPV and the development of high-grade 
cervical lesions.16 Detailed methods of recruitment and follow-up until 33 months after intake 
have been published previously.16, 29 In short, between June 1990 and December 1992, 353 
women were referred to the colposcopic outpatient clinic (VU University medical centre, 
Amsterdam, The Netherlands) with an abnormal cervical cytology result of mild, moderate 
or severe dyskaryosis. Until December 1996 each participant had been monitored for cervical 
disease every 3-4 months by testing for hrHPV, cytology, and colposcopy. Three expert 
colposcopists assessed serial colpophotographs and gave a consensus impression of the lesion. 
Only when they suspected a CIN3 lesion covering three or more cervical quadrants, or when 
a cervical smear result suspect of cervical cancer was found, a biopsy had been taken. At the 
end of the study in December 1996, all women had a colposcopic examination with mandatory 
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biopsy (median 36 months, range 1-75). Women identified with high-grade disease (CIN2+) 
were treated according to Dutch guidelines. In Figure 3.1 follow-up procedures are depicted 
in a flowchart.
Procedures
Cytology results were originally reported using a classification that predated the currently used 
classification; therefore all cytological referral slides were retrieved from the archives for blind 
review by an expert gynaeco-pathologist (FvK). Dotted slides were scored and dichotomized 
into (≤)BMD, or >BMD. Women of whom no referral slide could be retrieved were excluded from 
this study.
Between December 1996 and December 2009 all women were monitored by cytological 
population-based screening once every 5 years. Interim-colposcopies were performed 
according to national guidelines.30 To complete the data obtained from routine screening, we 
invited all women to visit the outpatient clinic (VU University medical centre) for additional 
cytology and hrHPV testing during 2009 (Figure 3.1). If travel distance was a limitation to 
participate, women were offered the possibility of performing a hrHPV test at home by self-
sampling. These test results are similar to those acquired by a physician.31-32 Women who had 
had a hysterectomy were censored at the date of hysterectomy. 
Two cervical specimens were obtained from women who visited the outpatient clinic 
(Cervex-brush, Rovers Medical Devices, Oss, The Netherlands). The first specimen was 
collected in liquid-based cytology medium (Surepath, Tripath Imaging, Burlington NC, USA), 
cytologically examined, and classified according to the CISOE-A classification, which is easily 
translatable into the Bethesda 2001 classification.7 The second specimen was stored in Universal 
Collection Medium® (Qiagen Corporation, Gaithersburg, MD, USA) for hrHPV testing. Women 
who self-sampled returned their cervicovaginal specimen for hrHPV testing by mail. All hrHPV 
samples were tested with the clinically validated GP5+/6+ PCR with enzyme-immunoassay read-
out using a cocktail probe for 14 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 
68), according to established protocols.33-34 The PCR products of hrHPV-positive women were 
subsequently genotyped by reverse line blot hybridization. Samples that were negative for any 
specific probe in this reverse hybridization assay were considered positive for uncharacterized 
subtypes or variants (HPV X). 
A standard colposcopic assessment was performed when a cytological test was abnormal 
at the threshold of borderline dyskaryosis, or when the hrHPV test was positive (Figure 3.1). 
Biopsies were taken of all suspect lesions. Histological specimens were graded as CIN0 (no 
dysplasia), CIN1, CIN2, CIN3, adenocarcinoma in situ (AIS) or invasive cancer35 and classified 
according to the highest abnormality found in biopsy or treatment specimen. Women who 
developed CIN2+ were treated according to present guidelines but were censored at time of 
treatment. 
In December 2009 the hospital database and the Netherlands nationwide network and 
registry of histopathology and cytopathology (PALGA; Bunnik, The Netherlands) were reviewed 
for all women, irrespective of attendance, to ascertain details of any additional relevant events 
and procedures. Ethical approval was obtained from the Ethics Board of the VU University 
medical centre. All women who attended the outpatient clinic or participated by self-sampling 
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Figure	3.1	 Flowchart of follow-up procedures. 
BMD, borderline or mild dyskaryosis; hrHPV, high-risk type of the human papillomavirus; CIN, Cervical 
Intraepithelial Neoplasia.
a referral for colposcopy when once a cytology result of >BMD, or twice a result of BMD is detected.
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provided additional signed informed consent. The study is registered in the Dutch trial register 
(NTR1470). 
Stat i s t ica l  ana lys i s
In order to report long-term CIN risks in women with dyskaryosis, this study was designed as a 
follow-up of an observational cohort.16 
As the original study was designed such that no interference with natural history would 
occur; a biopsy had only been taken when a colposcopic impression of CIN3 covering three 
or more cervical quadrants was present, or when a cytology result was suspect of cancer. As a 
consequence, the exact time at which CIN3+ lesions had developed was difficult to assess. We 
have calculated the 5-year, 10-year and overall risks until detection of CIN3+ using different 
approaches. In the first approach we equalled the event time to the time of the first abnormal 
cytological result of moderate dyskaryosis or worse. In the second approach the event time 
was equalled to the time of histological diagnosis. As the difference between the risks of these 
approaches were minimal (data not shown), we applied the second approach in further analyses. 
In women without an event, data were right-censored at the date of the last registered test.
The primary endpoint was the cumulative risk of CIN3+. We repeated the calculations with 
CIN2+ as secondary endpoint because treatment of CIN2 is common practice in most western 
countries. Both CIN3+ and CIN2+ included cases of AIS, adenocarcinoma (AC) and squamous 
cell carcinoma (SCC).
The cumulative CIN3+ risk was estimated by Kaplan-Meier analysis for the total group as well 
as for subgroups of different cytological and hrHPV test results at time of referral. In addition 
we repeated the calculations after dichotomising in younger (<30 years) and older (≥30 years) 
women. Differences in cumulative risk curves between subgroups were assessed by log-rank 
tests. 
For women who did not develop high-grade CIN within 6 months after inclusion, we reset 
the time at 6 months to 0 to estimate the value of retesting with cytology, hrHPV or both after 
6 months and the risk of persistent hrHPV infection (log-rank tests). For women who had not 
developed high-grade CIN at 5 years after inclusion, time was reset from 5 years to 0 to estimate 
the CIN3+-risk from 5 years onwards.
By Cox regression we calculated CIN hazard ratios and 95% confidence intervals (CIs) to 
compare different test result combinations. Overall cumulative risks were calculated for 
different hrHPV genotypes to determine whether genotyping has additional value in the follow-
up of women with abnormal cytology, focusing on HPV16. All calculations were performed 
using SPSS (Version 17.0, SPSS Inc., Chicago Illinois, USA). All tests were two-sided and the level 
of significance was set at 0.05.
RESuLTS
Of the original 353 women, 11 (3.1%) were excluded as no referral slide could be retrieved for 
review. For the remaining 342 women (median age 31 years, range 17-54) maximum follow-up 
depended on accrual date and ranged from 17.0 to 19.5 years. The total number of women 
years in our study was 3152. Overall censoring percentages were 13.2% (45/342) at 5 years, 
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21.6% (74/342) at 10 years, and 36.5% (125/342) at 15 years after detection of an abnormal 
cytological test result. During follow-up four women died of unrelated disease, six moved 
abroad, and 23 had a hysterectomy. None of the women had received prophylactic hrHPV 
vaccination.
During follow-up 105 (30.7%) CIN3+ cases were identified. Three were invasive cancers, of 
which two were SCC and one AC; two were AIS and 100 CIN3. CIN2 was diagnosed in another 36 
women. The cumulative risk curve of developing CIN3+ after an abnormal cytological test result 
in our cohort is shown in Figure 3.2. The 5-year CIN3+ risk was 31.1% (95%CI 26.1-36.6) and the 
risk in the next 5 years was 1.6% (0.5-4.9). Of all CIN3+, 96.2% (101/105) were detected within 5 
years of follow-up.
Table 3.1 shows the 5- and 10-year risks of developing CIN3+ in 227 hrHPV-positive women 
(66.4%) and 115 hrHPV-negative women (33.6%). Only three (2.9%) of 105 CIN3+ lesions were 
found in women who were hrHPV negative at baseline. These were all CIN3 lesions. HrHPV-
negative women had a 5-year CIN3+ risk of 1.9% (95%CI 0.5-7.0) and a risk of 1.1% (0.2-6.4) in 
the next 5 years. These risks were 45.1% (95%CI 38.4-52.0) and 2.1% (0.5-7.8), respectively, in 
hrHPV-positive women. Of the hrHPV-positive women 84.6% (192/227) were infected with a 
single hrHPV type, 31 (13.7%) had a double infection and four (1.8%) were infected with three or 
Figure	3.2	 Cumulative risk curve of CIN3+ in 342 women with abnormal cytology (mild to severe dyskaryosis) at 
baseline. 
CIN3+, Cervical Intraepithelial Neoplasia grade 3 or cancer.
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more hrHPV types. All women who developed AIS or invasive cancer had only one hrHPV type: 
both SCC and one AIS contained HPV16, the AC harboured HPV18, and one AIS was positive 
for HPV45. In 93.3% (98/105) of CIN3+ cases, the same hrHPV type was present both in the 
lesion and at baseline, including both AIS, the AC and one SCC. Of one SCC no hrHPV typing 
information was available. 
The most prevalent type was HPV16 (105/227, 46.3%), followed by HPV31 (29/227, 12.8%), 
HPV18 (22/227, 9.7%) and HPV33 (18/227, 7.9%). The CIN3+ risk of women infected with HPV16 
was higher than that of women infected with other hrHPV types (Wald-statistic 6.85, p=0.009). 
The 5-year risk in HPV16-positive women was 56.5% (95%CI 46.5-66.0) and this was 36.5% (27.9-
46.1) in nonHPV16-positive women. The risks in the subsequent 5 years were 0.01% (95%CI 0.0-
10.7) and 3.4% (0.8-12.2), respectively. After stratification in two age categories, we found that 
in younger women (<30 years), HPV16-positive women had a significantly higher CIN3+ risk than 
nonHPV16-positive women (Wald statistic 13.01, p=0.003, Table 3.1). Their 5-year CIN3+ risks 
were 61.5% (95%CI 46.8-74.4) and 19.9% (10.6-34.3), respectively. In older women (≥30 years) 
Table	 3.1	Value of hrHPV testing during follow-up of women with abnormal baseline cytology; 5-year and 
10-year risks.
Baseline At	risk
	CIN3+	 CIN2+
5-year 10-year 5-year 10-year
Risk	
(%) 95%CI
Risk	
(%) 95%CI
Risk	
(%) 95%CI
Risk	
(%) 95%CI
All women 342 31.1 26.1-36.6 32.2 26.9-38.0 38.7 33.6-44.1 41.6 36.2-47.2
HPV negative 115 1.9 0.5-7.0 3.0 0.9-9.2 11.8 7.0-19.2 14.7 9.0-23.1
HPV positive 227 45.1 38.4-52.0 47.0 39.9-54.2 52.3 45.7-58.8 55.2 48.4-61.8
HPV16 105 56.5 46.5-66.0 56.5 46.1-66.3 60.0 50.2-69.1 61.1 51.0-70.3
nonHPV16 122 36.5 27.9-46.1 38.7 29.5-48.8 45.7 37.0-54.7 50.2 41.0-59.3
nonHPV16, 18, 31, 33, 45 61 24.4 14.7-37.7 26.6 16.1-40.6 36.4 25.3-49.2 41.8 29.9-54.7
Age < 30 years HPV positive 104 40.4 30.7-51.0 41.8 31.6-52.8 49.5 39.8-59.3 54.0 43.9-63.8
HPV16 49 61.5 46.8-74.4 61.5 46.2-74.8 65.8 51.4-77.8 58.1 43.5-71.4
nonHPV16 55 19.9 10.6-34.3 22.8 12.3-38.3 35.2 23.6-48.9 41.5 28.8-55.4
Age ≥ 30 years HPV positive 123 51.5 42.5-60.4 51.5 42.1-60.8 55.5 46.6-64.1 56.4 47.2-65.2
HPV16 56 52.1 38.9-65.1 52.1 38.3-65.5 55.2 42.0-67.7 55.2 41.5-68.1
nonHPV16 67 51.1 39.1-63.0 51.1 38.5-63.6 55.7 43.8-67.0 57.3 44.9-68.8
Clearance <6-months a 50 2.2 0.4-12.2 2.2 0.3-13.1 14.6 7.2-27.3 14.6 7.0-28.0
6-month persistence a 166 56.0 45.0-63.7 57.5 49.2-65.4 61.0 53.2-68.2 64.4 56.5-71.6
Persistence HPV16 77 67.2 55.8-76.9 67.2 55.4-77.2 68.4 57.1-77.9 69.9 58.4-79.4
Persistence nonHPV16 89 45.8 35.1-56.9 48.9 37.6-60.4 54.7 44.1-64.9 59.8 48.9-69.8
CIN3+, Cervical Intraepithelial Neoplasia grade 3 and cancer; CIN2+, Cervical Intraepithelial Neoplasia grade 2, 3 
and cancer; 95%CI, 95% confidence interval; HPV, human papillomavirus; 6-month persistence, at baseline and 
at 6 months at least one detected hrHPV type is similar.
a All hrHPV-negative women at baseline and all women with a follow-up of less than 6 months were excluded.
Time to event is set equal to histological diagnosis of CIN3+ or CIN2+ lesion.
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we found no difference in CIN3+ risk between HPV16-positive women and nonHPV16-positive 
women (Wald statistic 0.08, p=0.78). Their respective 5-year risks were 52.1% (95%CI 38.9-65.1) 
and 51.1% (39.1-63.0). 
In women infected with hrHPV types other than HPV16, 18, 31, 33 and/or 45 the CIN3+ risk 
remained 24.4% (95%CI 14.7-37.7) in the first 5 years and was 2.9% (0.5-15.1) in the following 5 
years. These risks were similar for both the age categories.
Women with transient hrHPV infections had a lower CIN3+ risk than women who had a 
persistent 6-month hrHPV infection (Wald-statistic 17.3; p=0.0003). The 5-year CIN3+ risk was 
2.2% (95%CI 0.4-12.2) in women who cleared their infection and 56.0% (48.0-63.7) in women 
with a persistent infection. Within the persistent group, the risk of developing CIN3+ was higher 
in women positive for HPV16 (67.2%, 95%CI 55.8-76.9) than in women in whom other hrHPV 
types persisted (45.8%, 35.1-56.9, Wald-statistic 4.73; p=0.03). 
Women were divided into two groups according to referral cytology; 210 (61.4%) women 
had a smear of BMD and 132 (38.6%) a smear of >BMD. In both these groups the median of 
cytological screens between 1996 and 2009 was 3.0 (range 1-9; p=0.71, Mann-Whitney). 
Border l ine  and  mi ld  dyskaryos i s  (Tab le  3 . 2a)
Forty-seven of 210 (22.4%) women with BMD developed CIN3+. Their 5-year CIN3+-risk was 
22.5% (95%CI 17.0-29.1) and their risk in the subsequent 5 years was 0.7% (0.1-4.5). Immediate 
hrHPV testing clearly stratified these women with regard to cumulative risk (Wald-statistic 11.08, 
p=0.001, Figure 3.3A). A negative hrHPV-test result, present in 84 (40.0%) women, reduced the 
5-year CIN3+ risk to 0.01% (95%CI 0.0-5.1), whereas a positive test result increased this risk to 
37.5% (29.0-46.9). The risks for the subsequent 5 years were 0.01% (95%CI 0.0-5.7) and 1.6% (0.2-
9.5%), respectively. Women positive for HPV16 had a higher CIN3+ risk than women infected 
with other hrHPV types (Wald-statistic 5.60; p=0.02). Their 5-year risk was 49.8% (95%CI 36.2-
63.4) versus 29.8% (18.4-40.2) in women infected with other hrHPV types. The 5-year risk 
remained 26.5% (95%CI 14.1-44.3) in women infected with hrHPV types different from HPV16, 
18, 31, 33 and 45.
The risk of women who tested hrHPV positive at baseline was further stratified by follow-up 
testing after 6 months with either cytology or hrHPV (Wald-statistic 8.51; p=0.004 and 37.38; 
p<0.0001, respectively). 
After women with a follow-up shorter than six months had been excluded, the CIN3+ risk 
of women who complied with the present follow-up algorithm of repeat cytology testing after 
6 months was calculated. Women with normal cytology after 6 months had a 5-year CIN3+ risk 
of 4.9% (95%CI 1.6-13.8), whereas women with an abnormal test result had a risk of 30.9% (23.0-
40.1). Risks in the next 5 years were 0.01% (95%CI 0.0-7.1) and 1.4% (0.2-8.5). 
After stratification for age, results for both age groups were statistically not different, 
although the risks in the younger age group were slightly lower than in the older age group 
(data not shown).
Border l ine  and  mi ld  dyskaryos i s  (Tab le  3 . 2b)
Fifty-eight of 132 (43.9%) women with baseline moderate to severe dyskaryosis developed 
CIN3+ and their risk was 45.1% (95%CI 36.4-54.1) in the first 5 years and 3.5% (0.9-12.2) in the 
57
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Figure	3.3		Cumulative risk curve of CIN3+ in women with borderline to mild dyskaryosis (BMD, n=210, A) and in 
women with moderate to severe dyskaryosis (>BMD, n=132; B) at baseline, according to baseline hrHPV status. 
CIN3+, Cervical Intraepithelial Neoplasia grade 3 or cancer; hrHPV, high-risk type of the human papillomavirus; 
HPV-positive (continuous) women and HPV-negative (dotted) women.
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subsequent 5 years. Also in this group immediate hrHPV testing stratified the CIN3+ risk (Wald-
statistic 12.31, p=0.0005, Figure 3.3B). HrHPV-positive women (76.5%) had a 5-year risk of 56.6% 
(95%CI 46.4-66.3) and this was 2.9% (0.5-15.4) in the subsequent 5 years. The 5-year risk for 
women positive for HPV16 was similar to the risk for nonHPV16-positive women (Wald-statistic 
1.01; p=0.31). Thirty-one (23.5%) women tested hrHPV negative and had a 5-year CIN3+ risk of 
7.3% (95%CI 2.0-23.6) and of 4.2% (0.6-23.2) in the subsequent 5 years. Additional testing after 6 
months with either cytology, hrHPV, or both did not further stratify the risk (Wald statistic 0.07, 
p=0.80; 0.02, 0.90 and 0.009, 0.93, respectively). Also after age stratification no groups could 
be identified with a low enough risk to return to routine screening.
Analyses  w i th  C IN2+  as  endpoint
Results of analyses with CIN2+ as endpoint were similar to those with CIN3+ as endpoint (Tables 
3.1 and 3.2). The 5-year CIN2+ risk for women with abnormal cytology was 38.7% (95%CI 33.6-
44.1) and this risk was 4.7% (2.4-9.0) between 5 and 10 years. Of all 141 CIN2+ lesions, 124 (87.9%) 
were detected in women who were hrHPV positive at baseline. Their 5-year CIN2+ risk was 52.3% 
(95%CI 45.7-58.8) and 6.1% (2.7-13.1) in the next 5 years. HPV16-positive women had a 5-year 
CIN2+ risk (60.0%, 95%CI 50.2-69.1) similar to the risk in women infected with other hrHPV types 
(45.7%, 37.0-54.7, Wald-statistic 3.32; p=0.07). Women who tested hrHPV negative at baseline 
had a 5-year risk of 11.8% (95%CI 7.0-19.2) and a risk of 3.3% (1.1-9.6) in the subsequent 5 years.
The 5-year CIN2+ risk in women with BMD was 31.0% (95%CI 25.0-37.8), their risk in the next 
5 years was 3.0% (1.1-7.8). A negative hrHPV-test result at baseline reduced the 5-year risk to 
9.9% (95%CI 5.1-18.5), whereas a positive test increased the risk to 44.9% (37.1-52.9). HPV16-
positive women had a significantly higher risk than women infected with other hrHPV types 
(55.3%, 95%CI 41.8-68.1 versus 38.7, 28.1-50.5).
The CIN2+-risk in women with >BMD was 51.2% (95%CI 42.6-59.7) in the first 5 years and 
8.4% (3.5-18.8) in the next 5 years. A negative hrHPV test result reduced the 5-year risk to 16.9% 
(95%CI 7.4-34.2) and a positive hrHPV test result increased this risk to 61.4% (51.5-70.4%). HPV16 
had a similar CIN2+ risk as other hrHPV types in women with >BMD (Wald-statistic 0.01; p=0.91).
DISCuSS ION 
This study describes the long-term cumulative risk of developing CIN3+ after detection of 
abnormal cytology. For women with an abnormal smear (≥BMD) the 5-year CIN3+-risk was 31.1% 
and the risk in the next 5 years was 1.6%. We stratified these risks according to referral cytology 
and found that both women with BMD and women with >BMD referral cytology had an increased 
risk of developing CIN3+ within the first 5 years after detection. This risk was twice as high in 
women with >BMD compared with women with BMD (45% versus 22%). In the subsequent 5 
years only for women with >BMD an increased risk (3.5%) remained, while for women referred 
with BMD this risk was with 0.7% similar to that of the general population.6  
Immediate hrHPV testing stratified the CIN3+ risk of women with an abnormal smear 
(≥BMD). Almost all CIN3+ lesions (102/105), including all invasive carcinomas, were found in 
women testing hrHPV positive. Almost half of all hrHPV-positive women were infected with 
HPV16; these women had a significantly higher CIN3+ risk than women infected with other 
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hrHPV types.17, 27-28, 36-37 This risk difference was only found in younger women (<30 years), while in 
older women (≥30 years) the risks between women positive for HPV16 and women positive for 
other hrHPV types were similar. This is in line with another study that found that the mean age 
of women with HPV16-associated cancer was significantly lower than of nonHPV16-associated 
cancer.38 All CIN3+ in HPV16-positive women were identified within 5 years after detection of 
abnormal cytology, while lesions associated with other hrHPV types were also found in the 
5 years hereafter. This suggests that HPV16 has its main oncogenic effect within a shorter 
timeframe and at a younger age than other hrHPV types.38-39 
The CIN3+-risk was lower in women who cleared the virus than in women with persistent 
hrHPV infections, with the highest risks for women with a persistent HPV16 infection.17, 37, 40-41
Women wi th  BMD
In correspondence with another Dutch study36, almost 25% of women with BMD developed 
CIN3+. The majority was diagnosed within the first 5 years, while in the subsequent 5-year 
period their CIN3+ risk was similar to the risk of the general population.2, 6 This implicates that 
women with BMD who did not develop CIN3+ within 5 years may return to routine screening. 
Other studies also found a negligible increase in high-grade CIN cases between 5 and 10 year 
after diagnosis of BMD cytology.26-28 
Meta-analyses concerning women with BMD have found that immediate hrHPV testing 
better identifies women at risk of developing CIN3+ than repeat cytology after 6 months.4, 14 
Our study confirms these findings. Women with baseline BMD and normal cytology after 6 
months (31%) had a 5-year risk of 5%, while this risk was less than 0.1% in women with BMD and 
a negative hrHPV test at baseline (40%). Therefore we support the referral of hrHPV-negative 
women with BMD to routine screening.2, 15, 18, 21, 24 In both these groups the 5-year CIN2+ risk 
remained approximately 10%. After revision, all these lesions remained CIN2 and we believe 
most of them would regress over time. However, additional testing with either cytology or 
hrHPV after 6 months may be considered to minimize the risk of CIN2. 
Women with BMD who tested hrHPV positive at baseline had a 5-year CIN3+ risk of almost 
40% and are in need of additional testing and/or colposcopy.2, 5-6, 15 Although hrHPV genotyping 
did identify HPV16-positive women to have the highest risk, the risk of women positive for 
other hrHPV types remained so high (28%) that colposcopic referral was required, leaving 
hrHPV genotyping without additional value.
Another strategy to identify women at risk for CIN3+ is hrHPV testing after 6 months, 
allowing viral clearance.22, 42 In our study, almost half (99/210) of the women with BMD tested 
hrHPV negative after 6 months. As none of them developed CIN3+, this confirms the usefulness 
of this alternative strategy. However, also with this strategy the 5-year CIN2+ risk in hrHPV-
negative women remains 10%. 
Women wi th  >BMD
As almost half of the women with >BMD cytology developed a CIN3+ lesion, we support 
referring all women with >BMD to colposcopy.2, 6 Although immediate hrHPV testing did stratify 
the risk of developing CIN3+, no group was identified with a risk low enough to refrain from 
colposcopy. Therefore we do not advocate hrHPV testing in this group.
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Study  l imi tat ions
Our study has several limitations. First, the initial study was designed such that no interference 
with natural history would occur and therefore had a “wait and see” period to allow the 
development of real precursor lesions (CIN3), instead of transient lesions (CIN2). When CIN2+ 
lesions were detected women were treated, which is in contrast to another observational 
study.43 The waiting period is also an explanation for the later diagnosis of CIN3+ lesions in 
our study than found in a joint European cohort study in which the majority of disease was 
diagnosed within 12 months.44 
Second, our study comprises a relatively small cohort of 342 women. Although the 
censoring percentage at 10 years was only 20%, just one event was diagnosed after 10 years 
of follow-up. Therefore, we describe the risks up to 10 years and presented 95%CI to assess 
all risks as precisely as possible, providing a general impression on the long-term CIN-risk of 
women with an abnormal smear (≥BMD). Our results corroborate and extend the data of other 
(long-term) cohorts.19-21, 23, 26-27, 41, 44 As most CIN3+ were detected within 5 years of referral 26, the 
presented overall 5- and 10-year CIN3+-risks are with 31.1% and 32.2% nearly similar. These risks 
were higher than reported previously by Dillner (6-year risk 19%) and Sherman (10-year risk 
10.2%; 95%CI 7.6-12.9).26, 44 Possible explanations include differences in the study population, 
that is the relatively large proportion (39%) of women with >BMD, and the strict endpoint of 
biopsy taking in the initial study. Other studies often acted on less severe suspicions, thereby 
increasing the detected number of lower grade CIN lesions. 12, 26-27 A number of CIN2 lesions 
that would have been detected in countries with less conservative referral thresholds such as 
the United States and the United Kingdom, will in The Netherlands have developed into CIN3+ 
lesions before detection. This explains the relatively higher number of CIN3+ lesions and the 
relatively lower number of CIN2 lesions.
Finally, the median age was relatively low. However, conclusions did not differ greatly after 
recalculating the risks for 196 women aged ≥30 years (data not shown). 
Conc lus ions
In conclusion, our study confirms the increased CIN3+ risk in women with dyskaryosis. Bearing 
in mind the limitations of our study, we recommend the following: 
Women with BMD should receive additional hrHPV testing for risk assessment. HrHPV-
negative women may be referred to routine screening as their 5-year CIN3+ risk is negligible. 
HrHPV-positive women should be referred for additional testing and/or colposcopy. When 
these women do not develop CIN3+ within 5 years, they also may be referred to population-
based screening. Women with >BMD should all be referred for colposcopy and as their CIN3+ 
risk is elevated for at least 10 years long-term monitoring is required.
Tr ia l  reg is ter
Dutch trial register, NTR 1470
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Introduct ion 
15% of women treated for high-grade Cervical Intraepithelial Neoplasia (CIN2/3) develop 
residual or recurrent CIN2, CIN3 or cervical cancer (CIN2+), most of which are diagnosed within 
2 years of treatment. To gain more insight into the long-term predictive value of different post-
treatment strategies, we assessed the long-term cumulative risk of post-treatment CIN2+ and 
different follow-up algorithms to identify women at risk of residual and recurrent disease.
Methods
Women who were included in three studies in The Netherlands and who were treated for CIN2/3 
between July, 1988, and November, 2004, were followed up by cytology and testing for high-
risk human papillomavirus (hrHPV) at 6, 12 and 24 months after treatment, and subsequently 
received cytological screening every 5 years. The primary endpoint was the cumulative risk 
of post-treatment CIN2+ by December, 2009. We also assessed the cumulative risk of CIN2+ 
in women with three consecutive negative cytological smears and women with negative co-
testing with cytology and hrHPV at month 6 and 24. 
Resu l ts
435 women were included, 76 (17%) of whom developed post-treatment CIN2+, of which 39 were 
CIN3+. The 5-year risk of developing post-treatment CIN2+ was 16.5% (95%CI 13.0-20.7) and 
the 10-year risk was 18.3% (13.8-24.0). The 5-year risk of developing post-treatment CIN3+ was 
8.6% (95%CI 6.0-12.1) and the 10-year risk was 9.2% (5.7-14.2%). Women with three consecutive 
negative cytological smears had a CIN2+ risk of 2.9% (95%CI 1.2-7.1) in the next 5 years and of 
5.2% (2.1-12.4) in the next 10 years. The 5-year risk of CIN3+ was 0.7% (95%CI 0.0-3.9) and the 
10-year risk was 0.7% (0.0-6.3). Women with negative results for co-testing had a 5-year risk of 
CIN2+ of 1.0% (95%CI 0.2-4.6) and a 10-year risk of 3.6% (1.1-10.7). The 5-year risk of CIN3+ was 
0.0% (95%CI 0.0-3.0) and the 10-year risk was 0.0% (0.0-5.3). 
Discuss ion
The 5-year risk of post-treatment CIN2+ in women with three consecutive negative cytological 
smears or negative co-testing for cytology and hrHPV at 6 and 24 months was similar to that 
of women with normal cytology in the population-based screening programme and therefore 
justifies their return to regular screening. 
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INTRODuCTION
Women diagnosed with high-grade cervical lesions (Cervical Intraepithelial Neoplasia grade 2 
or 3 [CIN2/3]) are treated by ablative surgery or by excision to prevent progression to cervical 
cancer.1-2 Despite treatment, approximately 15%3 (range 5-25%)3-8 of these women will develop 
residual or recurrent (post-treatment) high-grade disease. Because of this substantial risk close 
surveillance of these patients is standard practice. In The Netherlands, national guidelines 
recommend repeat cytological testing at 6, 12 and 24 months after initial treatment and, if 
necessary, yearly thereafter until three consecutive smears are read as normal.1 After three 
consecutive negative smears women return to population-based cytological screening every 
5 years. In other countries, such as the United Kingdom (UK) and the United States of America 
(USA), treated women are screened yearly until 5 or 10 years after treatment.9-11
The presence of high-risk human papillomavirus (hrHPV) is a prerequisite not only 
for development of primary CIN2/3 or cervical cancer 12, but also for development of post-
treatment CIN2/3. Effective ablative treatment not only results from removal of the lesion, but is 
associated with elimination of the responsible hrHPV infection.6, 13-14 Post-treatment surveillance 
that combines testing with cytology and hrHPV (co-testing), has a negative predictive value of 
over 99% to detect women at risk of developing post-treatment CIN2/3.3, 7, 15 Strategies that 
include hrHPV testing are therefore suggested as an alternative to conventional surveillance 
with cytology only.3-4, 6, 15-16 In one such proposed strategy, the 12-month visit is omitted in 
women who test negative for co-testing at 6 months, but co-testing is done again at month 
24.3, 14, 17 A simulation model predicted that different co-testing strategies would not result in an 
increase in use of  colposcopy or an increased proportion of missed CIN2/3.18
Since most CIN2/3 is diagnosed within 2 years after treatment, studies on identification of 
women at risk are predominantly confined to this period.4, 7, 14, 16-17 However, the risk of developing 
recurrent CIN grade 3 or cancer (CIN3+) is significantly increased for 10 or even 25 years after 
treatment.5, 8, 19 This finding, combined with an absence of international consensus on optimum 
surveillance strategies after initial treatment 6, 9, suggests that more insight is needed into the 
long-term predictive value of different post-treatment strategies.
We aimed to assess the long-term rate of recurrence of CIN2+ and CIN3+ and the 
effectiveness of the present cytological algorithm at detecting post-treatment disease. We 
also investigated whether alternative post-treatment surveillance strategies, which include 
co-testing, could reduce the number of screens needed after treatment, without reducing 
the effectiveness of the strategy at identifying women with a long-term risk of post-treatment 
disease.
MATERIALS  AND METHODS
Study  populat ion
In this cohort study we included women who had participated in one of three previous studies 
14, 17, 20  that monitored women by hrHPV testing and cytology at 6, 12 and 24 months after 
treatment for CIN2/3. All women had been treated by large loop excision of the transformation 
zone (LLETZ) or cold-knife conisation. The studies were done in hospitals in the Randstad 
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region, The Netherlands. All hrHPV tests had been done by a single laboratory and all 
cytology had been reviewed in one institution (VU University Medical Center, Amsterdam, The 
Netherlands). Because of these similarities, data were pooled into a single database for joint 
statistical analysis. Patients were excluded if data were incomplete or if they had been treated 
for persistent low-grade disease.
Ethical approval was obtained from the ethics board at all hospitals. All women who 
attended the outpatient clinic or participated by self-sampling provided additional signed 
informed consent.
The study is registered in the Dutch trial register, NTR1468. 
Procedures
To complete the data obtained from population-based screening, we invited all women to 
visit the outpatient clinic (VU University Medical Center, Amsterdam, The Netherlands or 
ErasmusMC University Medical Center, Rotterdam, The Netherlands) for additional cytology 
and hrHPV testing between January and December, 2009. If travel distance was a limitation, 
women were offered the possibility of doing a hrHPV test at home by self-sampling. Results 
from these home-based hrHPV tests are similar to those acquired by a physician.21-22 Women who 
had had a hysterectomy were censored at the date of hysterectomy. Data on demographics, 
medical history and lifestyle were collected. Women were asked about smoking habits, oral 
contraceptive use, condom use, parity, and number of sexual partners. Standard questionnaires 
were used. 
Two cervical specimens were obtained from women who visited the outpatient clinics 
(Cervex-brush, Rovers Medical Devices, Oss, The Netherlands). The first specimen was collected 
in liquid-based cytology medium (in Amsterdam: Surepath, Tripath Imaging, Burlington NC, 
USA; in Rotterdam: Thinprep, Hologic, Marlborough MA, USA), cytologically examined and 
classified according to the CISOE-A (Composition, Inflammation, Squamous epithelium, 
Other and endometrium, Endocervical columnar epithelium, and Adequacy of the smear) 
classification, which can easily be translated into the Bethesda 2001 classification.23 The second 
specimen was stored in Universal Collection Medium (Qiagen Corporation, Gaithersburg, MD, 
USA) for hrHPV testing. Women who did hrHPV self-sampling returned their cervico-vaginal 
specimen for hrHPV testing by mail. All samples were tested with the clinically validated hrHPV 
GP5+/6+ primer-mediated PCR with enzyme-immunoassay read-out using a cocktail probe for 
14 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), according to established 
protocols.24-25 The PCR products of hrHPV-positive women were subsequently genotyped by 
reverse line blot hybridization. Samples that were negative for any specific probe in this reverse 
hybridization assay, were deemed positive for uncharacterised subtypes or variants.
We did a standard colposcopic assessment when a cytological test was abnormal at the 
threshold of atypical squamous cells of undetermined significance (or borderline dyskaryosis), 
or when a hrHPV test was positive. Biopsies were taken of all suspect lesions. Histological 
specimens were graded as CIN grade 0 (no dysplasia), 1, 2, 3, or invasive cancer 26 and classified 
according to the highest histological abnormality found in biopsy or LLETZ. Women, who 
developed post-treatment disease (CIN2+), were treated according to present guidelines 1 and 
received further follow-up tests but were censored for this study.
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In December 2009, hospital databases and The Netherlands nationwide network and 
registry of histopathology and cytopathology (PALGA; Bunnik, The Netherlands) were reviewed 
for all women, irrespective of attendance, to ascertain details of any additional relevant events 
and procedures. 
The primary endpoint was the cumulative risk of post-treatment CIN2+, because treatment 
of CIN grade 2 is common practice in The Netherlands.1 We repeated the calculations for CIN3+, 
because this is a more adequate surrogate for precancer. For the purpose of this study residual 
and recurrent disease were combined and defined as post-treatment CIN. This study was limited 
to the follow-up of squamous lesions. Post-treatment CIN2+ and CIN3+ included squamous cell 
carcinoma. Total time at risk was measured as the period between the date of initial treatment 
and the last registered testing date or the midpoint between the date of detection of post-
treatment CIN and the date of the cytological test result before the colposcopic referral. 
For women who had not developed CIN at 24 months after treatment, we also estimated the 
risk of post-24-month CIN. For these analyses, we reset time at 24 months after treatment to 0 
months. We wanted to identify women who could be referred to population-based screening 
after a close surveillance period of 2 years and women who should remain under more intense 
surveillance. In particular, we tested the association between the post 24-month CIN risks in 
those women and the cytological and hrHPV test results obtained in the first 24 months after 
treatment. 
Stat i s t ica l  ana lys i s
Because this study was designed as a follow-up study, the maximum sample size was limited 
to the number of women who had participated in the initial trials.14, 17, 20 Data were interval-
censored in case of a CIN2+ event and right censored otherwise. Data were interval-censored in 
case of a CIN3+ event and right censored if lost to follow-up, or if a CIN2 lesion was diagnosed.
The cumulative risk of post-treatment CIN was estimated by maximizing the non-parametric 
likelihood,27 which adjusts for interval censoring between the dates of successive visits. If the 
maximum likelihood estimate of a cumulative risk was not unique, the largest risk estimate was 
reported. 95% Confidence intervals (95%CIs) were calculated with the score test. Differences in 
cumulative risk curves between subgroups were assessed by exact log-rank tests for interval-
censored data with Sun’s scores measured from baseline to the date of detection of CIN2+.28 
By Cox regression, we calculated CIN hazard ratios (HRs) and 95%CIs to compare different 
follow-up test results in the first 24 months. Similar analyses were done to compare test results 
6 months after treatment. Time to CIN was set as the midpoint of the time between detection 
of the CIN lesion and the cytological test result before the colposcopic referral. The reported 
HRs were adjusted for treatment centre, original cohort and year of treatment.
The cumulative CIN risks and exact log-rank tests were done with the interval R package29 
within statistical software program R (version 2.12).30 Exact permutation p-values were 
approximated by Monte Carlo simulation. The Cox regression analyses were done with SPSS 
(version 17.0). For all tests, the level of significance was set at 0.05.
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Role  o f  the  funding  source
The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. All authors had full access to all the data and the 
corresponding author had final responsibility for the decision to submit for publication.
RESuLTS
Of the 445 women from the previous studies, five could not be identified because of incomplete 
patient data and another five from one study 17 had been treated for persistent low-grade 
disease and were excluded. The remaining 435 women were monitored by population-based 
screening once every 5 years, as per standard practice in The Netherlands. Table 4.1 provides 
details of individual study designs, inclusion and exclusion criteria, and location. 
Maximum follow-up depended on accrual date and ranged from 5.0 to 21.5 years. The total 
number of women years in our study was 3464. Of 435 women included, 74 (17%) were censored 
at 5 years, 216 (50%) at 10 years and 289 (66%) at 15 years after treatment.
Table	4.1	Characteristics of initial cohorts.
Nobbenhuis	et	al.14	 Hogewoning	et	al.	20 Bais	et	al.17	
Number of women 184 78 183
Inclusion criteria Treatment for CIN2/3 Treatment for CIN2/3 Treatment for CIN2/3
Exclusion criteria Previous cervical 
treatment
Concomitant cancer
Previous exposure to 
diethylstilbestrol
Previous cervical 
treatment
Regular condom use at 
baseline
Previous cervical 
treatment
Concomitant or previous 
cancer
Immune comprising 
conditions
Hospitals VU University Medical 
Center
Albert Schweitzer 
Hospital 
VU University Medical 
Center 
ErasmusMC University  
Medical Center 
Albert Schweitzer 
Hospital
Years of Inclusion 1990-1996 1995-2002 2002-2004
Cytology37 CISOE-A CISOE-A CISOE-A 
hrHPV-test GP5+/6+ PCR GP5+/6+ PCR GP5+/6+ PCR
Median follow-up (range; 
months)
24 (3–76) 15 (3–85) 24 (3–24)
Tests done at month 3, 6, 9, 12 and 24 3, 6, 12, 18 and 24 6, 12 and 24
Median age (range; years) 31 (21–70) 34 (22–54) 35 (22-56) 
 Women with CIN2+ ≤24 
months after treatment (%)
27 (15%) 6 (8%) 16 (9%)
CIN, Cervical Intraepithelial Neoplasia; CISOE-A, Composition, Inflammation, Squamous epithelium, Other and 
endometrium, Endocervical columnar epithelium, and Adequacy of the smear; hrHPV, high-risk type of the 
human papillomavirus.
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Of the 435 women (median age 33, range 21-70 years) four died of unrelated disease during 
follow-up, five moved abroad, and 27 had a hysterectomy. None of the women received 
prophylactic HPV vaccination during follow-up. At initial treatment 358 (82%) of 435 women 
had been treated by an LLETZ procedure, the remaining 77 women (18%) had a cold-knife 
conisation. 344 (79%) of 435 women were treated for a CIN 3 lesion. Before initial treatment, 
399 (93%) of 430 women who had an available hrHPV test tested positive for hrHPV. HPV16 was 
the most prevalent type (255/399, 64%), followed by HPV31 (48/399, 12%), HPV33 (43/399, 11%) 
and HPV18 (34/399, 9%). Of the 399 hrHPV-positive women, 338 (85%) were infected with one 
hrHPV type, 55 (14%) had a double infection and six (2%) had a triple infection.   
During follow-up 76 CIN2+ cases were identified: two were invasive cancers and were 
diagnosed after 14 and 28 months, 37 were CIN3 and 37 CIN2. The median time until detection 
of CIN2/3 was 15.5 months (range 3-153). 41 of 76 CIN2+ lesions were found within 2 years of 
treatment. Figure 4.1 shows the interval censored cumulative risks of post-treatment CIN2+ and 
CIN3+. CIN2+ and CIN3+ were detected not only during the post-treatment surveillance period, 
but also in the subsequent population-based screening programme. 
Of all 76 women who developed post-treatment CIN2+, 72 were hrHPV positive at baseline 
and all 39 women who developed post-treatment CIN3+ tested positive at baseline. 54 women 
diagnosed with post-treatment CIN2+, and 33 of the women diagnosed with CIN3+, including 
the two women who developed invasive carcinoma, tested positive for HPV16, In both patients 
who developed carcinoma and in 45 of 74 patients with CIN2/3, the hrHPV type in the post-
treatment lesion was the same as was present at initial treatment.
Table 4.2 shows the 5-year and 10-year risks of CIN2+ for all confounding risk factors. We 
noted a difference in the risk of developing post-treatment CIN2+ for original cohort (Sun-
score statistic 12.1; p=0.05), treatment centre (Sun-score statistic 15.1; p=0.03) and year of 
treatment (Wald statistic 6.44; p=0.01). Neither in the pooled nor in the separate cohorts (data 
not shown) were significant differences found in the risk of developing post-treatment CIN2+ 
for treatment modality (Sun-score statistic 1.76; p=0.58) or severity of the initial lesion (5.56; 
p=0.10). Women with negative hrHPV tests had a similar risk of post-treatment CIN2+ as those 
with a positive test (Sun-score statistic 1.15; p=0.66), but none of the hrHPV-negative women 
developed a CIN3+ lesion. There was no significant difference in 5-year and 10-year risks of 
developing CIN2+ between women who tested hrHPV negative and those who tested positive 
(Table 4.2); however the number of women who tested negative was low.
6 months after treatment, 87 (21%) of 424 available hrHPV tests were positive and 65 (15%) 
revealed the same hrHPV type as detected at baseline. More women who were positive for 
HPV16 developed CIN2+ than did those infected with other hrHPV types (40 of 56 women 
versus 13 of 31, p=0.02). The 5-year risk of CIN2+ was 66.2% (95%CI 52.6-77.5) in women positive 
for HPV16 and 39.7% (23.9-57.9) in those negative for HPV16. However, the time to develop 
post-treatment CIN2+ was similar between these two groups (18 versus 17 months, p=0.94, 
Mann-Whitney test). The 5-year risk of developing post-treatment CIN2+ was 28.6% (95%CI 
10.9-56.6) in women infected with hrHPV types different from HPV16, 18, 31, 33, and 45. 46 of 
65 women in whom the same hrHPV type was found at baseline and 6 months after treatment 
developed CIN2+ compared with seven of 22 of those infected with a new hrHPV type at 6 
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Figure	4.1	 	Cumulative risk curves of post-treatment CIN2+ and CIN3+. 
CIN, cervical intraepithelial neoplasia; Cumulative risk curves of (A) post-treatment CIN2+ and (B) post-treatment 
CIN3+. Because of interval-censored data the risk curves are not unique. Every cumulative risk curve within the 
shaded boxes gives the same fit to the data because of interval censoring.
A
B
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Table	4.2	Risk of developing CIN2+ according to different confounding risk factors.
5-year	risk	(95%CI) 10-year	risk	(95%CI)
Cohort
Nobbenhuis et al14 20.1% (14.8-26.8) 21.9% (16.2-28.9)
Hogewoning et al20 12.1% (6.3-22.8) 13.8% (6.2-28.1)
Bais et al17 11.4% (6.9-18.2) 29.9% (15.0-50.8)
Treatment centre
VUmc 18.7% (14.3-24.1) 20.5% (15.2-27.1)
Albert Schweitzer 9.7% (4.9-18.4) 11.5% (4.7-25.3)
ErasmusMC 9.2% (3.8-20.7) 35.1% (13.1-66.0)
Treatment modality
LLETZ 15.0% (11.4-19.5) 18.1% (13.1-24.5)
Conisation 15.9% (8.8-27.0) 15.9% (7.9-29.4)
Severity of initial lesion
CIN2 9.3% (4.4-18.5) 11.1% (3.5-29.8)
CIN3 16.7% (12.9-21.4) 19.3% (14.4-25.4)
hrHPV status at initial treatment
Negative 13.4% (4.6-33.1) 13.4% (1.8-56.8)
Positive 15.5% (12.0-19.8) 18.1% (13.5-23.8)
Smoking at initial treatment
Never 8.7% (3.7-19.0) 12.6% (4.6-30.3)
Ex-smoker 17.2% (9.8-28.4) 18.9% (9.5-34.2)
1-10 cigarettes per day 9.1% (3.1-23.6) 12.1% (3.3-35.6)
>10 cigarettes perday 27.1% (17.4-39.6) 33.5% (20.0-50.3)
Oral contraceptive use
Yes 13.0% (6.0-26.0) 13.0% (6.0-26.0)
No 17.3% (12.3-23.8) 22.2% (14.9-31.7)
Condom use
Yes 16.3% (8.1-30.0) 16.3% (5.1-41.2)
No 16.4% (11.6-22.8) 21.1% (14.2-30.2)
Birth
None 5.0% (1.7-13.8) 9.0% (2.9-24.7)
≥1 20.8% (15.1-28.0) 24.7% (16.7-34.9)
Sexual partners
<5 17.5% (10.8-27.1) 18.7% (10.4-31.3)
≥5 15.6% (10.3-22.9) 21.6% (13.1-33.4)
95%CI; 95% confidence interval; LLETZ, large loop excision of the transformation zone; CIN, cervical 
intraepithelial neoplasia; hrHPV, high-risk type of the human papillomavirus.
Risk was measured by maximum likelihood estimate.
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months (p=0.004). The 5-year risk of a 6-month persistent hrHPV infection was 66.2% (95%CI 
53.6-76.9) and the risk of a newly detected hrHPV infection at 6 months 27.9% (13.1-49.8).
12 months after treatment 41 (10%) of 400 women tested for hrHPV. 30 women (8%) were 
also positive after 6 months; all these women were diagnosed with the same hrHPV type as 
detected at baseline. Nine of the 41 women who were hrHPV positive after 12 months were 
hrHPV negative after 6 months and in only two of these the same hrHPV type was diagnosed 
as at baseline. 6-months data were missing for two women.  After 24 months 28 of 348 (8%) 
women were hrHPV positive; 10 (3%) were still infected with their original hrHPV type, eight 
of whom were positive for HPV16. Of the ten women still infected with their original hrHPV 
type, one did not develop high-grade post-treatment disease; one was diagnosed with invasive 
carcinoma, six with CIN3, and two with CIN2. The other 18 women were infected with a new 
hrHPV type at either 12 (two women) or 24 months (16 women).
In 2009, additional tests were obtained from 215 of 435 (49%) women, of whom 178 (83%) 
had both cytology and hrHPV test results available. Seven (3%) of 215 women had an abnormal 
cytology result and 27 (13%) tested positive for hrHPV, of whom 10 had HPV16. 29 (13%) of 215 
women had abnormal test results, three of whom had CIN3 and two CIN2.
The 5-year risk of developing post-treatment CIN2+ was 16.5% (95%CI 13.0-20.7) and the 
10-year risk was 18.3% (13.8-24.0). The development of CIN2+ could be predicted by 6-month 
testing with cytology, hrHPV, or both all p<0.0001; Table 4.3). In two studies14, 20 the first testing 
point was after 3 months; thus, we also analysed the predictive values of the first test results, 
acquired after a median of 4 months (range 2-10). These showed similar results to those after 6 
months, but with lower HRs (data not shown). The 5-year risk of CIN2+ in women with negative 
cytology was 5.8% (95%CI 3.6-9.3) and of women with an abnormal cytology result it was 46.2% 
(36.0-56.7). For women with a negative hrHPV test this risk was 4.4% (95%CI 2.5-7.5) and for 
those with a positive test 56.9% (46.0-67.2). Women whose co-testing results were negative 
had a 5-year risk of CIN2+ of 3.0% (95%CI 1.5-6.1) compared with a risk of 41.0% (32.5-50.0) for 
women who had at least one positive test result.
Women with three consecutive negative smears had a lower risk of developing CIN2+ than 
women with at least one abnormal cytological test result at 6, 12 or 24 months (p<0.001; Table 
4.3; Figure 4.2). The corresponding HR for women with at least one positive test result compared 
with those with three negative smears was high (Table 4.3). The 5-year risk of developing CIN2+ 
in women with three negative smears was 2.9% (95%CI 1.2-7.1) and the 10-year risk was 5.2% (2.1-
12.4). In women with at least one positive test, corresponding risks were 18.2% (95%CI 11.9-26.8) 
and 21.9% (14.2-32.1). 
Women who tested negative for co-testing at 6 and 24 months after treatment had a lower 
risk of CIN2+  than women with at least one positive test result (p<0.001; Table 4.3; Figure 4.2). 
The 5-year risk of developing CIN2+ in women who tested negative for co-testing was 1.0% 
(95%CI 0.2-4.6) and the 10-year risk was 3.6% (1.1-10.7) In those with at least one positive test, 
these risks were 17.8% (95%CI 12.0-25.7) and 21.1% (14.0-30.5). 
214 (49%) women completed the questionnaires which were analysed to identify additional 
risk factors for post-treatment CIN2+. The women from whom questionnaires were obtained, 
had similar properties to the full group in terms of hrHPV-positivity at baseline, proportion with 
CIN2, and mean age (data not shown); thus we considered this sample to be representative of 
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the study population. In this subgroup, we noted that smoking around the treatment date was 
associated with an additional risk of developing CIN2+ (Sun-score statistic 19.06; p=0.01). In a 
post-hoc analysis, we found that this risk was only increased in women who smoked more than 
ten cigarettes per day; their 5-year and 10-year risks of developing CIN2+ were around 30%, 
whereas the risks for women who had never smoked were much lower (Table 4.2). We did not 
identify an additional risk of CIN2+ for women who used oral contraceptives (Sun-score statistic 
Table	4.3	Prediction of recurrent high-grade disease according to different follow-up algorithms.
Number	
at	risk	a
CIN2+	after	treatment CIN3+	after	treatment
n	(%) HR	(95%CI)	b n	(%) HR	(95%CI)	b
Testing	at	6	months
All 435 76 (17.5) 39 (9.0)
hrHPV negative 337 22 (6.5) 7 (2.1)
hrHPV positive c 87 53 (60.9) 16.84 (10.06 – 28.19) 32 (36.8) 29.30 (12.62 – 68.02)
Normal cytology 326 25 (7.7) 9 (2.8)
≥ ASC-US c 98 49 (50.0) 8.87 (5.36 – 14.68) 30 (30.6) 13.00 (6.00 – 28.19)
Co-testing negative 283 13 (4.6) 4 (1.4)
hrHPV positive or ≥ ASC-US, or 
both c
135 61 (45.2) 13.70 (7.43 – 25.25) 35 (25.9) 22.50 (7.88 – 64.28)
Testing	at	both	6	and	24	months
All 391 35 (9.0) 13 (3.3)
Cytology triple negative d 254 9 (3.5) 1 (0.4)
At least one result ≥ ASC-US c 137 26 (19.0) 6.13 (2.65 – 14.21) 12 (8.8) 26.26 (3.27 – 210.81)
hrHPV negative at 6 months
Co-testing negative at 24 months 255 7 (2.7) 1 (0.4)
hrHPV positive or ≥ ASC-US or 
both at 24 months
136 28 (20.6) 8.05 (3.43 – 18.88) 12 (8.8) 28.51 (3.62 -  222.64)
Co-testing negative at 6 months
Normal cytology at 24 months 249 8 (3.2) 1 (0.4)
≥ ASC-US at 24 months 142 27 (19.0) 7.08 (3.03 – 16.51) 12 (8.5) 24.53 (3.14 – 191.54)
hrHPV negative at 24 months 241 6 (2.5) 1 (0.4)
hrHPV positive at 24 months 150 29 (19.3) 8.51 (3.44 – 21.02) 12 (8.0) 26.02 (3.29 – 205.59)
Co-testing negative  at 24 months 221 4 (1.8) 0
hrHPV positive or ≥ ASC-US or 
both at 24 months
170 31 (18.2) 10.42 (3.60 – 30.14) 13 (7.6)
CIN, cervical intraepithelial neoplasia; HR, Hazard Ratio; hrHPV, high-risk type of the human papillomavirus; 
ASC-US, atypical squamous cells of undetermined significance; co-testing negative, hrHPV testing negative 
and normal cytology. 
a data for testing at both 6 and 24 months excludes women who developed post-treatment disease within 24 
months or who were follow-up for less than 24 months. 
b adjusted for treatment centre, original cohort and year of treatment. 
c including two women with invasive squamous cell carcinoma. 
d normal cytology results at month 6, 12 and 24 months.
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Figure	4.2	 Prediction of post-treatment disease according to different algorithms. 
CIN, cervical intraepithelial neoplasia; hrHPV, high-risk type of the human papillomavirus. 
Post-treatment surveillance by the algorithm of (A) cytological testing at 6, 12 and 24 months for predicting post-
treatment CIN2+, (B) co-testing (hrHPV and cytology) at 6 and 24 months for predicting post-treatment CIN2+, 
(C) cytological testing at 6, 12 and 24 months for predicting post-treatment CIN3+, and (D) co-testing (hrHPV and 
cytology) at 6 and 24 months for predicting post-treatment CIN3+. Because of interval-censored data the risk 
curves are not unique. Every cumulative risk curve within the shaded boxes gives the same fit to the data because 
of interval censoring. For all figures, p<0.0001.
A
B
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3.58; p=0.20), did not use condoms (3.58; p=0.38), had given birth (5.15; p=0.06), or had more 
than five sexual partners (3.19; p=0.57; Table 4.2).
Results of analyses of the risk of post-treatment CIN3+ were similar to those for CIN2+ (Table 
4.3; Figure 4.1). The 5-year risk of developing CIN3+ was 8.6% (95%CI 6.0-12.1) and the 10-year 
risk of developing post-treatment CIN3+ was 9.2% (5.8-14.2).
Women with three consecutive negative smears had a lower risk of developing CIN3+ than 
women with at least one abnormal cytological test result at 6, 12 or 24 months (p<0.0001; Table 
4.3; Figure 4.2). The 5-year risk of CIN3+ in women with three negative smears was 0.7% (95%CI 
0.0-3.9) and their 10-year risk was 0.7% (0.0-6.3). The 5-year and 10-year risks for women with 
at least one positive test were 8.3% (95%CI 4.1-15.9) and 11.6% (5.9-21.6), respectively. 
Women who tested negative for co-testing at 6 and 24 months after treatment had a lower 
risk of developing CIN3+ than women with at least one positive test result (p<0.0001; Table 4.3; 
Figure 4.2). The 5-year and 10-year CIN3+ risks for women who tested negative for co-testing 
were 0.0% (95%CI 0.0-3.0) and 0.0% (0.0-5.3), respectively. For those with at least one positive 
test, corresponding risks were 7.5% (95%CI 3.8-14.3) and 10.5% (5.3-19.6).
Smoking around the treatment date was associated with an increased risk of developing 
CIN3+ (Sun-score statistic 12.3; p=0.03). The respective 5-year and 10-year risks were 17.6% 
(95%CI 9.7-29.9) and 21.2% (9.9-39.7) in women who smoked more than ten cigarettes per day 
compared with 1.7% (0.3-9.8) and 4.1% (0.7-21.7) in women who had never smoked.
DISCuSS ION
Women treated for a CIN2+ lesion had a 10-year interval-censored long-term CIN2+ recurrence 
rate of 18%.The 10-year risk of women with three negative cytological test results was reduced 
to 5% and the risk for women with negative co-testing results was 4%. We consider women who 
satisfy these conditions to be successfully treated. The 5-year risks of post-treatment disease 
in these women are such that they do not need to be followed up more closely than women 
in population-based screening (every 5 years) and could therefore return to this programme 
(Panel: Research in context).
In our study, over half of the post-treatment CIN2+ lesions were detected within 2 years of 
follow-up. Hereafter the risk declined, in agreement with Melnikow and colleagues, who found 
that after 6 years of post-treatment follow-up the risk of CIN is equal to women with negative 
cytology in population-based screening.5 
In accordance with Strander and colleagues, our study confirmed that one-time testing 
with hrHPV is not sufficient to identify women at risk for post-treatment CIN2+.31 Also, after 
one-time testing with cytology a 5-year CIN2+ risk of 6% remained.
The present post-treatment surveillance strategy, which consists of three cytological 
smears, is effective at identifying women at risk of post-treatment disease. Women with 
three consecutive negative smears had a 3% risk of developing post-treatment CIN2+ in the 
following 5 years. None of the women developed an invasive carcinoma. According to Dutch 
guidelines, these women are referred to population-based screening.1 This is supported by a 
policy suggested by Castle and colleagues, in which women with a 3-year risk of 2% or less may 
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Panel : 	RESEARCH	 IN 	CONTExT
Systemat ic  rev iew 
In 2004, our group published a review and meta-analysis that compared high-risk human 
papillomavirus (hrHPV) testing with either resection margins or cervical cytology to predict 
post-treatment disease in women treated for cervical intraepithelial neoplasia (CIN) grade 2 
or 3 (CIN2/3).3 We searched PubMed for articles and reviews on hrHPV testing in the follow-
up of women treated for CIN2/3 to gather additional information. Four reviews, published 
between 2004 and 2009, reported a higher sensitivity and negative predictive value for 
hrHPV testing than for cytology in prediction of high-grade post-treatment disease and 
confirmed the additional value of hrHPV testing in the follow-up of these women.6, 33-35 
Most of the studies included in these reviews, as well as the identified published studies, 
had a maximum follow-up of 5 years. This finding suggested that long-term data on the 
performance of hrHPV testing in this high-risk population were needed.
Interpretat ion 
Results of previous studies have suggested hrHPV testing is valuable in post-treatment 
surveillance, because of its high negative predictive value in the first 2 years after 
treatment. We found that the risk of CIN2+ in women who had three consecutive 
cytological negative smears or negative co-testing results was similar to the 5-year risk 
of CIN2+ of women with normal cytology in the general population.36 Therefore these 
women can be referred to regular population-based screening. All women with other 
test result combinations than mentioned above should receive additional testing or 
colposcopic examination, or both, because they have a substantial risk of developing 
post-treatment disease within the next 5 years. 
For the follow-up of women treated for high-grade disease we advocate the 
incorporation of hrHPV testing (co-testing) at 6 and 24 months after treatment. If hrHPV 
testing is unavailable, women should be tested cytologically at 6, 12 and 24 months after 
treatment.
be followed by regular interval screening 32, and contrasts with the annual cytological follow-up 
done in other countries.10-11
When hrHPV-testing was added to post-treatment surveillance, similar effective recognition 
of women at risk was obtained by testing at fewer time points. The 5-year risk of 3% after three 
consecutive negative smears is similar to the risk found in women who have negative co-
testing results at 6 months, showing that the high negative predictive value of co-testing is 
mainly because of a negative hrHPV test. In the algorithm of co-testing at 6 and 24 months only 
4 of the 221 women who tested negative for all tests developed post-treatment CIN2+, and only 
two of these women developed a CIN2+ lesion in the first 5 years after testing negative. This risk 
is similar to the risk of CIN2+ found in women who tested negative for cytology in the Dutch 
population-based screening programme.33
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We confirm that women negative for co-testing at 6 months post-treatment can miss the 12-
month testing point and return for co-testing after 24 months 3, 18 because of the high sensitivity 
of co-testing.3-4, 16-17 This is not a screening setting, but follow-up of a potentially lethal disease, 
and thus negative predictive value and sensitivity are valued higher than specificity, and priority 
is given to co-testing instead of sole hrHPV testing. A benefit of fewer follow-up visits might be 
that women experience less psychosocial distress.  
The population-based screening programme in The Netherlands ends at age 60 years, and 
thus we would like to add a comment regarding women treated for CIN2/3 after the age of 55 
years. For women who have a negative algorithm in the first 2 years after treatment, a check 
after 5 and 10 years should be done because these women would no longer be invited for tests 
through the national screening programme. This recommendation is further substantiated 
by the fact that the risk of post-treatment disease in successfully treated women increases by 
about 2.5% between 5 and 10 years of follow-up.   
Most treated women are free of hrHPV infection within 6 months.4, 6, 13, 15-16 These women 
have a lower risk of developing post-treatment CIN2+ than women without clearance.4, 6-7, 15-16 
Women infected with HPV16 have a higher recurrence rate than women infected with other 
hrHPV types 4, although these lesions did not develop sooner. Despite the higher risk of CIN2+ 
in HPV16-positive women, women infected with hrHPV types other than 16, 18, 31, 33 and 45 
still had a 5-year CIN2+ risk of almost 30% and therefore also need treatment. Thus, we do not 
advocate inclusion of genotyping in the follow-up.
Study  l imi tat ions
Our study has several limitations. First, the number of events that were diagnosed after 6 years 
of follow-up was small. To assess the risks in this study as precisely as possible, we estimated 
these risks with interval censoring and provided 95%CIs. However, these 95%CIs are wide 
because of the limited number of women in our study. Second, we might have missed some 
women with post-treatment CIN2+ because of incompleteness of the registry. The Netherlands 
nationwide registry covers over 99% of all Dutch laboratories and is judged to be particularly 
accurate for women attending the outpatient clinic; therefore, we expect such incompleteness 
to be minimal. Third, we combined three studies, which had partly been undertaken in 
different hospitals, had slightly different follow-up protocols and had been done over different 
timeframes. By adjusting our results for treatment centre, cohort and year of treatment, we 
have corrected for these differences. Finally, our data could have limited applicability to other 
populations. Because all hospitals in The Netherlands follow the same national guidelines, our 
conclusions can be extended throughout the country. The main conclusion of referring women 
with negative post-treatment surveillance algorithms to population-based screening is also 
applicable to other developed countries that have a population-based screening programme, 
because in most of these countries screening-intervals are equal to (every 5 years) or shorter 
than (every 3 years) in The Netherlands. 
Ideally, our findings would be confirmed by a randomised controlled trial that would 
compare our suggested strategies. However, this trial would need to include a large group of 
treated women who were followed for over 10-15 years. Furthermore, such a study would be 
difficult to do because of continuous development of new screening methods.
86
4.1
Lo
n
G
-tErm
 c
In
 rISk In
 trEAtEd
 w
o
m
En
Conc lus ions
In conclusion, women who have three consecutive negative cytological tests can be referred 
to population-based screening, because their 5-year risk of developing CIN2+ is less than 
3%.32 By adding hrHPV testing to post-treatment surveillance, testing after 12 months can be 
omitted in women negative for co-testing at six months. Women negative for co-testing at 
both 6 and 24 months after treatment had a 5-year risk of developing post-treatment CIN2+ of 
1.0% and a negligible risk of developing CIN3+. These risks are similar to the risks of women with 
normal cytology in population-based screening and therefore these women could be referred 
to regular screening. However, women who do not have negative screening algorithms post-
treatment should receive additional testing or colposcopic examination, or both. 
Tr ia l  reg is ter
Dutch trial register, NTR 1468.
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Introduct ion
Currently, women treated for high-grade cervical intraepithelial neoplasia (CIN 2/3) are 
followed-up by cytology to monitor them for residual and recurrent (post-treatment) disease. 
This systematic review and meta-analysis determine the test performance of testing for high-
risk types of the human papillomavirus (hrHPV), cytology and co-testing (combined hrHPV 
testing and cytology) in predicting high-grade post-treatment disease (CIN2+). 
Methods
Studies that compared at least two of three post-treatment surveillance methods, and were 
published between January 2003 and May 2011, were identified through a bibliographic database 
search (PubMed, Embase.com and Wiley/Cochrane Library). Identification of relevant studies 
was conducted independently by two reviewers with a multi-step process. The reference 
standard used to diagnose post-treatment disease was histologically confirmed CIN2+. 
Sensitivity, specificity, diagnostic odds ratios and relative sensitivity and specificity were 
calculated for each study. Pooled estimates were calculated using a random effects model 
if heterogeneity among studies was significant, otherwise by using a fixed effects model. 
Estimates were reported with 95% confidence intervals (95%CIs).
Resu l ts
Out of 2410 potentially relevant citations, 8 publications, incorporating 1513 treated women, 
were included. Pooled sensitivities were 0.79 (95%CI 0.72-0.85) for cytology, 0.92 (0.87-0.96) 
for hrHPV testing, and 0.95 (0.91-0.98) for co-testing. HrHPV testing was more sensitive than 
cytology to predict post-treatment CIN2+ (relative sensitivity 1.15; 95%CI 1.06-1.25). Pooled 
specificities were 0.81 (95%CI 0.74-0.86) for cytology, 0.76 (0.67-0.84) for hrHPV testing and 
0.67 (0.60-0.74) for co-testing. HrHPV testing and cytology had a similar specificity (relative 
specificity 0.95, 95%CI 0.88-1.02).
Discuss ion
This review indicates that the hrHPV test should be included in post-treatment testing 6 months 
after treatment, because hrHPV testing has a higher sensitivity than cytology in detecting high-
grade post-treatment disease and has a similar specificity.
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INTRODuCTION
Women with high-grade cervical precursor lesions (Cervical Intraepithelial Neoplasia grade 2 
(CIN2) and grade 3 (CIN3)) are treated by local excision or ablation to prevent progression to 
cervical cancer.1-2 Despite treatment, approximately 10.2% (95%CI 6.7-13.8)3 of these women are 
diagnosed with residual or recurrent (post-treatment) high-grade disease.3-9 Because of this 
substantial risk, many countries use surveillance strategies to identify post-treatment disease. 
These strategies fluctuate greatly between countries in both content, including follow-up 
modalities like cervical cytology, testing for high-risk types of the human papillomavirus 
(hrHPV) and colposcopy, either separately or in combination, and length of post-treatment 
surveillance.10-11 
Current Dutch national guidelines recommend cervical cytological testing at 6, 12 and 
24 months after treatment, and, if necessary, annually for five years until three consecutive 
smears are read as normal.2 After three consecutive negative smears, women return to five-
yearly population-based routine screening. In contrast, treated women in the United Kingdom 
have a cytological examination at six and 12 months after treatment and, irrespective of the 
results, annual cytology for the subsequent nine years before reconsidering a return to routine 
screening.12 In the United States annual cytology is even recommended for at least 20 years.13 In 
summary, treated women are followed more closely between two and 20 years before returning 
to population-based screening. 
Besides cytology, several other risk factors, including cone margin status, positive 
endocervical curettage and age, have been studied to predict recurrent cervical disease. 
However, these predictors are suboptimal.11 For excision margins, for instance, previous studies, 
summarized in a review of Zielinski and colleagues, found that the sensitivity varied between 
39 and 100%.9 Besides, this characteristic has shown to be less sensitive than cytology or hrHPV 
testing in predicting post-treatment disease.9, 14
More and more evidence is gathered concerning the use of hrHPV-testing during the 
follow-up period, because the presence of hrHPV is not only a prerequisite for the development 
of primary high-grade CIN 15, but also for the development of post-treatment CIN.3, 6, 9, 11, 16-20 
It is assumed that effective treatment not only removes the pre-malignant lesion, but also 
eliminates the responsible hrHPV infection.17, 21 In women who develop post-treatment CIN 
the hrHPV infection stays present and is therefore associated with disease recurrence.11, 17, 
21 The sensitivity of hrHPV-testing to detect post-treatment CIN outweighs that of cytology 
(approximately 90% versus 75%) 3, 9, 11, 16, 20, at the cost of a lower 9, 16 or similar 3, 19-20 specificity. 
Because this is not a screening setting, but post-treatment surveillance of a potentially lethal 
disease, sensitivity is valued higher than specificity. Strategies which include hrHPV testing are 
suggested as an alternative for conventional post-treatment surveillance.4, 9-11, 14, 22 The majority 
of all treated women clear their hrHPV infection within 6 months 23 and have a significantly 
lower risk of developing post-treatment CIN3+ than women without hrHPV clearance.4, 6, 11, 14, 
22 In the surveillance of treated women combined testing with cytology and a hrHPV test (co-
testing) results in a negative predictive value of over 99% to detect those at risk of developing 
post-treatment disease.6, 9, 14  
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Previously published systematic reviews have examined the value of hrHPV testing in the 
context of post-treatment surveillance of CIN. All found a higher sensitivity for sole hrHPV 
testing or co-testing, compared to sole cytological testing.3, 9, 11, 16, 19-20 The review most recently 
published included studies up to 2007.16    
We conducted this systematic review and meta-analysis to summarize and update current 
knowledge of the value of cytology, hrHPV testing and co-testing used in post-treatment 
surveillance. Besides describing the individual studies, we also determined the pooled 
sensitivity and specificity, diagnostic odds ratio and relative sensitivity and specificity.
MATERIALS  AND METHODS
Search  s t rategy
We searched the databases of PubMed, Embase.com, Wiley/Cochrane Library and WHO 
International Clinical Trials Registry for relevant studies published between January 2003 
and April 2011. For this computer-aided search we used the following terms (including 
synonyms and closely related words) as index terms and free-text words: “vaginal smear” or 
“human papillomavirus” and “conisation” or “loop excision” or “CIN lesions” and “randomized 
controlled trials” or “systematic reviews”. For the last two concepts we used predefined filters. 
These searches were not limited by language of publication. The example strategy for PubMed 
is presented in Supplementary Table 4.1 (S1).
Previous systematic reviews or meta-analyses on the same subject as well as references 
of retrieved articles were used to search for additional relevant studies that could have been 
missed by the electronic search. Identification of relevant studies was conducted independently 
by two reviewers (MK and MU) with a multistep process (Figure 4.3). First, titles of the full list 
of citations were reviewed, followed by an assessment of abstracts of citations with potentially 
relevant titles. Disagreements were resolved by consensus. Finally, full-text articles of selected 
abstracts were considered for introduction in the review. We developed a data extraction sheet 
based on Cochrane guidelines 24-25 to collect all relevant data from the studies, which was used 
by two reviewers (MK and MU). Disagreements were resolved after discussion. The following 
data were extracted: author, year and language of publication, country of study, population 
characteristics, study design, true positive (TP), false positive (FP), true negative (TN) and false 
negative (FN) values. The authors of papers which did not state the values to construct a 2x2 
table were contacted. 
Two independent reviewers (MK and MU) graded the methodological quality of the 
selected studies with a modified version of the QUality Assessment of Diagnostic Accuracy 
Studies (QUADAS) tool.26 This modified version consists of 11 items on methodological 
characteristics that have the potential to introduce bias and are described in Supplementary 
Table 4.2 (S2). Items were scored positive (criteria satisfied), negative (criteria not satisfied), 
or unclear. We kept out two items (index test results blinded and relevant clinical information 
available) because hrHPV testing is performed by an objective test and is independent of clinical 
information. Furthermore we added the item “selection bias”. Disagreements between the two 
extracting authors were resolved by consensus. Assessment of quality results was categorized.
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Inc lus ion  and  exc lus ion  c r i ter ia
To be included, both prospective and retrospective studies had to meet several inclusion 
criteria: (1) women should have been treated for CIN2/3 by either conisation (laser or cold-
knife) or LLETZ (Large Loop Excision of the Transformation Zone) procedure; (2) post-
treatment surveillance should include at least two out of the following three methods; hrHPV 
testing, cytology, and/or co-testing (combined testing of cytology and hrHPV) at six months 
after treatment; (3) the positive endpoint, residual or recurrent high-grade post-treatment 
disease should be defined as a histological diagnosis of CIN2, CIN 3, adenocarcinoma in situ 
(AIS), adenocarcinoma, or squamous cell carcinoma (CIN2+). A negative endpoint should 
be defined as either a histological confirmation of no, or low-grade, disease (CIN0/1), or a 
repetitive negative cytological test result.
Both studies in which hrHPV testing was performed by Hybrid Capture II (HCII), as studies in 
which this was performed by the polymerase chain reaction (PCR) method were included. Both 
the sensitivities and negative predictive values of these tests to detect post-treatment CIN3+ 
seem similar, being 100% and 99% respectively 27 and show a good agreement.28 In addition, we 
checked their similarity empirically by performing a bivariate regression analysis with type of 
hrHPV test as dichotomous covariate.
For a study to be considered for pooling, we required colposcopic evaluation of all positive 
test results in all women. Positive test results were defined as abnormal cytological test 
results, characterized as borderline dysplasia or worse, equivalent to atypical cells of unknown 
significance (ASCUS) or worse, and as hrHPV tests, positive for any hrHPV type. 
Studies were excluded from this review, when they concerned the follow-up of women 
treated for adenocarcinoma in situ (AIS) or low-grade cervical disease (CIN1). Other exclusion 
criteria were studies concerning the follow-up of pregnant women, HIV-infected women, 
women exposed to diethylstilbestrol (DES) in utero, and studies concerning prophylactic HPV 
vaccination. Also studies with a follow-up of less than 12 months were discarded.
Stat i s t ica l  ana lys i s
Outcome measures were the pooled estimates of sensitivity and specificity, the pooled estimate 
of the diagnostic odds ratio (DOR), and the pooled estimates of relative sensitivity and relative 
specificity. The DOR was defined as the odds of a positive test result in subjects with disease 
divided by the odds of a positive test result in subjects without disease.29 The relative sensitivity 
was computed as the ratio of the sensitivity of the hrHPV test tot the cytology test, and the 
relative specificity was computed analogously.
In order to select the appropriate pooling method, the heterogeneity among the studies of 
each outcome measure was tested with Cochran’s Q and quantified by I2. 30-31 If Cochran’s Q was 
significant, the effects were pooled using a random effects model (REM) 32, otherwise a fixed 
effects model (FEM) was used.
The sensitivity and specificity were pooled after applying the Freeman-Tukey double arcsine 
transformation 33-34 and presented with a Clopper-Pearson exact 95% confidence interval 
(95%CI).35 The 95%CI of the DOR was based on the standard error of the logarithm of the 
DOR. In all studies, cytology and hrHPV tests had been performed in all women. Therefore the 
standard error of the relative sensitivity and relative specificity was computed as the standard 
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error of a relative risk of binary matched-pairs data.36 A continuity correction of 0.5 was applied 
if the discordant cell frequencies equalled zero.
The DOR as a measure of the discriminatory power of a test assumes that the thresholds 
between the different outcome categories remain constant over the included studies.37 To check 
this assumption, the Pearson correlation between the logit true positive rate (TPR) and the logit 
false positive rate (FPR) was calculated for cytology, hrHPV testing and co-testing.38 As a second 
check of heterogeneity across studies, Moses’ regression model was fitted.39 Finally, to check 
whether the type of hrHPV test used, or quality of the study differentially affected the sensitivity 
or specificity, a bivariate regression analysis of sensitivity and specificity was performed using 
maximum likelihood estimation with type of hrHPV test or study quality as covariates.40
The sensitivity and specificity were pooled using R (version 2.13.0).41 The DOR was pooled, 
and the Pearson correlation between the logit TPR and logit FPR and Moses’ regression model 
was fitted using Meta-DiSc (version 1.4).42 The relative sensitivity and relative specificity 
were pooled in  Review Manager (version 5.1.2)43, by importing the standard errors from a 
spreadsheet analysis in Microsoft Excel (2003). The bivariate regression analysis was performed 
in SAS (version 9.2). An effect with p-value <0.05 was considered statistically significant.
RESuLTS
The combined literature search identified 2410 citations. Of these, 2345 were excluded on title 
and abstracts, leaving 65 citations for full text review. Finally 9 citations met all criteria and were 
included in this review (Figure 4.3).4, 14, 28, 44-49 However, one study was later excluded, as the 
author did not respond to repetitive questioning about study design and results.28 
The eight studies remaining were heterogeneous in study characteristics, like study design, 
choice of hrHPV testing methods and the assessment of disease status at entry and end of 
follow-up (Table 4.4). Concerning design, seven studies were prospective, and one study 
was a case-control analysis. HrHPV testing was performed using HC2 testing in four studies, 
and PCR testing in three studies. In one study both techniques were performed. All studies 
collected samples for cytology and hrHPV-testing six months after treatment. One study had a 
significant longer follow-up than all other included studies.46 Therefore, data for this study was 
recalculated for a follow-up of 2 years.
In all studies combined, 1513 women had been treated for CIN2/3. The number of women 
per study varied between 63 and 485. The age of the participants ranged between 19 and 83 
years. Treatment failure, expressed in terms of residual and recurrent CIN2+, ranged from 4.0% 
to 11.9%. Recurrence rates of CIN2+, sensitivities as well as DORs of the individual studies and 
pooled values at six months post treatment are shown in Figure 4.4. 
The correlation between the logit TPR and logit FPR was not significant for all diagnostic 
tests (cytology r=0.024, p=0.96; hrHPV r = 0.49, p = 0.18; and co-testing: r = 0.42, p = 0.26). 
Moses’ linear regression model did not significantly improve the constant model (cytology: p 
= 0.21, hrHPV: p = 0.80, and co-testing: p = 0.67), giving further support for the assumption of 
a constant DOR over studies.
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Diagnost ic  accuracy
The sensitivity of cytological testing 6 months after treatment in predicting post treatment 
CIN lesions varied between the studies between 0.67 and 1.0. For sensitivity, the test for 
heterogeneity between studies was not significant (Q(7)=5.08, p=0.65; I2=0.0%). The pooled 
sensitivity was 0.79 (95%CI 0.72-0.85). The specificity of cytology ranged from 0.64 to 0.91 and 
heterogeneity between studies was significant (Q(7)=48.76, p<0.0001; I2=85.6%). The pooled 
Figure	 4.3	 Study selection process for systematic reviews on 
accuracy of tests for detection of post-treatment CIN2+.
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specificity was 0.81 (95%CI 0.74-0.86). The pooled DOR of cytology was 13.81 (95%CI 9.17-20.80) 
and there was no evidence for statistically significant heterogeneity (Q(7)=7.16, p=0.41; I2=2.2%).
In the studies the sensitivity of hrHPV-testing varied between 0.87 and 1.0. For sensitivity, 
the test for heterogeneity between studies was not significant (Q(7) =6.04, p=0.53; I2=0.0%). 
The pooled sensitivity was 0.92 (95%CI 0.87-0.96). The specificity of hrHPV ranged from 0.57 
to 0.88 and heterogeneity between studies was significant (Q(7)=91.38, p<0.0001; I2=92.3%). 
Table	 4.4	 Study characteristics of the individual studies that investigated the performance of hrHPV and 
cytology (6 months after treatment) in predicting residual and recurrent high-grade disease.
Study Year Country
Participant
final/initial
Recurrencea	
CIN2+	(%)
Follow-up	in	
months	(range)
hrHPV
test Study	design
Cecchini44 2004 Italy 84/84 10 (11.9) 23 (11-40)
PCR
Prospective cohort study including 84 women (mean age 34.3) treated for CIN2/3 by LLETZ between February 
1999 and June 2001. Follow-up at six months after treatment included hrHPV-testing, cytology and colposcopy. 
Method of PCR- testing: type-specific HPVE6/E7 PCR. Method of cytology: not specified
Sarian47 2004 Brazil 88/107 11 (10.2) 17 HC2
Prospective cohort study including 88 women (mean age 34 years, range 20-60) treated for CIN2/3 by LLETZ 
between March 2001 and December 2002. Follow-up at six months after treatment for hrHPV-testing, cytology 
and colposcopy. Biopsies were taken if cytology revealed HSIL, or if a suspect area was present. Method of 
cytology: glass slide, specimen taken with Ayre spatula and endocervix brush.
Alonso14 2006 Spain 203/224 24 (11.8) 20 (6-66) HC2
Prospective cohort study including 203 women (mean age 38.6 years, range 22-83) treated for CIN2/3 by LLETZ 
between May 1998 and October 2004. Follow-up at 6 months after treatment included hrHPV-testing, cytology 
and colposcopy. Biopsies were taken if abnormal cytology (≥ASC-US) or hrHPV–positivity was present. Women 
with two consecutive negative cytological smears and negative colposcopy were considered negative for 
recurrence, irrespective of the hrHPV test result. Method of cytology: glass slide, specimen taken with Ayre 
spatula and cytobrush.
Kreimer4 2006 USA 485/610 32 (6.6) 24
HC2
PCR
Prospective cohort study including 485 women (median age 24 years, range 21-28) treated for CIN2/3 by LLETZ 
between January 1997 and December 1998. Follow-up at 6 months after treatment included hrHPV-testing, 
including genotyping, and cytology. For analyses, data from HC2 testing was used and women with missing 
hrHPV test results were excluded. Method of PCR- testing: PGMY09/11 PCR. Method of cytology: liquid-based 
cytology.
Verguts49 2006 Belgium 72/72 6 (8.0) 24 HC2
Prospective cohort study including 72 women (mean age 40 years, range 22-78) treated for CIN2/3 by LLETZ 
between February 2000 and February 2003. Follow-up at three to six months after treatment included hrHPV, 
cytology and colposcopy. Biopsies were taken if any suspected area was present. Method of cytology: liquid-
based cytology, taken with Cervex-brush.
Smart48 2010 New-Zealand 100/100 4 (4.0) 18 HC2
Prospective cohort study including 100 women (mean age 32 years, range 19-66), treated for CIN 2/3 by LLETZ 
or conization between January 2007 and January 2008. Follow-up (mean 9 months; range 3-18) included hrHPV-
testing, cytology and colposcopy. Biopsies were taken if any suspect area was seen. One woman with inadequate 
cytology was excluded from analyses. Method of cytology: liquid-based cytology, taken with Cervex-brush.
Heymans45 2011 Belgium 63/63 n.a. >24 PCR
Case control study (1:2) including 63 women (median age cases 40.9 years and controls 35.5 years) treated 
for CIN 2/3 by LLETZ or conization between January 2001 and December 2007. Follow-up at six months after 
treatment included hrHPV-testing, including genotyping, and cytology. Method of PCR- testing: type-specific 
HPVE6/E7 PCR. Method of cytology: liquid-based cytology, taken with Cervex-brush.
Kocken46 2011 Netherlands 435/445 45b (10.8) 24† PCR
Prospective cohort study including 435 women (mean age 34.9 years, range 21-70) treated for CIN2/3 by LLETZ 
or conization between July 1988 and November 2004. Follow-up at six months after treatment included hrHPV-
testing, including genotyping, and cytology. Colposcopy was performed if abnormal cytology (≥ASC-US) or 
hrHPV–positivity was present. For analyses, data was limited to 2 years of follow-up. Method of PCR- testing: 
GP5+/6+ PCR. Method of cytology: partly glass slides, others not specified.
CIN, cervical intraepithelial neoplasia; hrHPV, high-risk type of the human papillomavirus; LLETZ, large-loop 
excision of the transformation zone; PCR, polymerase chain reaction; HC2, Hybrid-Capture 2 test; n.a, not 
applicable
a includes all residual and recurrent disease. 
b for analyses data was limited to 2 years of follow-up.
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Table	 4.4	 Study characteristics of the individual studies that investigated the performance of hrHPV and 
cytology (6 months after treatment) in predicting residual and recurrent high-grade disease.
Study Year Country
Participant
final/initial
Recurrencea	
CIN2+	(%)
Follow-up	in	
months	(range)
hrHPV
test Study	design
Cecchini44 2004 Italy 84/84 10 (11.9) 23 (11-40)
PCR
Prospective cohort study including 84 women (mean age 34.3) treated for CIN2/3 by LLETZ between February 
1999 and June 2001. Follow-up at six months after treatment included hrHPV-testing, cytology and colposcopy. 
Method of PCR- testing: type-specific HPVE6/E7 PCR. Method of cytology: not specified
Sarian47 2004 Brazil 88/107 11 (10.2) 17 HC2
Prospective cohort study including 88 women (mean age 34 years, range 20-60) treated for CIN2/3 by LLETZ 
between March 2001 and December 2002. Follow-up at six months after treatment for hrHPV-testing, cytology 
and colposcopy. Biopsies were taken if cytology revealed HSIL, or if a suspect area was present. Method of 
cytology: glass slide, specimen taken with Ayre spatula and endocervix brush.
Alonso14 2006 Spain 203/224 24 (11.8) 20 (6-66) HC2
Prospective cohort study including 203 women (mean age 38.6 years, range 22-83) treated for CIN2/3 by LLETZ 
between May 1998 and October 2004. Follow-up at 6 months after treatment included hrHPV-testing, cytology 
and colposcopy. Biopsies were taken if abnormal cytology (≥ASC-US) or hrHPV–positivity was present. Women 
with two consecutive negative cytological smears and negative colposcopy were considered negative for 
recurrence, irrespective of the hrHPV test result. Method of cytology: glass slide, specimen taken with Ayre 
spatula and cytobrush.
Kreimer4 2006 USA 485/610 32 (6.6) 24
HC2
PCR
Prospective cohort study including 485 women (median age 24 years, range 21-28) treated for CIN2/3 by LLETZ 
between January 1997 and December 1998. Follow-up at 6 months after treatment included hrHPV-testing, 
including genotyping, and cytology. For analyses, data from HC2 testing was used and women with missing 
hrHPV test results were excluded. Method of PCR- testing: PGMY09/11 PCR. Method of cytology: liquid-based 
cytology.
Verguts49 2006 Belgium 72/72 6 (8.0) 24 HC2
Prospective cohort study including 72 women (mean age 40 years, range 22-78) treated for CIN2/3 by LLETZ 
between February 2000 and February 2003. Follow-up at three to six months after treatment included hrHPV, 
cytology and colposcopy. Biopsies were taken if any suspected area was present. Method of cytology: liquid-
based cytology, taken with Cervex-brush.
Smart48 2010 New-Zealand 100/100 4 (4.0) 18 HC2
Prospective cohort study including 100 women (mean age 32 years, range 19-66), treated for CIN 2/3 by LLETZ 
or conization between January 2007 and January 2008. Follow-up (mean 9 months; range 3-18) included hrHPV-
testing, cytology and colposcopy. Biopsies were taken if any suspect area was seen. One woman with inadequate 
cytology was excluded from analyses. Method of cytology: liquid-based cytology, taken with Cervex-brush.
Heymans45 2011 Belgium 63/63 n.a. >24 PCR
Case control study (1:2) including 63 women (median age cases 40.9 years and controls 35.5 years) treated 
for CIN 2/3 by LLETZ or conization between January 2001 and December 2007. Follow-up at six months after 
treatment included hrHPV-testing, including genotyping, and cytology. Method of PCR- testing: type-specific 
HPVE6/E7 PCR. Method of cytology: liquid-based cytology, taken with Cervex-brush.
Kocken46 2011 Netherlands 435/445 45b (10.8) 24† PCR
Prospective cohort study including 435 women (mean age 34.9 years, range 21-70) treated for CIN2/3 by LLETZ 
or conization between July 1988 and November 2004. Follow-up at six months after treatment included hrHPV-
testing, including genotyping, and cytology. Colposcopy was performed if abnormal cytology (≥ASC-US) or 
hrHPV–positivity was present. For analyses, data was limited to 2 years of follow-up. Method of PCR- testing: 
GP5+/6+ PCR. Method of cytology: partly glass slides, others not specified.
CIN, cervical intraepithelial neoplasia; hrHPV, high-risk type of the human papillomavirus; LLETZ, large-loop 
excision of the transformation zone; PCR, polymerase chain reaction; HC2, Hybrid-Capture 2 test; n.a, not 
applicable
a includes all residual and recurrent disease. 
b for analyses data was limited to 2 years of follow-up. The pooled specificity was 0.76 (95%CI 0.67-0.84). The pooled DOR of hrHPV testing was 
34.68 (95%CI 18.87-63.73) and there was no evidence for statistically significant heterogeneity 
(Q(7)=3.39, p=0.85; I2=0.0%).
The sensitivity of co-testing varied between 0.90 and 1.0. For sensitivity, the test for 
heterogeneity between studies was not significant (Q(7)=5.41, p=0.61; I2=0.0%). The pooled 
sensitivity was 0.95 (95%CI 0.91-0.98). The specificity varied between 0.36 and 0.78 and 
heterogeneity between studies was significant (Q(7)=47.26, p<0.0001; I2=85.2%). The pooled 
specificity was 0.67 (95%CI 0.60-0.74). The pooled DOR of co-testing was 35.86 (95%CI 17.59–73.11) 
and there was no evidence for statistically significant heterogeneity (Q(7)=2.36, p=0.94; I2=0.0%).
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Figure	4.4	Meta-analysis of the sensitivity and specificity, including pooled estimates, of testing 6 months after 
treatment with cytology, hrHPV or co-testing. 
TP, true positives; FP, false positives; FN, false negatives; TN, true negatives; FEM, fixed effects model; REM, 
random effects model; DOR, diagnostic odds ratio. Forest plots of sensitivity (left) and specificity (right).
A bivariate regression model was fitted to test the influence of the two types of hrHPV 
tests, HC2 and PCR on sensitivity and specificity. Adding of the hrHPV test type as a covariate 
explained 11.5% of the between-study variance for cytology, which was not significant (t(7) = 
1.25, p = 0.25). Also for hrHPV and co-testing the addition of the hrHPV test type as a covariate 
explained a not significant part of the between-study variance (hrHPV 7.7%, (t(7) = 0.81, p = 
0.45) and co-testing 31.9%, (t(7) = 2.15, p = 0.07)).
Overall, hrHPV-testing after six months predicted post-treatment CIN with significantly 
higher sensitivity (relative sensitivity 1.15; 95%CI 1.06-1.25 (Z=3.27, p=0.001)) than cytology and a 
similar specificity (relative specificity 0.95; 0.88-1.02 (Z=1.53, p=0.13)).
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Methodolog ica l  qua l i ty  o f  inc luded  s tud ies
Table 4.5 summarizes the methodological quality of the 8 included studies. All studies included 
a representative patient spectrum of women treated for high-grade cervical disease. One 
case-control study was included and selection bias could not be excluded.45 We added this 
criterion and although most studies imply that women were continuously included, this was 
only explicitly mentioned in one study.44 The reference standard was adequate in all studies. 
All studies defined a positive test result of post-treatment disease as a histological finding of 
CIN2+. A negative test result was verified by colposcopy in five studies. In the three studies 
remaining a negative test result was verified by consecutive negative cytological smears.14, 45-46 
One of these studies46 was a multi-cohort study and in two of the three incorporated studies 
test results were confirmed with a colposcopic examination in all women, and in the third study 
absence of disease was confirmed by three consecutive negative cytological smears17. In every 
study all patients were assessed within two years. Complete verification with the reference 
standard was performed in four studies.4, 14, 47, 49 In three other studies not all patients were 
examined by colposcopy, but were considered free of disease by cytological examination.14, 
45-46 One study performed a colposcopy in all patients at 6 months after treatment, but did not 
specify when colposcopies were performed later in follow-up.48 In none of the studies hrHPV 
was part of the reference standard. Moreover, in most studies the reference standards were 
interpreted without knowing the results of the hrHPV-test. Only in two studies women were 
referred on basis of the hrHPV test result.14, 46 For the case-control study this item could not 
be assessed.45 Of interest might be that only one study explicitly mentions biopsy taking in all 
Table	4.5	Summary of methodological quality. Review authors’ judgments about each methodological quality 
item for each included study.
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Representative spectrum? + + + + + + + +
Selection bias ? - ? ? ? ? ? +
Acceptable reference standard? + + + + + + + +
Appropriate timing of tests and verification of outcome? + + + + + + + +
Partial verification avoided? + + + + + + + +
Differential verification avoided? - - ? - + + + +
Incorporation avoided? + + + + + + + +
Reference test results blinded? - ? + + + + + +
Uninterpretable results reported? + + + + + + + +
Withdrawals explained? + + + + + + + +
Minus sign = negative score, plus sign = positive score, question mark = unclear whether item scores negatively 
or positively.
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women irrespective of any test result4, in all other studies biopsy taking is dependant of either 
visual impression14, 47-49 or abnormal cytological test results.14, 44, 46-47 If present, uninterpretable 
results were mentioned in all studies. Although in one study the percentage “missing” was 
higher in the group without post-treatment disease than in the group diagnosed with post-
treatment CIN2+ (13.7% versus 5.9%), this difference was not significant (p=0.295, Fisher’s 
exact).4 Half of the studies had no withdrawals to explain and the remaining studies dealt with 
this item appropriately.
The included studies differed in only 3 items of the QUADAS list (Table 4.5); selection bias, 
differential verification and blinding of reference test results. These three items were each 
separately added as a dichotomous covariate to the bivariate regression models that were also 
used to test the effect of the hrHPV test type. A rating of ‘+’ was counted as present, a rating of 
‘?’ or ‘–‘ as absent. Separate addition of each item as a covariate did not improve the bivariate 
regression models of cytology, hrHPV-testing or co-testing significantly (data not shown). 
DISCuSS ION
In this systematic review we described the value of 6-month testing for cytology and/or hrHPV 
in the surveillance of women treated for CIN2/3 and confirmed the advantage of implementing 
hrHPV in the follow-up of women treated for high-grade CIN as found in previously conducted 
meta-analyses.3, 9, 11, 16, 19-20 HrHPV testing has a significantly higher sensitivity than cytology, 
indicated by a relative sensitivity of 1.15 (95%CI 1.06-1.25), without decreasing the specificity 
(relative specificity 0.95, 0.88-1.02).  
We measured the DOR to compare the three different tests (hrHPV, cytology and co-
testing). The DOR of co-testing testing was higher than the DOR of hrHPV-testing or cytology. 
This indicates that the overall discriminative power of co-testing is the best. As approximately 
10%3 of women treated for CIN2/3 develop high grade post-treatment disease, it seems logical 
to choose a test that assures a minimal risk of high-grade disease in this group and to select 
the test with the highest sensitivity. The pooled sensitivity of co-testing was with 0.95 (95%CI 
0.91-0.98) also higher than the sensitivity of sole cytological or hrHPV testing. However, the 
pooled specificity was only 0.67, resulting in approximately 10% more women referred for 
repeat testing or colposcopy, or both.  
Sources  o f  b ias  and  potent ia l  sources  o f  heterogene i ty
The purposes of a quality assessment are to identify potential sources of bias and to estimate 
their impact. The overall methodological quality of the included studies was generally good 
(Table 4.5), however study characteristics between studies varied. For instance, although the 
average age in most studies was approximately 35 years, one study included women with a 
median age of 24 years (range 21-28).4  As both the prevalence of CIN and of hrHPV varies with 
age, this factor may influence the test accuracy across the studies. Another difference was that 
percentages of recurrence were given for the total follow-up period. Most studies measured 
follow-up until 24 months after treatment and by limiting the follow-up of Kocken et al. to two 
years46, studies became more homogeneous. Another point to address is that we considered 
the first hrHPV testing moment to be at 6 months after treatment. Yet, some studies performed 
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hrHPV tests before 4, 47, 49 or after 14, 48 6 months. Because hrHPV infections clear over time 17, 21, the 
risk of developing post-treatment disease will also diminish over time and this could possibly 
affect the sensitivity of the test.
Other possible reasons for heterogeneity between the studies may be explained by 
different collection methods of material (e.g. liquid based cytology versus conventional glass 
slides) and different execution of the analyses (e.g. either single pathologist or review of all 
cytology and/or histology).
Based on our methodological appraisal the most likely sources of bias are selection 
bias and differential verification bias. Selection bias arises when women are not included in 
a consecutive order. Only one of the cohort studies44 mentions the inclusion of patients to 
be explicitly consecutive, the other studies only describe to include women within a certain 
timeframe. However, the populations included in these studies seem to be consecutive and 
are most likely comparable to one another. But, as for instance, this would have resulted in an 
exclusion of more difficult cases, it could have resulted in a lower number of false positives and 
false negatives and hence to increased estimates of sensitivity and specificity.
Differential verification bias arises if two different reference tests are used and the tests 
have different accuracy. Some of the studies included in our analysis avoided this problem 
because they performed colposcopic examinations in all women, irrespective of their test 
results.4, 44, 47, 49 However, only one study has, besides performing a colposcopy, also taken a 
biopsy in all subjects to verify the presence, or absence, of cervical disease. Other studies only 
referred for exit-colposcopy when abnormal test results were found.14, 46 Some studies did not 
specify when women were referred for colposcopy.48 These last studies are therefore prone to 
(detection) bias. Differential verification bias could have resulted in an overestimation of both 
sensitivity and specificity. However, women with repetitively negative cytological test results 
have a low risk of harbouring high-grade disease46 and therefore we expect this type of bias to 
be of limited influence.
The included studies remained statistically heterogeneous concerning specificity. 
Consequently we used a random effect model to calculate the pooled estimates that were 
heterogeneous. Until better-conducted studies, such as large randomized controlled trials 
with histological verification of all subjects, independent of hrHPV or cytology results, are 
available, the pooled estimate provides clinically relevant information. 
Study  l imi tat ions
Our study provides evidence suggesting that hrHPV-testing is more accurate for the diagnosis 
of post-treatment cervical disease than cytology. Although this is in line with previous reviews, 
these results are based on a small number of studies.
Also our review is limited to a follow-up of two years as almost all included studies had 
a follow-up restricted to this period and thereby hampering long-term information of the 
different test performances. This information is relevant, as the risk of developing recurrent 
disease is significantly increased for over 10 years after treatment.5, 7, 18 Only two studies were 
identified describing hrHPV testing in long-term follow-up.46, 50 One of these studies excluded 
residual/recurrent disease developed within two years of treatment and only described the 
performance of the hrHPV test. Therefore no comparison could be made with the performance 
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of cytology and this study was excluded for analysis in this review.50 One study that described 
the long-term prediction of hrHPV and/or cytology at 6 months after treatment remained.46 
In this study the sensitivities of hrHPV and cytology in detecting post-treatment disease 
decreased when the total follow-up time increased. For cytology, the sensitivity in the total 
study with a follow-up up to 21.5 years was 66% (95%CI 55-76) compared to a sensitivity of 78% 
in the first two years (Figure 4.4). For hrHPV testing, these values were 72% (95%CI 61-81) and 
87%, respectively. This could illustrate the acquisition of new hrHPV types or re-infection/
reactivation of the same hrHPV types that will eventually result in high-grade lesions. Another 
possibility might be the presence of false negative HPV tests, due to integration of the viral 
DNA targeted in the HPV test in the genome of the host cell.
Another limitation is that only 6-month testing is measured. Several studies indicated that 
one test moment is insufficient to predict post-treatment disease and that therefore repeat 
testing should be performed.46, 50 However, although some authors have described follow-up 
algorithms for post-treatment surveillance, pooling of these data was not possible. 
A final limitation is that although a large number of citations were reviewed, this review 
might be subject to publication bias. However, the impact that publication bias has on 
diagnostic accuracy systematic reviews is unknown.51
Conc lus ions
This review clearly indicates that post-treatment testing at 6 months after treatment should 
include hrHPV testing. HrHPV testing after 6 months has a higher sensitivity than and a 
similar specificity as cytology. The sensitivity of co-testing is even higher than of the separate 
individual tests. As women treated for CIN2/3 have a high risk of developing recurrent disease, 
sensitivity is valued higher than specificity and therefore hrHPV testing (or co-testing) should 
be incorporated in post-treatment surveillance. As even the sensitivity of co-testing is not 
sufficiently high to rely on a single test moment, repeat testing is necessary to identify all 
women at risk for post-treatment disease.46 Several studies already indicated that women 
testing negative for co-testing after 6 months could omit the 12-month test moment and 
return for monitoring at 24 months after treatment. However, more information, especially 
on long-term recurrence and cost-effectiveness is needed to recommend a definite follow-up 
algorithm.
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SuPPLEMENTARY  DATA
Supplementary	Table	4.1	Search strategy using PubMed (April 6th, 2011)
(“Vaginal Smears”[Mesh] OR “Papillomaviridae”[Mesh] OR “DNA Methylation”[Mesh] OR “Biopsy”[Mesh:NoExp] 
OR “Colposcopy”[Mesh] OR methylation*[tiab] OR colposcop*[tiab] OR smear*[tiab] OR papanicolaou[tiab] 
OR hpv[tiab] OR papillomavir*[tiab] OR biops*[tiab]) AND (conizati*[tiab] OR conisati*[tiab] OR lletz[tiab] OR 
letz[tiab] OR leep[tiab] OR (loop[tiab] AND (excision*[tiab] OR electroexcision*[tiab])) OR “Conization”[Mesh] 
OR “Cervical Intraepithelial Neoplasia”[Mesh] OR cin[tiab] OR “cervical intraepithelial”[tiab] OR “Uterine Cervical 
Dysplasia”[Mesh] OR ((cervical[tiab] OR cervix[tiab]) AND dysplas*[tiab])) AND ((randomized controlled trial[pt] 
OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR 
trial[tiab] OR groups[tiab]) OR ((review*[tiab] OR search*[tiab] OR survey*[tiab] OR handsearch*[tiab] OR hand-
search*[tiab]) AND (databa*[tiab] OR data-ba*[tiab] OR bibliograph*[tiab] OR electronic*[tiab] OR medline*[tiab] 
OR pubmed*[tiab] OR embase*[tiab] OR Cochrane[tiab] OR cinahl[tiab] OR psycinfo[tiab] OR psychinfo[tiab] OR 
cinhal[tiab] OR “web of science”[tiab] OR “web of knowledge”[tiab] OR ebsco[tiab] OR ovid[tiab] OR mrct[tiab] OR 
metaregist*[tiab] OR meta-regist*[tiab] OR ((predetermined[tiab] OR pre-determined[tiab]) AND criteri*[tiab]) 
OR apprais*[tiab] OR inclusion criteri*[tiab] OR exclusion criteri*[tiab]) OR (review[pt] AND systemat*[tiab]) 
OR “systematic review”[tiab] OR “systematic literature”[tiab] OR “integrative review”[tiab] OR “integrative 
literature”[tiab] OR “evidence-based review”[tiab] OR “evidence-based overview”[tiab] OR “evidence-based 
literature”[tiab] OR “evidence-based survey”[tiab] OR “literature search”[tiab] OR ((systemat*[ti] OR evidence-
based[ti]) AND (review*[ti] OR literature[ti] OR overview[ti] OR survey[ti])) OR “data synthesis”[tiab] OR 
“evidence synthesis”[tiab] OR “data extraction”[tiab] OR “data source”[tiab] OR “data sources”[tiab] OR “study 
selection”[tiab] OR “methodological quality”[tiab] OR “methodologic quality”[tiab] OR cochrane database 
syst rev[ta] OR meta-analy*[tiab] OR metaanaly*[tiab] OR metanaly*[tiab] OR meta-analysis[pt] OR meta-
synthesis[tiab] OR metasynthesis[tiab] OR meta-study[tiab] OR metastudy[tiab] OR metaethnograph*[tiab] OR 
meta-ethnograph*[tiab] OR Technology Assessment, Biomedical[mh] OR hta[tiab] OR health technol assess [ta] 
OR evid rep technol assess summ[ta] OR health technology assessment[tiab]))
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Supplementary	 Table	 4.2 Checklist for the QUality Assessment of Diagnostic Accuracy Studies (QUADAS), 
modified version.26
nr Item	definition Item	question Assessment
1 Representative spectrum?
Was the spectrum of included patient’s representative 
of the patients who will receive the test in practice?
Yes: patients treated by conisation (either LLETZ or cone) for cervical intraepithelial neoplasia grade 2 or 3 
(CIN2/3). 
Unclear: reporting insufficient to assess this item.
No: inclusion of healthy controls. 
2 Selection bias avoided?
Were included women included on a continuous 
basis?
Yes: women were explicitly included on a continuous basis.
Unclear: continuous selection is not explicitly mentioned.
No:  women were not continuously included (e.g. case control study).
3
Acceptable
reference standard?
Is the reference standard likely to correctly classify the 
target condition?
Yes: histological confirmation of CIN2+ is considered as presence of disease, absence of disease is either 
confirmed by colposcopy or by repetitive negative cytology results.
Unclear: reporting insufficient to assess this item.
No: no histological confirmation of presence of disease or no repetitive negative cytology results.
4
Acceptable timing 
of tests and verification of outcome?
Is the time period between reference standard and 
index test short enough to be reasonably sure that 
the target condition did not change between the two 
tests?
‘Yes’ for all studies because all studies assessed disease status within 2 years of follow-up.
5 Partial verification avoided?
Did the whole sample or a random selection of the 
sample, receive verification using a reference standard 
of diagnosis?
‘Yes’ for all studies as all patients performed either a colposcopy in all patients or were considered negative for 
disease because of ≥2 cytological negative smears. 
6 Differential verification avoided?
Did all patients receive the same reference standard 
regardless or do some the index test result?
Yes: irrespective of the index test result the same reference standard  is performed.
Unclear: reporting insufficient to assess this item.
No: the result of the index test affected the policy of verification (e.g. a positive hrHPV test results in 
colposcopy) or different reference standards were performed.
7 Incorporation avoided?
Was the reference standard independent of the 
index test (i.e. the index test did not form part of the 
reference standard)?
Yes: the hrHPV test is not part of the reference standard.
Unclear: reporting insufficient to assess this item.
No: the hrHPV test is part of the reference standard.
8 Index test results blinded?
Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Not applicable. The performed hrHPV tests (both HCII and PCR) are objective tests.
9 Reference test results blinded?
Were the reference test results interpreted without 
knowledge of the results of the index test? 
Yes: hrHPV test was performed prior to or simultaneously with reference test of hrHPV test results were 
blinded.
Unclear: reporting insufficient to assess this item.
No: hrHPV test was performed and assessed with knowledge of the results of the reference standard.
10 Clinical data available?
Were the same clinical data available when test results 
were interpreted as would be available when the test 
is used in practice? 
Not applicable. The performance of the(automated) hrHPV test is not influenced by the availability of clinical 
data.
11 Uninterpretable results reported?
Were uninterpretable or intermediate test results 
reported?
Yes: the number of patients with indeterminate hrHPV test results has been reported.
Unclear: reporting insufficient to assess this item.
No: the number of patients with indeterminate hrHPV test results has not been reported.
12 Withdrawals explained? Were withdrawals from the study explained? 
Yes:  the number of withdrawals has been reported and reasons have been explained or there were no 
withdrawals.
Unclear: reporting insufficient to assess this item.
No: the number of withdrawals has not been reported.
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Supplementary	 Table	 4.2 Checklist for the QUality Assessment of Diagnostic Accuracy Studies (QUADAS), 
modified version.26
nr Item	definition Item	question Assessment
1 Representative spectrum?
Was the spectrum of included patient’s representative 
of the patients who will receive the test in practice?
Yes: patients treated by conisation (either LLETZ or cone) for cervical intraepithelial neoplasia grade 2 or 3 
(CIN2/3). 
Unclear: reporting insufficient to assess this item.
No: inclusion of healthy controls. 
2 Selection bias avoided?
Were included women included on a continuous 
basis?
Yes: women were explicitly included on a continuous basis.
Unclear: continuous selection is not explicitly mentioned.
No:  women were not continuously included (e.g. case control study).
3
Acceptable
reference standard?
Is the reference standard likely to correctly classify the 
target condition?
Yes: histological confirmation of CIN2+ is considered as presence of disease, absence of disease is either 
confirmed by colposcopy or by repetitive negative cytology results.
Unclear: reporting insufficient to assess this item.
No: no histological confirmation of presence of disease or no repetitive negative cytology results.
4
Acceptable timing 
of tests and verification of outcome?
Is the time period between reference standard and 
index test short enough to be reasonably sure that 
the target condition did not change between the two 
tests?
‘Yes’ for all studies because all studies assessed disease status within 2 years of follow-up.
5 Partial verification avoided?
Did the whole sample or a random selection of the 
sample, receive verification using a reference standard 
of diagnosis?
‘Yes’ for all studies as all patients performed either a colposcopy in all patients or were considered negative for 
disease because of ≥2 cytological negative smears. 
6 Differential verification avoided?
Did all patients receive the same reference standard 
regardless or do some the index test result?
Yes: irrespective of the index test result the same reference standard  is performed.
Unclear: reporting insufficient to assess this item.
No: the result of the index test affected the policy of verification (e.g. a positive hrHPV test results in 
colposcopy) or different reference standards were performed.
7 Incorporation avoided?
Was the reference standard independent of the 
index test (i.e. the index test did not form part of the 
reference standard)?
Yes: the hrHPV test is not part of the reference standard.
Unclear: reporting insufficient to assess this item.
No: the hrHPV test is part of the reference standard.
8 Index test results blinded?
Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Not applicable. The performed hrHPV tests (both HCII and PCR) are objective tests.
9 Reference test results blinded?
Were the reference test results interpreted without 
knowledge of the results of the index test? 
Yes: hrHPV test was performed prior to or simultaneously with reference test of hrHPV test results were 
blinded.
Unclear: reporting insufficient to assess this item.
No: hrHPV test was performed and assessed with knowledge of the results of the reference standard.
10 Clinical data available?
Were the same clinical data available when test results 
were interpreted as would be available when the test 
is used in practice? 
Not applicable. The performance of the(automated) hrHPV test is not influenced by the availability of clinical 
data.
11 Uninterpretable results reported?
Were uninterpretable or intermediate test results 
reported?
Yes: the number of patients with indeterminate hrHPV test results has been reported.
Unclear: reporting insufficient to assess this item.
No: the number of patients with indeterminate hrHPV test results has not been reported.
12 Withdrawals explained? Were withdrawals from the study explained? 
Yes:  the number of withdrawals has been reported and reasons have been explained or there were no 
withdrawals.
Unclear: reporting insufficient to assess this item.
No: the number of withdrawals has not been reported.
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Assessment  o f  women at  r i sk  o f  deve lop ing  h igh-grade 
cerv ica l  d i sease ;  pre -  and  post- t reatment  cons iderat ions
The development of cervical cancer is preceded by a long period of well-defined premalignant 
stages in which these lesions can be diagnosed and treated before they will result in invasive 
cancer.1-2 In developed countries this has resulted in nationwide cervical cancer screening 
programmes which have lead to a substantial reduction of incidence and mortality of cervical 
cancer.3-6 Prevention includes a whole spectrum of measurements: screening, triage of equivocal 
test results, colposcopic examination of abnormal test results, treatment and post-treatment 
surveillance. Improvements could be made by improving the tests used, by increasing the 
experience of those performing and interpreting these tests and by increasing the number 
of women participating in the prevention programme. The health benefit of women could be 
improved even further when a priori thresholds concerning the risk of developing high-grade 
cervical disease would be adopted for closer surveillance, colposcopy, or treatment.7 In 2007, 
Castle and colleagues proposed such an algorithm.7 In this proposal, a CIN3+ risk of less than 
2% in the subsequent 2-3 years justifies referral to the screening programme, a risk between 
2 and 10% requires retesting, and a risk of 10% or more referral for colposcopic examination.7 
In the Netherlands the 5-year CIN3+ risk in women with normal cytological test results in the 
population-based screening programme is 0.7%.8 This risk is considered acceptable to the 
Dutch general population, the health authorities, and the professionals.8 
Hence, in this thesis we use an adapted threshold of a 5-year CIN3+ risk of 0.7% to refer 
women to routine screening. With the results of the studies described in this thesis, current 
guidelines on cervical cancer screening and follow-up of women treated for high-grade CIN 
can be improved. Modifications in the existing guidelines for certain categories of women with 
abnormal test results or CIN will be discussed in the following sections.
Pre- t reatment  cons iderat ions
Although prevention programmes vary widely by country, all screening programmes should, 
irrespective of the screening method chosen, suffice to key requirements, being broad 
coverage of the screening population and adequate follow-up of women with abnormal test 
results.  
In the Netherlands, a cytology-based cervical screening programme is in place in which all 
women between 30 and 60 years of age are invited every 5 years for cytological examination.9 
The vast majority (96.5%) of these women have normal cytology and a risk of 0.7% of developing 
CIN3+ in the following 5 years.8, 10 These women are recalled in the next screening round.8 In 
women with abnormal test results a similar risk should be reached before they can be referred 
back to the population-based screening programme. 
Women wi th  abnormal  cy to logy  in  populat ion-based  screen ing
In the Dutch population-based screening programme approximately 3.5% of the women have 
an abnormal cytological test result.8, 11 Most of these abnormalities will not result in cervical 
carcinoma, however those susceptible to malignant progression should be detected in an early 
stage. As hrHPV is necessary for the development of cervical cancer, truly progressive lesions 
may be detected sooner when hrHPV DNA-testing is added to the screening programme.
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About 1.0% of screened women have a >BMD test result (equivalent to moderate dyskaryosis 
or worse, ≥PAP3a2, HSIL, or CISOE-A ≥S5, ≥O4, and/or ≥E6).8, 11 Currently, these women are 
referred for a colposcopic examination as their risk of developing high-grade disease within 
the next 5 years is over 50%.7-8, 12-13 Additional testing with hrHPV at baseline, or after 6 months, 
identifies no subgroup that has a low enough risk refraining from colposcopic examination, let 
alone from referral to population-based screening. Our study (Chapter 3) demonstrated that 
the CIN3+ risk in the subsequent 5 years was still 5 times higher than the accepted risk of 0.7%. 
Therefore these women should be monitored more closely, also if their initial colposcopic 
examination does not reveal high-grade disease.
Conc lus ions  for  women hav ing  >BMD cy to log ica l  test 
resu l ts :
All women with >BMD should be referred for colposcopy without additional testing for 
hrHPV.
The risk of developing high-grade CIN is increased for at least 10 years, and therefore 
long-term monitoring is required, also in women with negative colposcopy at baseline.
A BMD test result (equivalent to borderline or mild dyskaryosis, PAP2/3a1, ASCUS/LSIL, CISOE-
A: S2-4, O3, or E3-5) is found in 2.5% of all screened women.8 Approximately 10-20% of these 
women harbour a high-grade lesion that warrants further investigation.14-15 Therefore Dutch 
guidelines recommend women with this test result to repeat the smear after 6 months.16 All 
women with a ≥BMD repeat smear should be referred for colposcopy, while women with normal 
cytology will be retested one year later (18 months after the initial BMD smear). The majority 
of referred women, however, will have insignificant lesions that will regress spontaneously.14 
To reduce the number of referrals and colposcopies, the Netherlands Society of Pathology 
(NVVP) published updated guidelines in 2006, in which laboratories may choose to include 
a hrHPV test in the repeat visit after 6 months (see Figure 1.5).17 Women who test negative for 
both cytology and hrHPV after 6 months may directly return to population-based screening12, 
18, as negative co-testing has a very high negative predictive value.14, 19-20 In Chapter 3 we confirm 
the negligible 10-year CIN3+ risk of this group. Only women with a hrHPV-positive BMD test 
result and/or cytology of >BMD (irrespective of a hrHPV test result) are referred for colposcopy. 
All remaining women (having hrHPV positive normal cytology, or hrHPV-negative BMD) are 
retested after one year.17 So, by adding hrHPV testing in the follow-up of these women, the 
number of follow-up visits can be decreased as the risk of women who are one time negative 
for hrHPV is equal to the risk of women who are two times negative for cytology.
Other studies state that women also could be stratified by baseline hrHPV-testing.7, 19, 21-22 
According to our study this is an appropriate alternative for delayed hrHPV testing. The (long-
term) CIN3+ risks after immediate and delayed (after 6 months) hrHPV testing are similar in 
both groups. The advantage of delayed testing is that approximately 20% of the women will 
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have cleared their hrHPV infection in these 6 months, which will result in a lower referral rate 18, 
23 with similar cost-effectiveness.24 A disadvantage is that more women will be lost-to-follow-up 
with delayed testing than with direct testing.
Women testing hrHPV-positive have an increased CIN3+ risk (>30%) and should be 
monitored more closely with cytology, hrHPV-testing, colposcopy or a combination of these.7-8 
When no CIN3+ lesion has developed within 5 years, their CIN3+ risk in the subsequent 5 years 
is with 0.7% equal to the risk of women with normal cytology in routine screening and they may 
therefore return to the screening programme (Chapter 3).25-26
Additional hrHPV-testing in the risk assessment of women with a BMD test result is not 
recommended in women aged 29 and below. In this age group up to 80%27 of the BMD-women 
are likely to test positive for hrHPV infections which are mainly transient28 and will not develop 
into high-grade disease. Therefore, additional hrHPV-testing is not useful. In contrast, the 
prevalence of hrHPV is approximately 30% in women with BMD aged 30 years and above.8 For 
this group hrHPV-testing can improve the selection of women at risk of developing high-grade 
CIN lesions for a period of up to 10 years. 
Conc lus ions  for  women hav ing  BMD cy to log ica l  test 
resu l ts :
The number of visits to the outpatient clinic for women with BMD can be decreased, 
when hrHPV testing is added to their follow-up schedule.
Women negative for hrHPV (either at baseline or at delayed testing after 6 months) 
should be referred to the population-based screening programme.
Women positive for hrHPV who do not develop CIN3+ within 5 years may then be referred 
to the population-based screening programme as their risk in the subsequent 5 years is 
similar to women with normal cytology in the routine screening programme.
Recent  deve lopments
Recently new developments in cervical cancer screening and prevention have been subject 
of discussion in the Netherlands. Although not the main focus of this thesis, we describe 
three of these developments, namely prophylactic HPV vaccination, primary screening with 
hrHPV testing, and self-sampling. As stated previously, the validation and implementation of 
new techniques should be carefully assessed to the risks accepted on previously determined 
thresholds. 
Prophy lac t ic  hrHPV vacc inat ion
The first development is the recent introduction (2009) of a prophylactic hrHPV vaccine for 
12-year old girls in the Dutch National Immunisation Programme with a (temporarily) catch-
up for 13 to 16-year old girls.29 Although it will take decades before the full advantages (i.e. 
reduction of cervical cancer rates) will be apparent29-30, vaccinated women will be invited to 
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attend cervical cancer screening in the near future. While cross-protection of these HPV 16/18 L1 
vaccines has been described, and even with a theoretical attendance of 100%, these screening 
programmes will remain in place, because these vaccines do not cover more than 80% of all 
carcinomas.30 On the long run screening guidelines might have to be adjusted for vaccinated 
women. Furthermore, it should also be considered whether vaccinated and non-vaccinated 
women would need to receive similar, or different, screening programmes. Modelling studies 
about these issues have been described previously.31-32 These models demonstrated that by 
adding vaccination to screening a reduction in cervical cancer mortality between 50 and 81% 
could be reached without exceeding the cost-effectiveness threshold of 20,000 euro/QALY 
(quality-adjusted life year).
Populat ion-based  hrHPV screen ing
The second development involves the recent advise of the Health Council of the Netherlands 
to use hrHPV-testing as the primary test in population-based screening to improve screening 
efficacy.11 This will be implemented in the Netherlands in 2013 and comprises primary hrHPV 
testing in 5 screening rounds (at the ages of 30, 35, 40, 50 and 60 years). Women who test 
positive for hrHPV at the age of 40, 50, or 60 years, and are negative for cytological triage at 
baseline and after 6 months, should be screened again 5 years later. 
The decision to change from cytological based screening to primary hrHPV screening was 
based on results of numerous cross-sectional studies and several longitudinal randomised 
controlled trials. These trials all revealed a higher cross-sectional sensitivity of primary hrHPV-
testing than of cytological screening in detecting high-grade cervical lesions (approximately 
95% versus 65%).8, 25, 33-40 Moreover a reduction of 50% of CIN3 and cervical carcinoma was found 
in the second screening round (3-5 years later) of the women tested with hrHPV if compared to 
cytology indicating superior protection in the HPV group. Thus a negative hrHPV test provides 
a greater reassurance against cervical disease than testing negative for cytology.34, 41 Or, in 
other words, a negative hrHPV test will result in a lower proportion of cancers occurring in 
women apparently adequately screened by cytology. Consequently, by using hrHPV-testing 
the screening interval can be increased, without a rise in high-grade cervical lesions in the 
meantime, because high-grade disease and cancer are detected sooner.25, 33, 35-37, 41 In addition, 
the sensitivity of hrHPV-testing is similar to the sensitivity of combined testing with hrHPV and 
cytology, which strengthens the decision to use hrHPV as a stand alone screening test.35, 38
However, the specificity of hrHPV-testing is approximately 5% lower than the specificity 
of cytological testing.33 Because this is a screening setting in which women have a low a priori 
risk of harbouring high-grade disease, the number of false positively tested women should 
preferably be as low as possible to prevent unnecessary retesting and referral. So in short, 
screening by hrHPV-testing can detect premalignant lesions that would otherwise grow slowly 
to the point of detection by less sensitive methods like cytology and colposcopy, but also results 
in a higher number of abnormal test results. The majority of the approximately 5% of the Dutch 
women who test positive for hrHPV 8 will have transient infections that would clear without 
treatment.36-38 Therefore, some form of triage should be performed in hrHPV-positive women. 
Rijkaart and colleagues have analysed several triage strategies in these women.42 The authors 
have found that baseline triaging with cytology, followed by cytological testing after one year 
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was an effective option. Women who test negative for cytology at both visits may be referred to 
routine screening, while those with abnormal test results should be referred for a colposcopic 
examination.33, 39, 42 Another effective triage strategy includes cytology with HPV16/18/31/33/35 
genotyping, however, a major disadvantage of this strategy was the high overall colposcopy 
rate. Depending on the screening interval used, different triage options could be preferred. In 
the Netherlands cytological triage is currently chosen as preferred choice. A modelling study 
has shown that primary hrHPV-testing with cytological triage can be cost-effective compared 
to cytology-based screening, provided fewer screening rounds will be present and the price 
of the hrHPV testing is not exceeding €30,-.43 In the future more objective markers, such as 
methylation markers, may be implemented in triaging hrHPV-positive women. Naturally, well-
trained colposcopists will remain important for an appropriate risk assessment, also in a hrHPV-
based screening programme.
Another benefit of primary hrHPV-testing would be the improved detection of glandular 
lesions.44-46 However, although hrHPV-testing seems to be an excellent way to detect both 
squamous and adenocarcinoma, a special interest should be paid to very rare carcinomas 
(less than 1% of all cervical carcinomas) which appear to be hrHPV-unrelated, such as minimal 
deviation carcinoma and cervical clear-cell carcinoma (CCAC).47 This thesis (Chapter 2) describes 
the rather weak link between hrHPV and this last type of cancer, and we therefore conclude 
that hrHPV-testing will be insufficient to detect these tumours. So, when there are indications 
that a certain group of women has an increased risk of developing these rare hrHPV-unrelated 
carcinomas, such as women who are prenatally exposed to DES, it is recommendable to offer 
co-testing, consisting of both hrHPV and cytology to these women. However, since precursor 
lesions of CCAC are still unknown, the prevention of this cancer subtype will pose a challenge 
in which the role of cytological screening remains limited to detect the invasive tumour at the 
lowest possible stage.
Conc lus ion:
Women with an increased risk of rare and hrHPV-unrelated adenocarcinomas, for 
instance CCAC in women prenatally exposed to DES, should not only be screened by 
hrHPV-testing, but should also receive cytological screening.
Se l f - sampl ing
In addition to implementing hrHPV-testing as primary test in population-based screening, the 
Health Council of the Netherlands also recommends to send a device for self-sampling cervico-
vaginal material to women, who repetitively not responded to invitations for the screening 
programme, for hrHPV-testing.11
This seems an effective method to increase the coverage of population-based screening, 
as up to 40% of the non-attendees respond by returning their self-sampler.48-50 Furthermore, 
relatively more high-grade cervical lesions are found in this group.48-50 Testing for hrHPV on 
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self-collected material has proven to be just as sensitive as hrHPV-testing on physician-collected 
material.51-52 A limitation is that the sample is often of insufficient quality to perform reliable 
cytology on.53 Therefore women who test hrHPV positive on self-collected vaginal material 
should have an extra visit to their physician for taking a triage smear. To prevent this extra visit 
to the physician, alternative and more objective triage markers that are directly applicable on 
self-collected material, such as DNA methylation markers, are presently evaluated in the triage 
algorithm of hrHPV positive women detected by self-collected samples.54  
Post- t reatment  cons iderat ions
Despite all efforts in the screening programme each year approximately 5000 women are treated 
for high-grade cervical disease by the destruction or excision of the entire transformation 
zone. These methods are effective in 90% of the cases, which implicates that 10% of treated 
women will be diagnosed with residual or recurrent (post-treatment) disease.14 To detect post-
treatment disease quickly, treated women are monitored closely so that it is possible to repeat 
conservative treatment when residual or recurrent disease is detected. Although most post-
treatment disease is diagnosed within 2 years of treatment 55-57, the risk of developing post-
treatment disease is increased for a much longer period.58-60 The current surveillance protocol 
in the Netherlands is cytology-based, and women with three consecutive negative test results 
(at 6, 12 and 24 months after treatment) return to the population-based screening programme.61 
The 5-year risk of these women to develop CIN3+ is similar to women with normal cytology 
in the population-based screening programme and is considered acceptable by Dutch health 
authorities.8 This is in striking contrast to the annual cytological post-treatment surveillance of 
these women for at least ten62 or twenty63 years in the United Kingdom and United States. This 
thesis (Chapter 4.1) confirms the effectiveness of the surveillance strategy in the Netherlands, 
as the 5-year CIN3+ risk of women with three consecutive negative smears was less than 1% and 
the CIN2+ risk over the same period was less than 3%. 
However, a substantial part of treated women do not comply with the complete follow-up 
schedule of three visits.64-66 In a Dutch study only half of the women treated for high-grade 
cervical disease completed the total follow-up programme of three cytological smears in the 
first two years after treatment.64 This might be resolved by reducing the number of visits in 
post-treatment surveillance.
Therefore, the implementation of new techniques, which are at least equal in test 
characteristics as the current surveillance programme, could be considered. In line with the 
implementation of hrHPV testing in population-based screening, the use of hrHPV in post-
treatment surveillance has been studied extensively.14, 56, 67-74 Our meta-analysis (Chapter 4.2) 
confirmed that hrHPV-testing after treatment is more sensitive (relative sensitivity 1.15, 95% CI 
1.06-1.25) than cytology with equal specificity (relative specificity 0.95, 0.88-1.02).14, 68, 70 However, 
some studies displayed a slightly lower specificity for hrHPV testing, most likely because of 
different hrHPV prevalences between countries.69, 71 As treated women have a relatively high a 
priori risk of developing high-grade lesions, sensitivity is in this context considered to be more 
important than specificity. 
As a consequence of its high sensitivity, a single positive hrHPV test assures the early and 
accurate detection of women with an increased risk for progression to and development of 
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post-treatment disease. Most women clear their hrHPV infection within 6 months 68, 75 and 
those testing negative are not at risk of developing post-treatment disease and may therefore 
return to the population-based screening programme.68, 76-77 Because sole HPV testing still has 
a few false negative test results (sensitivity of 95%) and does not detect hrHPV types which 
are not part of the routinely used test panel, co-testing with both cytology and hrHPV could 
be performed as alternative in a diagnostic setting.68, 72, 74 This combination has shown to have 
the highest sensitivity to detect post-treatment disease and accordingly the highest negative 
predictive value (Chapter 4).67-68, 72, 78 Several studies have demonstrated that women who test 
negative for co-testing 6 months after treatment could omit the 12-month visit during follow-
up.67-68, 72, 74 Our study (Chapter 4.1) confirms the value of hrHPV-testing in post-treatment 
surveillance; the CIN2+ risk after three consecutive negative cytological tests was with 2.9% 
similar to the risk after one time co-testing at 6 months after treatment (3.0%), illustrating that 
the negative predictive value of co-testing is mainly because of a negative hrHPV test.
Although some advocate a single test moment post-treatment72, we favour a strategy with 
two recall dates, because a single recall relies too much on the sensitivity of the HPV test. 
Another reason is that a single recall moment might be too early to detect post-treatment 
disease developed by re-infection of the cervical epithelium, as women with a history of CIN 
have higher acquisition rates of HPV.20
Coupé and colleagues have performed cost-effectiveness analyses for different follow-up 
strategies including hrHPV testing. They showed that hrHPV testing at 6 months followed by 
co-testing at 24 months is more cost-effective than the current surveillance protocol.79 Co-
testing at both 6 and 24 months is slightly more costly than the current algorithm, but detects 
the most cases of post-treatment disease.74, 79 
Considering the high negative predictive value of hrHPV-testing in the first two years 
after treatment and the long-term predictive value described in Chapter 4.1 of this thesis, the 
current Dutch surveillance guidelines of women treated for high-grade disease (CIN2/3) should 
be modified. 
We advocate monitoring women treated for high-grade premalignant disease by hrHPV-
testing and cytology (co-testing) 6 months after treatment. A meta-analysis (Chapter 4.2) 
showed that 60% of treated women test negative for co-testing and these women can omit the 
12-month visit and return for testing at 24 months after initial treatment. However, when one 
of the tests performed at 6 months is positive, a colposcopy (with biopsy) is indicated. Women 
who are diagnosed with high-grade disease are treated, while those with no or low-grade disease 
should be retested by co-testing 12 months after initial treatment. False negative test results are 
corrected at the 24-month visit. Again, a colposcopy is required in women with an abnormal test 
result. Women with no or low-grade disease, and those with negative cytology at 12 months are 
retested 24 months after initial treatment. So, all women are retested by co-testing at 24 months 
after treatment to avoid missing cervical carcinoma because of detection problems. Only women 
who test negative for both tests at 6 and 24 months should be referred to population-based 
screening, as their risk of developing CIN3+ in the next 5 years is negligible (Chapter 4.1). Women 
with one or both tests positive at 24 months after treatment should be examined with colposcopy 
and retested. This could be done by co-testing after 30 and 48 months after initial treatment and 
only women testing negative at 2 consecutive time points are referred to the population-based 
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Figure	5.1	Proposed follow-up schedule for women treated for high-grade CIN. 
CIN, Cervical Intraepithelial Neoplasia; hrHPV, high-risk type of the human papillomavirus; PBS, population-
based screening.
a Close surveillance consisting of 
a) cytology after 6, 12, and 24 months; referral to population-based screening programme or co-testing once 
every 5 years when all three tests are negative;
b) co-testing (both cytology and hrHPV) after 6 and 24 months; referral to population-based screening 
programme or co-testing once every 5 years when both tests are negative at both time points.
screening programme (Figure 1). When hrHPV-testing is not available or possible post-treatment 
monitoring with cytology at 6, 12 and 24 months is a good alternative, as the 5-year CIN3+ risk 
in women who test negative at all time points is similar to women with normal cytology in 
population-based screening (Chapter 4.1). Because population-based screening ends at age 60, 
women treated after the age of 55, also those with a negative post-treatment algorithm, should 
receive additional testing after 5 and 10 years, because they will no longer be invited for tests 
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through the regular programme, while the risk of post-treatment disease in successfully treated 
women increases by about 2.5% between 5 and 10 years of follow-up.
It is important to keep in mind that current adjustments only apply to women treated 
for CIN2/3. Until more research has been performed, we support the current guideline to 
follow women treated for AIS for 5 consecutive years because of the endocervical location 
and increased risk of multifocality. However, also these women could benefit from including 
hrHPV-testing in post-treatment surveillance.
It is possible that in the future cytology will be replaced by a more objective and reproducible 
molecular test. An alternative follow-up algorithm may include HPV16 genotyping, as women 
infected with this hrHPV type have a higher risk of developing post-treatment disease than 
women infected with other hrHPV types.80-81 However, in Chapter 4.1 we demonstrate that the 
risk for women positive for hrHPV types other than HPV16 remains considerable.74, 80 Therefore, 
other options for post-treatment surveillance are investigated. One of these options could be 
including additional molecular markers (i.e. CADM1 and MAL). Currently a Dutch multicenter 
prospective trial “Simplified Monitoring of post-treatment CIN2/3 women by molecular testing 
for hrHPV and methylation markers” (SIMONATH) investigates whether addition of these 
markers could result in a model in which women negative for a panel of markers at 6 months 
can be referred to population-based screening directly. 
Conc lus ions  for  women t reated  for  h igh-grade  cerv ica l 
d i sease :
For optimal post-treatment surveillance hrHPV-testing should be included in the follow-
up algorithm of treated women.
Women with two negative co-testing results of both hrHPV-testing and cytology at 6 
and 24 months after treatment, or three negative cytology results (6, 12 and 24 months) 
have a 5-year CIN2+ risk that is at least similar to women with normal cytology in the 
population-based screening programme and should be referred to population-based 
screening (or should be seen once every 5 years).
Overall, as long as there is no flawless instrument to prevent cervical cancer, the search for 
the perfect prevention tool will continue. Despite developments as prophylactic vaccination 
and better screening techniques, cervical cancer will not disappear in the future. Therefore 
the screening and monitoring of women at risk of developing cervical cancer will remain 
important. This applies especially for developing countries, which have the highest burden of 
disease, and where the most important achievement would be that (affordable) prevention will 
become available for all.
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RECOMMENDATIONS
Recommendat ions  for  women hav ing  >  BMD cy to log ica l 
test  resu l ts :
1. All women with > BMD should be referred for colposcopy. 
Additional hrHPV testing will not identify women with a low enough risk (CIN2+ risk of 
<10%) to refrain from colposcopy. So, additional hrHPV testing has no clinical value.
2. Also for women diagnosed with > BMD and a negative colposcopy result (CIN0/1) 
close surveillance using co-testing (both cytology and hrHPV) at 6 and 24 months after 
diagnosis, or cytology at 6, 12, and 24 months after diagnosis is required.  
The CIN3+ risk of women having > BMD is increased for at least 10 years, even for women 
with negative colposcopy at baseline. The CIN3+ risk is 45% in the first 5 years after 
diagnosis of > BMD and 3.5% in the subsequent 5 years. Therefore, they should receive 
a surveillance programme similar to other women with an increased risk of developing 
CIN3. Monitoring could be performed with co-testing (both cytology and hrHPV) after 6 
and 24 months, or with cytology after 6, 12 and 24 months. Only women testing negative 
at all time points should be referred to population-based screening programme.  a
a Referral to the population-based screening programme, or tested with co-testing once every 5 years.
Recommendat ions  for  women hav ing   BMD cy to log ica l 
test  resu l ts : b 
1. Women having BMD and who test positive for hrHPV should be referred for colposcopy.
These women have a risk of over 30% of harbouring a CIN3+ lesion
2. By adding hrHPV testing in the follow-up of women with BMD test results, the number 
of follow-up visits can be decreased.
As suggested by the Netherlands Society of Pathology17, the follow-up period of many 
women having BMD may be decreased by using hrHPV testing. The risk of women who 
test negative for both cytology and hrHPV after 6 months is with <1% similar to the risk of 
women who test negative for cytology after 6 and 18 months.
3. Women negative for hrHPV (either at baseline or at delayed testing after 6 months) 
should be referred to population-based screening programme.a
Women with a BMD test result who test negative for hrHPV at baseline have a negligible 
risk of <1.0% of developing CIN3+ in the next 10 years, and may return to population-
based screening programme (like women having BMD at baseline and a negative hrHPV-
test result after 6 months). a
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4. Women positive for hrHPV who do not develop CIN3+ within 5 years may then be 
referred to population-based screening programme. a 
Women having BMD, who have not developed CIN3+ within 5 years, have a CIN3+ risk in 
the subsequent 5 years of 0.7%, similar to the CIN3+ risk of women with normal cytology 
in the  screening programme.
a Referral to the population-based screening programme, or tested once with co-testing every 5 years.
b Since up to 80% of women below 30 years of age having BMD test results are likely to encounter a 
(transient) hrHPV infection, the abovementioned recommendations are only valid for women aged 30 
years and above.
Recommendat ions  for  women t reated  for  h igh-grade 
cerv ica l  d i sease :
1. HrHPV testing improves the sensitivity for residual and recurrent (post-treatment) 
CIN2/3 and should therefore be included in the follow-up algorithm of treated women.
To detect post-treatment disease, hrHPV testing is more sensitive than cytology (relative 
sensitivity 1.15, 95%CI 1.06 – 1.25) and has equal specificity (relative specificity 0.95, 0.88 
-1.02). So, a positive hrHPV test may better identify women with an increased risk for 
progression to and development of post-treatment disease. 
2. Women treated for CIN2/3 who have three consecutive negative cytological test results 
post-treatment should return to the population-based screening programme.a
Treated women with three consecutive cytological negative test results (at 6, 12 and 24 
months post-treatment) have a 5-year CIN3+risk of 0.4%, similar to women with normal 
cytology in the population-based screening programme.
3. Follow-up of women treated for CIN2/3 should be done by co-testing (both cytology 
and hrHPV).
In the diagnostic setting the risk of missing residual or recurrent (post-treatment) CIN2/3 
should be minimised as much as possible. The highest sensitivity (95%, 95%CI 91 – 98) of 
detecting post-treatment disease is reached by performing co-testing (both cytology 
and hrHPV). As the a priori risk of these women is relatively high, the most optimal 
follow-up algorithm is the strategy that has the highest sensitivity.
4. Women treated for CIN2/3 with negative co-testing (both cytology and hrHPV) results 
after 6 months may omit the 12-month screening visit 
Women testing negative for both cytology and hrHPV have a very low risk of developing 
post-treatment disease (CIN3+ risk of 1.4%). CIN2+ risk after a single negative co-testing 
result (5-year CIN2+ risk of 3.0%) was similar to the risk after three consecutive negative 
cytological test results (5-year CIN2+ risk of 2.9%).
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5. Women treated for CIN2/3 with two negative co-testing results (both cytology and 
hrHPV) should return to population-based screening programme.a 
Women who test negative for co-testing twice (at 6 and 24 months post-treatment) 
should be referred to population-based screening programme 1, as their risk of 
developing CIN3+ in the next 5 years is negligible (0.0%, 95%CI 0.0 – 3.0).
a Referral to the population-based screening programme, or tested once with co-testing every 5 years.
The recommendations mentioned above concern the current population-based screening 
programme with cytology as primary screening method.
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As cervical cancer is an important health problem worldwide with over a half million patients a 
year and as it is the fourth most common cause of cancer-related death in women, improving 
the prevention of this disease is a continuing and important process. A major reduction of 
cancer incidence and mortality has occurred in countries with cervical cancer screening. 
Because cervical cancer develops through different premalignant stages it can be detected in 
a premalignant stage, allowing treatment before these stages would be able to develop into 
cervical cancer. Chapter	1 gives a general introduction about the cervix, human papillomavirus 
(HPV), the model(s) of cervical carcinogenesis and different measures that are taken to 
prevent cervical cancer. These measures include screening, triaging of abnormal test results, 
colposcopic examination, treatment and post-treatment surveillance.
In the vast majority of cervical cancers a persistent infection with high-risk HPV types 
(hrHPV) has been proven to be the causative agent in their carcinogenesis. Besides almost all 
cervical squamous cell carcinomas, approximately 95% of all cervical adenocarcinomas (ACs) 
are caused by a transforming infection with a hrHPV type. The remaining ACs are rare and 
sometimes seem hrHPV-unrelated, which could be caused by detection error or because these 
tumours are indeed caused by another, not HPV-related carcinogenic mechanism. Chapter	
2 describes the attribution of hrHPV in cervical clear-cell adenocarcinoma (CCAC), which 
are relatively rare tumours (<<1% of all cervical carcinoma). These tumours have a bimodal 
age distribution with one peak in the early twenties and another after menopause and are 
characterised by clear cytoplasm and Hobnail cells. In approximately 60% of the cases this 
tumour has been associated with intrauterine exposure to diethylstilbestrol (DES), a synthetic 
oestrogen which has been (falsely) used in the past to prevent miscarriages. In this study of 
28 women with CCAC, of whom 15 were DES-exposed in utero, hrHPV was found in 13 (46.4%) 
tumours. However, after performing immuno-histochemistry with p16INK4a and p53 to distinguish 
transient hrHPV infections from transforming, carcinogenic infections, only three carcinomas 
remained in which a causal relation of hrHPV and CCAC was plausible. This demonstrated a very 
limited role of hrHPV in the carcinogenesis of CCAC. None of the hrHPV-associated tumours 
were found in women prenatally exposed to DES. In DES-unrelated tumours only a minority 
(20-25%) seemed hrHPV mediated.
In the Dutch population-based screening programme approximately 2.5% of screened 
women have borderline or mild dysplasia (BMD, PAP2/3a1). These women are retested after 6 
months with either cytology of a combination of both cytology and HPV (co-testing), and after 
18 months with cytology. If the tests remain abnormal, women are referred for colposcopy. 
However, not all women with BMD comply with this protocol. Many studies have examined 
the short-term value of hrHPV-testing in predicting the cumulative risk of CIN3+. In Chapter	
3 we have evaluated the long-term cumulative CIN3+ risk in a group of 342 women with an 
abnormal cytological test result (≥ BMD). These women were followed for a time period of 
17 to 19.5 years after detection. Immediate hrHPV-testing clearly stratified the CIN3+ risk; 
almost all CIN3+ lesions (97.1%) were found in women who tested hrHPV positive. Almost 
half of all hrHPV-positive women were infected with HPV16; these women had a significantly 
higher CIN3+ risk than women infected with other hrHPV types. This risk difference between 
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HPV16-positive women and women positive for other hrHPV types, was only found in younger 
women (<30 years). In older women (≥30 years) the risks in both age groups were similar. The 
5-year CIN3+ risk was lower in women who had cleared the virus within 6 months than in women 
with persistent hrHPV infections (2.2% versus 56.0%), with the highest risks for women with a 
persistent HPV16 infection (67%).
We stratified the CIN3+ risks according to referral cytology and found that both women with 
BMD and women with >BMD referral cytology had an increased risk of developing CIN3+ within 
the first 5 years after detection. This risk was twice as high in women with >BMD compared to 
women with BMD (45% versus 22%). In the subsequent 5 years an increased risk (3.5%) remained 
for women with >BMD, while for women referred with BMD this risk was with 0.7% similar to that 
of the general population. Immediate (or delayed, i.e. after 6 months) hrHPV testing clearly 
stratified the risk in women with BMD; the 5-year risk in hrHPV-negative women was 0.01%, and 
in hrHPV-positive women 37.5%. Therefore we support the strategy to refer hrHPV-negative 
women with BMD to routine screening and to refer those who are hrHPV positive for additional 
testing or colposcopy. When these women do not develop CIN3+ within 5 years, they also may 
be referred to population-based screening. 
Additional (baseline) hrHPV-testing in women with >BMD did not result in a group with a 
risk low enough to refrain from colposcopy, therefore we do not advocate hrHPV testing in this 
group and advise to refer all these women for colposcopy. As their CIN3+ risk is elevated for at 
least 10 years, long-term monitoring is required.
Chapter	4 focuses on women treated for high-grade cervical disease (CIN2/3). As over 10% 
of treated women will develop residual/recurrent (post-treatment) high-grade cervical disease, 
they are closely monitored by cytological testing after treatment. Most published studies 
concern the risk-assessment of developing post-treatment disease up to a maximum of two 
years. Currently, treated women in the Netherlands are referred to population-based screening 
when they have three consecutive negative cytological test results after treatment. This means 
that it would take at least another three years before women are invited for population-based 
screening again. In order to evaluate the safety of the current regimen, long-term follow up 
data is essential. Also because in several other countries yearly follow-up for up to 10 years 
after treatment is common. As successful treatment is associated with the elimination of 
hrHPV, hrHPV testing has been suggested as an improvement in post-treatment surveillance. 
In Chapter	4.1 a multi-cohort study is described that includes 435 women followed between 
5 and 21.5 years after treatment. Different post-treatment test algorithms were analysed; sole 
cytological testing, sole hrHPV-testing and combined testing with both cytology and hrHPV 
(co-testing). The overall 5-year CIN2+-risk in this cohort was 16.5%. However, in women who 
tested consecutively negative for cytology (at 6,12 and 24 months after treatment) this risk was 
lowered to 2.9% and even to 1.0% in women who tested negative for co-testing at both 6 and 24 
months after treatment. The risk of developing CIN3+ in treated women with three consecutive 
negative cytological test results is similar to the risk of developing high-grade cervical disease 
in women who test negative for cytology (PAP1) in population-based screening. However, 
by adding hrHPV-testing to post-treatment surveillance, a better risk-assessment could be 
reached with even fewer visits.
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In order to judge the results found in this multi-cohort study, studies which compared 
different surveillance methods (cytology, hrHPV or co-testing), tested six months after 
treatment, were systematically reviewed in Chapter	4.2. After a bibliographic database search, 
relevant studies published between January 2003 and May 2011 were identified by two reviewers 
with a multi-step process. Then the selected studies were methodological assessed with a 
modified version of the QUADAS tool (QUality Assessment of Diagnostic Accuracy Studies). 
Eventually, only eight out of 2410 identified studies remained, incorporating 1513 treated 
women. The sensitivity of hrHPV testing to predict post-treatment CIN2+ was significantly 
higher than of cytology (relative sensitivity 1.15; 95%CI 1.06-1.25), while the specificity of these 
tests was similar (relative specificity 0.95, 95%CI 0.88-1.02). The sensitivity of co-testing was the 
highest (95%), however this combined test had the lowest specificity (67%). In summary, this 
review supports the inclusion of hrHPV testing in post-treatment monitoring protocols.
The general discussion in Chapter	5 summarises the findings of this thesis and discusses 
possible future prospects and clinical consequences.
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SAMENVATTING
Met meer dan een half miljoen nieuwe gevallen per jaar wereldwijd is baarmoederhalskanker een 
belangrijk gezondheidsprobleem. Verbeteringen in de preventie van baarmoederhalskanker is 
dan ook een continu proces. In landen met een (gestructureerd) bevolkingsonderzoek voor 
het opsporen van baarmoederhalskanker is de incidentie van en sterfte aan deze vorm van 
kanker aanzienlijk gedaald. Omdat baarmoederhalskanker in een premaligne stadium kan 
worden opgespoord, kunnen afwijkingen behandeld worden voordat deze invasief worden. 
Hoofdstuk	 1	 bevat een algemene introductie over de baarmoederhals, het humaan 
papillomavirus (HPV), de ontstaanswijze van baarmoederhalskanker en de verschillende 
maatregelen die gebruikt kunnen worden om baarmoederhalskanker te voorkomen. 
Deze maatregelen omvatten screening (door middel van het bevolkingsonderzoek op 
baarmoederhalskanker), het triëren van abnormale test resultaten, colposcopisch onderzoek, 
behandeling en follow-up na behandeling.
Bijna alle gevallen van baarmoederhalskanker worden veroorzaakt door een persistente 
infectie met een hoog-risico HPV type (hrHPV). Zo goed als alle plaveiselcel carcinomen en circa 
95% van alle glandulaire (adeno)carcinomen worden veroorzaakt door een transformerende 
hrHPV infectie. In de resterende 5% van de adenocarcinomen is geen hrHPV aantoonbaar. Dit 
kan veroorzaakt worden door een detectie fout of omdat deze tumoren inderdaad worden 
veroorzaakt door een ander, niet HPV gerelateerd carcinogeen mechanisme. 
Hoofdstuk	 2 beschrijft de bijdrage van hrHPV in heldercellige adenocarcinomen van 
de cervix (CCACs). CCACs zijn relatief zeldzame tumoren (<<1%) . Deze tumoren hebben een 
bimodale leeftijddistributie met een piek rond de leeftijd van 20 jaar en een piek rond de 
menopauze. Zij worden gekenmerkt door helder cytoplasma en zogenaamde Hobnail cellen. 
In ongeveer 60% van de gevallen zijn deze tumoren geassocieerd met diethylstilbestrol (DES) 
gebruik van de moeder tijdens de zwangerschap. DES is een synthetisch vervaardigd oestrogeen 
dat vroeger (onterecht) werd gebruikt om miskramen te voorkomen. In deze studie van 28 
vrouwen met CCAC, waarvan er 15 aan DES in de baarmoeder waren blootgesteld, werd in 13 
(46.4%) tumoren hrHPV aangetoond. Door het toepassen van een immuno-histochemische 
kleuring met p16INK4a en p53 kon onderscheid gemaakt worden tussen productieve, tijdelijke 
hrHPV infecties en transformerende, oncogene infecties. In slechts 3 van de 21 tumoren 
was hrHPV een aannemelijke oorzaak. Dit toonde de zeer bescheiden rol van hrHPV aan in 
de carcinogenese van CCAC. Geen van de hrHPV geassocieerde tumoren werd gevonden in 
vrouwen die intra-uterien waren blootgesteld aan DES, en in de overige vrouwen bleek slechts 
een minderheid (20-25%) door hrHPV veroorzaakt. 
In het Nederlandse bevolkingsonderzoek op baarmoederhalskanker (BVO) heeft circa 2.5% 
van alle gescreende vrouwen een lichte cytologische afwijking (PAP2/3a1, BMD, KOPAC-B P2-4, A3 
en/of C3-5). Deze vrouwen worden na 6 maanden opnieuw getest door middel van een uitstrijkje, 
of door een combinatie van een uitstrijkje én een hrHPV test (co-test). Na 18 maanden volgt in 
beide strategieën wederom een uitstrijkje. Vrouwen bij wie de testen afwijkend blijven, worden 
verwezen voor colposcopisch onderzoek. Echter, niet alle vrouwen volgen deze adviezen op. In 
de literatuur is de korte termijn voorspellende waarde van de hrHPV test op het ontstaan van een 
premaligne afwijking voor deze groep vrouwen uitgebreid beschreven. 
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In Hoofdstuk	3 hebben wij het cumulatieve lange-termijn risico op het ontwikkelen van 
CIN3+ beschreven in een groep van 342 vrouwen met een afwijkend uitstrijkje (≥ BMD, ≥ PAP2/3a1, 
KOPAC-B ≥P2, ≥A3 en/of ≥C3). Deze vrouwen werden gevolgd voor een periode tussen 17 en 19.5 
jaar na het detecteren van een afwijkende uitstrijk. Direct testen op hrHPV stratificeerde het 
CIN3+ risico; bijna alle CIN3+ laesies (97.1%) werden gevonden in vrouwen met een positieve 
hrHPV test. Bijna de helft van deze vrouwen was geïnfecteerd met HPV16. Zij hadden een 
significant hoger risico om CIN3+ te ontwikkelen dan vrouwen die geïnfecteerd waren met 
andere hoog-risico typen. Dit risicoverschil was alleen aanwezig in jonge vrouwen (onder de 
30 jaar). In de vrouwen boven de 30 jaar waren de risico’s in beide groepen gelijk. Vrouwen 
wiens immuunsysteem de infectie binnen 6 maanden klaarden, hadden een lager 5-jaars risico 
om CIN3+ te ontwikkelen dan vrouwen met een persisterende infectie (2.2% versus 56.0%). 
Vrouwen met een persisterende HPV 16 infectie hadden met 67% het hoogste 5-jaars risico. 
Naar aanleiding van de ernst van de cytologische afwijking bij verwijzing werden vrouwen 
verdeeld in twee groepen, BMD en >BMD. Beide groepen vrouwen hadden een verhoogd risico 
om CIN3+ te ontwikkelen in de eerste 5 jaren na het vinden van een afwijkend uitstrijkje. Dit 
risico was met 45% twee keer zo hoog in de vrouwen met een >BMD resultaat dan vrouwen met 
een BMD uitslag (22%). In de hierop volgende 5 jaren behielden vrouwen met een >BMD uitslag 
een verhoogd risico (3.5%), terwijl dit risico met 0.7% voor vrouwen met een BMD resultaat 
identiek was aan het 5-jaars risico van vrouwen met een normaal uitstrijkje in het BVO. Het 
risico op het ontwikkelen van CIN3+ kon voor vrouwen met BMD door middel van het direct (of 
na 6 maanden) testen op hrHPV gestratificeerd worden; het 5-jaars CIN3+ risico in vrouwen met 
een negatieve hrHPV test was nihil (0.01%), terwijl het risico voor vrouwen met een positieve 
test 37.5% bedroeg. Deze bevinding ondersteunt het voorstel om hrHPV-negatieve vrouwen 
met BMD te verwijzen naar het BVO, terwijl vrouwen met een positieve hrHPV test verder 
onderzocht moeten worden door middel van een herhaaltest of een colposcopisch onderzoek. 
Als deze vrouwen in de eerste 5 jaren na detectie geen afwijkingen ontwikkelen, dan kunnen 
ook zij hierna naar het BVO worden verwezen.
Het toevoegen van een hrHPV test in de groep vrouwen met een >BMD resultaat (KOPAC-
B: ≥P5, ≥A4 en/of ≥C6) leidde niet tot het identificeren van een groep vrouwen die kon afzien 
van aanvullend onderzoek. Derhalve is het niet nuttig om een hrHPV test te verrichten in de 
follow-up van vrouwen met een >BMD uitslag, maar moeten zij allen verwezen worden voor 
colposcopisch onderzoek. Aangezien hun CIN3+ risico minimaal 10 jaar verhoogd is, moeten 
deze vrouwen langdurig vervolgd worden.
Hoofdstuk	 4 beschrijft onderzoek dat vrouwen betreft die behandeld zijn voor een 
hoog-gradige premaligne cervix afwijking (CIN2/3). Aangezien circa 10% van de behandelde 
vrouwen opnieuw wordt gediagnostiseerd met een hoog-gradige afwijking, worden deze 
vrouwen door middel van cytologisch onderzoek nauwgezet in de gaten gehouden. De meeste 
gepubliceerde studies beschrijven het risico dat deze vrouwen hebben om in de eerste twee 
jaar na behandeling opnieuw een hoog-gradige laesies te ontwikkelen. Indien behandelde 
vrouwen drie achtereenvolgende normale uitstrijkjes hebben gehad (6, 12 en 24 maanden 
na behandeling), worden zij in Nederland terugverwezen naar het BVO. Dit houdt in dat het 
minimaal 3 jaar zal duren voordat deze vrouwen weer worden uitgenodigd voor het BVO. 
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Daarom is het essentieel om, ter evaluatie van het huidige beleid en met betrekking tot de 
risico inschatting voor deze vrouwen ook over lange-termijn data te beschikken. In andere 
landen worden deze vrouwen namelijk soms tot wel 10 jaar na behandeling met jaarlijkse 
uitstrijkjes gevolgd. Aangezien succesvolle behandeling geassocieerd is met de klaring van 
hrHPV, is het toevoegen van testen op hrHPV als verbetering in de follow-up van behandelde 
vrouwen voorgesteld. 
In Hoofdstuk	4.1 wordt een multi-cohort beschreven waarin 435 vrouwen worden gevolgd 
voor een periode tussen 5 en 21.5 jaar na behandeling. Er werden verschillende follow-
up algoritmes geanalyseerd; enkel testen met cytologie, enkel testen met hrHPV, of het 
gecombineerd testen met hrHPV én cytologie (co-test). Voor het totale cohort vrouwen was 
het 5-jaars CIN2+ risico 16.5%. Echter, in vrouwen met drie opeenvolgende normale cytologische 
uitstrijkjes (6, 12 en 24 maanden na behandeling) daalde dit risico tot 2.9%. Voor vrouwen die op 
2 momenten (6 en 24 maanden na behandeling) negatief testten voor zowel cytologie als HPV 
(co-test) daalde dit risico zelfs tot 1.0%. Het 5-jaars CIN3+ risico voor behandelde vrouwen met 
drie opeenvolgende normale uitstrijken was gelijk aan het risico van vrouwen met een normale 
cytologische uitstrijk in het BVO. Door het toevoegen van het testen op hrHPV in de follow-
up van behandelde vrouwen kan, met minder bezoeken, een nog betere risico-inschatting 
gemaakt worden.
Om de resultaten van deze multi-cohort studie in perspectief te plaatsen, is een systematische 
review verricht, waarvan de resultaten vermeld staan in Hoofdstuk	 4.2. De waarde van 
verschillende follow-up methoden (cytologie, hrHPV test of co-test) werden op 6 maanden 
na behandeling met elkaar vergeleken. Alle tussen januari 2003 en mei 2011 gepubliceerde, 
relevante studies werden door twee onderzoekers onafhankelijk van elkaar beoordeeld 
op relevantie via een multi-stap model. De geselecteerde studies werden methodologisch 
beoordeeld aan de hand van de QUADAS criteria (QUality Assessment of Diagnostic Accuracy 
Studies). Uiteindelijk werden acht van de 2410 oorspronkelijke studies geïncludeerd, waarin de 
gegevens van 1513 behandelde vrouwen werden beschreven. De sensitiviteit van het testen met 
hrHPV om de aanwezigheid van hoog-gradige residuen en recidieven (CIN2+) te voorspellen 
was significant hoger dan de sensitiviteit van cytologie (relatieve sensitiviteit 1.15; 95%CI 1.06-
1.25), terwijl de specificiteit van beide testen gelijk was (relatieve specificiteit 0.95, 95%CI 0.88-
1.02). De sensitiviteit van co-testen was met 95% het hoogst, echter de specificiteit hiervan was 
met 67% het laagst. Samenvattend ondersteunt dit review het includeren van het testen op 
de aanwezigheid van hrHPV in de follow-up van vrouwen behandeld voor een hoog-gradige 
premaligne cervix afwijking.
De algemene discussie in Hoofdstuk	5 vat alle bevindingen uit dit proefschrift samen en 
bespreekt toekomstige veranderingen en de klinische consequenties hiervan. Verder worden 
in dit hoofdstuk aanbevelingen gedaan om de huidige protocollen om baarmoederhalskanker 
te voorkomen, te verbeteren. 
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&L IST  OF  ABBREVIATIONS
L IST  OF  ABBREVIATIONS    
AC Adenocarcinoma
AGC Atypical glandular cells
AIS Adenocarcinoma in situ
ASC-H Atypical squamous cells, cannot exclude HSIL
ASCUS Atypical squamous cells of undetermined significance
ASIR Age-standardised incidence rate
ASMR Age-standardised mortality rate
BMD Borderline or mild dyskaryosis
CCAC Clear-cell adenocarcinoma of the cervix
CI Confidence Interval
CIN Cervical Intraepithelial Neoplasia
CIN2+ CIN2, CIN3 or cancer
CIN3+ CIN3 or cancer 
CISOE-A Composition, Inflammation, Squamous epithelium, Other and endometrium, 
 Endocervical columnar epithelium and Adequacy of the smear
CNR Central Netherlands Registry for clear-cell adenocarcinoma
Co-testing hrHPV testing and cytology taken at the same time point
DES Diethylstilbestrol
DBH Dot-blot-hybridization 
DNA Deoxyribonucleic acid
DOR Diagnostic odds ratio
EIA Enzyme immuno assay
FDA Food and Drug Administration
FEM Fixed effects model
FIGO International Federation of Gynaecology and Obstetrics
FPR False positive rate
HIV Human immunodeficiency virus
HPV Human papillomavirus
HR Hazard ratio
hrHPV High-risk type of the human papillomavirus
HSIL High-grade squamous intraepithelial lesion
IHC Immuno-histochemistry
ISH In situ hybridization
LiPA Line probe assay
LLETZ  Large loop excision of the transformation zone
lrHPV Low-risk type of the human papillomavirus
LSIL  Low-grade squamous intraepithelial lesion
mRNA Messenger ribonucleic acid
NTR Dutch trial register (Nederlands Trial Register)
PALGA The Netherlands nationwide network and registry of histopathology and 
 cytopathology
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PCR Polymerase chain reaction
QALY Quality adjusted life year
Rb Retinoblastoma
RCT Randomised controlled trial
REM  Random effects model
RLB Reverse line blotting
RLU Relative light unit
RNA Ribonucleïnezuur
SCC Squamous cell carcinoma
SCJ Squamo-columnar junction
TPR  True positive rate
TZ Transformation zone
UK United Kingdom
USA United States of America
WHO World Health Organisation
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&PHD PORTFOLIO
PHD PORTFOLIO
Name PhD student: Mariëlle Kocken
Erasmus MC Department: Obstetrics & Gynaecology
Research School:  Molecular Medicine
PhD period:  Dec 2005- May 2012
Promoteren:  Prof.dr Th.J.M. Helmerhorst, Prof.dr. C.J.L.M. Meijer
Co-promoteren:  Dr. J. Berkhof, Dr. W.G.V. Quint
Summary	of	PhD	training	and	teaching	activities	 ECTS
Courses
2011 Adobe Photoshop and Illustrator CS5 workshop, MolMed 0.3
2010 Short introduction course on Statistics & Survival Analysis for MDs, MolMed 0.4
2009 Biomedical English Writing and Communication, EUR 4.0
2008 Basic Methods and reasoning in Biostatistics, Boerhaave Institute, Leiden 1.2
2008 Introduction to Data-analysis, NIHES 0.9
2008 Principles of Research in Medicine and Epidemiology, NIHES 0.9
2008 Integrity in Medical Research, EUR 2.0
2008 Vulvar pathology, Stichting OOG 1.0
2007 Biomedical Research Techniques VII, MolMed 1.0
2005 Good Clinical Practice, Postgrade, Zeist 1.0
2005 Colposcopy course (basic and advanced), Stichting OOG 1.7
National and International presentations
2010 13th Biennial Meeting of the International Gynaecological Cancer Society, Prague, Czech 
Republic (oral)
2.0
2010 5th European Congress of the European Federation for colposcopy and cervical 
pathology, Berlin, Germany (oral)
2.0
2009 16th International Meeting of the European Society of Gynaecological Oncology, 
Belgrade, Serbia (poster)
1.5
2009 25th International Papillomavirus Conference and  Workshops, Malmö, Sweden (oral) 2.0
2008 Eurogin 2008, Nice, France (oral) 2.0
2008 Patient conference on HPV vaccination, ErasmusMC (oral) 0.2
2008 Wetenschapsdag 2008, Reinier de Graaf Hospital, Delft (oral) 0.2
2008 Netherlands Society of Medical Microbiology, Nieuwegein (oral) 0.2
2007 Comprehensive Cancer Centre Rotterdam, Zwijndrecht (oral) 0.2
2007 Workshop at LOVAH-conference, Utrecht (oral) 0.5
2006 WCU, Utrecht (oral) 0.2
2006 SBBW, Leiden (oral) 0.2
Seminars and workshops
2011 Symposium ‘Omzien in verwondering; vertrouwen in de toekomst’, ErasmusMC 0.2
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2010 Erasmus MC PhD Day 0.2
2008 Symposium ‘Jonge zwangerschap’, ErasmusMC 0.2
2008 Symposium ‘Facing a new era of cancer prevention’, VUmc, Amsterdam 0.2
2008 Symposium Nederlandse Vereniging voor Vulvapathologie, Delft 0.3
Teaching activities
2006, 2007 Practical course (VO) ‘Postmenopausal blood loss’, ‘Hormonal substitution therapy’ and 
‘Prolepses and urine incontinence’, ErasmusMC
1.0
2006, 2007 Practical course ‘Obstetrics Phantom’, VUmc, Amsterdam 0.4
Grants
2009 Simplified monitoring of post-treatment CIN 2/3 women by molecular testing for hrHPV 
and methylation markers (SIMONATH), Steenbergen RDM, Meijer CJLM, Helmerhorst 
ThJM. VUmc (klinische pathologie) & ErasmusMC (verloskunde en vrouwenziekten) VU 
2009-4413, KWF/NKB (2009-2011) 
2.0
Miscellaneous
2008, 2011 Diving medical examiner, Scott Haldane Foundation 2.0
2012 Review Manuscript for Acta Obstetricia et Gynecologica Scandinavica 0.5
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&ABOuT THE  AuTHOR

ABOuT THE  AuTHOR
Mariëlle Kocken was born on the 25th of July, 1976 in Rotterdam, the Netherlands. In 1994 she 
completed her secondary education (athenaeum) at the “Krimpenerwaard College” in Krimpen 
aan den IJssel. From 1994 to 2001 she studied medicine at the Erasmus University Rotterdam. 
Her internship at the department of Obstetrics & Gynaecology of the “Lievensberg Hospital” 
in Bergen op Zoom raised her interest in this specialism. After her registration as Medical 
Doctor she started working as a resident at the department of Obstetrics & Gynaecology of the 
“IJsselland Hospital” in Capelle aan den IJssel and later of the Reinier de Graaf Groep in Delft 
(under supervision of dr. J.C. Kuijpers / dr. W.A. ter Harmsel)
In December 2005 she commenced her PhD project “Risk assessment of cervical disease 
by hrHPV testing and cytology” in the HumaVac collaboration under supervision of prof. 
dr. Th.J.M. Helmerhorst and prof. dr. C.J.L.M. Meijer. She presented her work at different 
international conferences. In 2008 she became a certified diving medical doctor, combining 
her profession with one of her favourite hobbies
After a sabbatical in which she was traveling the world for four months, she started as 
a resident at the Pathology department of the VU University Medical Center in Amsterdam 
(under supervision of prof. dr. P. van der Valk) in November 2011.
Mariëlle lives together with Wilbert van Overloop in Rotterdam.
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&DANKWOORD
DANKWOORD
Dan nu het deel dat iedereen als eerste (en vaak ook als enige) leest bij ontvangst van een 
proefschrift. De afgelopen jaren heb ik hulp gehad van veel mensen en op deze plaats wil ik dan 
ook graag alle personen bedanken die op directe of indirecte wijze hebben bijgedragen aan de 
totstandkoming van dit proefschrift. In de volgende paragrafen zal ik een deel van hen in het 
bijzonder noemen. Mocht u van mening zijn dat uw naam ontbreekt, dan kunt u dit eenvoudig 
oplossen door uw naam hieronder zelf in te vullen:
Lieve……………………………………………………………………………., bedankt!
Uiteraard ben ik onnoemelijk veel dank verschuldigd aan alle vrouwen die deel hebben 
genomen aan de studies beschreven in dit proefschrift, zonder jullie was dit proefschrift er 
nooit gekomen!
Dan mijn twee promotores, prof. dr. Helmerhorst en prof. dr. Meijer. Ik heb veel geleerd van 
jullie expertise en jarenlange onderzoekservaring.
Beste Theo, je hebt me de ruimte en vrijheid  gegeven om rustig aan dit boekje te werken, 
zonder ook maar een moment het onderzoek (en mij) uit het oog te verliezen. Dank voor je 
kritische blik, grammaticale inbreng en de prettige discussies die we gevoerd hebben. 
Beste Chris, vanaf het begin klikte het uitstekend en ik dank je voor je enthousiasme. 
De danswedstrijd tegen Pekka Nieminen zal ik niet snel vergeten! Je creatieve blik om het 
onderwerp van mijn proefschrift na ruim drie jaar totaal om te gooien, heeft uiteindelijk in dit 
boekje geresulteerd. Dank voor het vertrouwen dat je altijd had in (mij en) de goede afloop!
Mijn beide co-promotores, dr. Berkhof en dr. Quint.
Beste Hans, ik wil je hartelijk danken voor het mij wegwijs maken in de wondere wereld van 
de statistiek. Dank voor je bereidheid, om “bij nacht en ontij” analyses met mij te draaien en te 
controleren. Jouw werk was essentieel voor het slagen van mijn proefschrift! 
Beste Wim, bedankt voor je hulp bij het ontcijferen van al die moeilijke microbiologische 
technieken en je “blik van buiten”.
Prof. dr. van der Zee, prof. dr. Bosman en prof. dr. Burger, dank voor het plaatsnemen in de 
kleine commissie en het snel beoordelen van mijn proefschrift. Ik wil professor Burger ook 
danken voor de gastvrijheid om in het ErasmusMC een plek te hebben om mijn proefschrift te 
voltooien. Prof. dr. Habbema, dank voor het plaatsnemen in de grote commissie.
Ik wil ook de senior leden van het HumaVac consortium noemen, zover deze niet al eerder 
vermeld zijn. Dank voor de mogelijkheid om binnen jullie groep onderzoek te doen. Het 
was bijzonder leerzaam om de wetenschap vanuit verschillende disciplines te benaderen. 
Op de maandagmiddag werd er over de resultaten van lopende, en de opzet van nieuwe 
onderzoekslijnen (die lang niet altijd het stadium van het A4-tje wisten te ontgroeien) veel 
gepuzzeld, maar nooit zonder de gezelligheid uit het oog te verliezen.
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Dr. Ter Harmsel, beste Bram, na een mooie tijd als AGNIO in Delft heb jij mij binnen HumaVac 
geïntroduceerd en nu, vele jaren later, ligt dan eindelijk het resultaat voor je! Ik ga ervan uit dat 
we ook in de komende jaren nog veelvuldig contact zullen hebben,  en wie weet heb je nog 
een plekje voor als ik over 5 jaar klaar ben…. Dank voor al je wetenschappelijke, maar vooral 
persoonlijke interesse.
Prof.dr. Verheijen, beste René, zo snel als jij op e-mails en verzoeken om artikelen te 
beoordelen reageert, zijn er maar weinig. Dank voor je bereidheid om te opponeren.
Prof.dr. Snijders, beste Peter, bedankt voor het superviseren van alle HPV bepalingen 
welke voor mijn studies nodig waren. Dank voor het plaatsnemen in de grote commissie (en 
eventueel breng ik je toga terug naar Amsterdam!).
Als er seniorleden zijn, dan natuurlijk ook juniorleden…
Jacqueline, jij komt verderop. Lieve Afra, Aaffie, wat hadden Jacq en ik geluk toen jij ons team 
kwam versterken. Samen functioneerden wij als een automatische drie-eenheid, waarin we 
elkaar vanzelfsprekend hielpen en stimuleerden. Dank voor al je spellingscorrecties, spontane 
en creatieve invallen en vooral voor het zijn wie je bent. Je werd ooit bij mij aangekondigd als 
“er is iemand nieuw, Afra, en het is een meisje” en nu ben jij als eerste zwanger van ons allemaal: 
Binnenkort is er iemand nieuw, Barry, en het is een…….;-).  Ik wil jullie beiden zeggen dat jullie 
de beste collega’s waren die ik me kon wensen.
Hierna breidden “de HPV meisjes” zich snel uit; Jacolien, Denise, Romy, Margot en 
Roosmarijn. Dank voor het overnemen van alle projecten, en succes met jullie eigen promotie! 
Margot, ik had me geen betere opvolger voor het “Simonath project” kunnen wensen, je bent 
een nog grotere pietje precies dan ik…. Dank voor al het werk dat je aan ons review hebt verzet, 
terwijl ik op reis was!
Alle co-auteurs, dank voor de prettige samenwerking, jullie hulp en waardevolle feedback 
op de artikelen in dit proefschrift. Hans Bulten, dank voor het doorspitten van de kelders van 
het Radboud op zoek naar clear-cell carcinomen. Frank dank voor het beoordelen van alle 
kleuringen. Astrid dank voor het afmaken van de submissie. Kees, Aagje en Mariëlle, dank voor 
de oorspronkelijke inclusies, door jullie persoonlijke benadering van destijds, waren de meeste 
vrouwen zonder meer bereid om aan mijn studie(s) deel te nemen. Anton, dank voor het je 
willen inlezen in programma’s die je waarschijnlijk nooit meer zal toepassen... Gemma, dank 
voor het kritisch lezen. Hans Ket, fijn dat jij als zoekspecialist de strategie wilde uitwerken om 
het review vorm te geven. Folkert, dank voor het reviseren van alle “oude” strijken, jammer dat 
we inmiddels de dunne-laag gebruiken, we hadden toch zo onze eigen classificatie bedacht.…..
Alle medewerkers van de poliklinieken Gynaecologie van het ErasmusMC, VUmc en RdGG, dank 
voor jullie medewerking aan mijn onderzoeken, net zoals de afdeling moleculaire pathologie 
van het VUmc. René Pol, dank voor het altijd beschikbaar te zijn voor de uitslagen. De 
secretariële ondersteuning was fantastisch; Tonia en Bea, dank voor het altijd een gaatje vinden 
in de agenda van “de baas”. Carla, Ingrid en Anita, dank voor alle administratieve back-up.
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Lieve “oude” collega’s; Het voordeel van werken in verschillende centra, is dat je ook heel veel 
leuke collega’s hebt! In Rotterdam hebben met name de kamergenoten van HS-508 (Sharon, 
Olivier, Lindy, Durk, Anne-Linde, Wendy, Yvonne en Maria) ervoor gezorgd dat ik altijd met 
plezier naar mijn werk toe ben gegaan. Samen konden we alles aan, en Koekela helpt altijd 
in geval van stress of nood! Ook alle andere promovendi, dank voor alle koffiemomentjes en 
gezellige lunches. (Met name de feestcommissie van de 22e.) Nicole, bedankt voor je hulp met 
het bellen om alle vrouwen te includeren tijdens je studententijd, succes met je eigen promotie!
In Amsterdam werd ik na verschillende locaties uiteindelijk “geadopteerd” door de arts-
echoscopisten; Ingeborg, wat was het leuk om na collega’s in Delft (weer) samen op een kamer 
te zitten! Aan de overige echoscopisten: “de HPV-hoek” is dan eindelijk echt vertrokken. Alle 
andere promovendi van de Gynaecologie, dank voor de gezelligheid! Dorien, Murat en Viola, 
dank voor de opvangmomenten in het hoofdgebouw. Maaike, succes met de laatste loodjes…. 
en dat gezamenlijke artikel dat komt er ook nog wel!
Lieve “nieuwe” collega’s van de pathologie van het VUmc, dank voor jullie warme welkom, 
waardoor ik met veel plezier ben begonnen aan de opleiding tot patholoog. Vooral wil ik jullie 
bedanken voor het feit dat ik in de eerste maanden van mijn opleiding de ruimte heb gekregen 
om dit proefschrift af te ronden. Nicole, dank voor je advies, toen ik het allemaal even niet 
zeker wist. 
Lieve vrienden, naast werk is ontspanning essentieel voor de productiviteit en daarom wil ik 
jullie dan ook danken voor jullie indirecte bijdrage. En zie hier het tastbare resultaat van mijn 
soms wat abstracte bezigheden. Mieke, Femke, Annelies en Marike, vanaf nu ben ik weer altijd 
beschikbaar! Moppies (Roos, Jesse en Leonie) nu is mijn “kindje” er dan ook (ik noem haar 
Niekoole). Oud-hugo’s van Oostzeedijk 80, ik kom nu echt een keer op kraam/ verjaardag/ 
samenwoonvisite. Dames 8 Rotterdam, niets werkt zo ontspannend als de frustraties er op het 
hockeyveld uitslaan. Ave, Etje en Fem, wanneer gaan we shoppen? Les, Es en An…PIT…NAT….
PIT. Marco, Esther, Karin en Pim, vanaf de middelbare school al vriendjes, heb jullie te lang niet 
gezien, komen jullie snel weer eten? Klooster, “Old-school”, en clubvriendjes van Wilbert, ik 
voel me ook bij jullie helemaal thuis!
Lieve schoonfamilie, dank voor het warme welkom in jullie familie. Jullie hebben mijn 
woordenschat uitgebreid met Zeeuwse klassiekers, heit? Jackolien en Hans, vanaf nu hebben 
jullie er voor Jeroen en Wouter een babysitter bij!
Lieve familie, ondanks dat het misschien jullie niet altijd even duidelijk was wat ik nu precies aan 
het doen was, dank voor jullie steun, geduld en begrip. Gemeenschappelijk verdriet heeft ons 
nog dichter bij elkaar gebracht en daardoor besef ik des te meer; ik bof maar met jullie allemaal 
(en daar bedoel ik dus zowel de warme als de koude kant mee!) Erik en Lonneke, is het nu al tijd 
om een kerstdiner te bedenken? 
Mam, dank voor alles wat jij me hebt meegegeven en dat me heeft gemaakt tot wie ik nu 
ben. Ik hou enorm veel van je! Frank, je gevoel voor humor is onnavolgbaar…..
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Lieve Cees, jammer dat je dit niet meer mee kan maken, maar wat zou je trots op me zijn 
geweest!
Mijn paranimfen, Jacqueline Louwers en Simone Merckel.
Lieve Jacqueline, Sjakkie, kennismaken op Leiden CS, wie had toen kunnen denken wat er 
allemaal nog voor ons lag. De lange dagen zijn het waard geweest, immers, nu promoveren 
we (bijna) tegelijk! Van half acht ’s-ochtends tot 10 uur ’s-avonds waren in het begin geen 
uitzondering, maar gelukkig vulden we elkaar goed aan en was er genoeg humor om de sleur 
te breken. Met jou heb ik bijna meer landen gezien dan met ieder ander, samen op congres was 
elke keer weer een feestje. Je hebt me alle jaren met raad en daad bijgestaan (ik kon immers 
altijd in het Amsterdamse logeren en een legendarisch ontbijtje van B-J scoren). Dank voor je 
vriendschap en ik ben blij en trots dat je vandaag naast me wil staan. 
Lieve Simpie, Simoontje, van huisgenootjes in de studententijd, in de loop der tijd steeds 
closer geworden. Vaak hebben we aan een halve zin genoeg. Ik vind het een eer en voorrecht 
om op jouw huwelijk je getuige te zijn geweest. Het is bewonderenswaardig hoe jij altijd alle 
ballen in de lucht weet te houden. Binnenkort mag je dat op ons (5-jaarlijkse?) weekendje 
weg toch nog eens een keertje uitleggen. Dank dat je op deze belangrijke dag mijn steun en 
toeverlaat wilt zijn. 
Lieve Wilbert, ik wil van elke dag samen met jou een feestje blijven maken. Het is de hoogste 
tijd om een volgend tripje te plannen. Ik hou van je. X.
Mariëlle
&
A
d
d
En
d
u
m
165

